Publicaties

Profiel Publicaties Activiteiten Onderwijs Nevenwerkzaamheden Contact

Expertises

Onderzoeksthema's

2022

Wetenschappelijke publicaties

Vreman, R. A., Bloem, L. T., van Oirschot, S., Hoekman, J., van der Elst, M. E., Leufkens, H. G. M., Klungel, O. H., Goettsch, W. G., & Mantel-Teeuwisse, A. K. (2022). The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs. International Journal of Health Policy and Management, 11(5), 642-650. https://doi.org/10.34172/ijhpm.2020.198

Ten Ham, R. M. T., Frederix, G. W. J., Wu, O., Goettsch, W., Leufkens, H. G. M., Klungel, O. H., & Hoekman, J. (2022). Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England. Value in Health, 25(3), 390-399. https://doi.org/10.1016/j.jval.2021.09.012

Komen, J. J., Pottegård, A., Mantel-Teeuwisse, A. K., Forslund, T., Hjemdahl, P., Wettermark, B., Hallas, J., Olesen, M., Bennie, M., Mueller, T., Carragher, R., Karlstad, Ø., Kjerpeseth, L. J., & Klungel, O. H. (2022). Oral anticoagulants in patients with atrial fibrillation at low stroke risk: a multicentre observational study. European Heart Journal. https://doi.org/10.1093/eurheartj/ehac111

Groenwold, R. H. H., Heerdink, E. R., & Klungel, O. H. (2022). Challenges in the Design, Registration, and Reporting of Noninferiority Trials. JAMA Psychiatry, 79(3), 191-192. https://doi.org/10.1001/jamapsychiatry.2021.3932

ON-TIME 3 investigators (2022). Impact of vomiting on P2Y12 platelet inhibition in patients with ST-elevation myocardial infarction: A prespecified subanalysis of the ON-TIME 3 trial. American Heart Journal, 243, 39-42. https://doi.org/10.1016/j.ahj.2021.08.011

Tavenier, A. H., Hermanides, R. S., Ottervanger, J. P., Tolsma, R., van Beurden, A., Slingerland, R. J., ter Horst, P. G. J., Gosselink, A. T. M., Dambrink, J-H. E., van Leeuwen, M. A. H., Roolvink, V., Kedhi, E., Klungel, O., Belitser, S. V., Angiolillo, D. J., Pustjens, T., Rasoul, S., Gho, B., Stein, M., ... van 't Hof, A. W. J. (2022). Impact of opioids on P2Y12 receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial. European Heart Journal - Cardiovascular Pharmacotherapy, 8(1), 4-12. https://doi.org/10.1093/ehjcvp/pvaa095

2021

Wetenschappelijke publicaties

Tavenier, A. H., Hermanides, R. S., Ottervanger, J. P., Belitser, S. V., Klungel, O., Appelman, Y., van Leeuwen, M., & van 't Hof, A. (2021). Sex Differences in Platelet Reactivity in Patients With ST-Elevation Myocardial Infarction: A Sub-Analysis of the ON-TIME 3 Trial. Frontiers in Cardiovascular Medicine, 8, 1-9. [707814]. https://doi.org/10.3389/fcvm.2021.707814

ten Ham, R. M. T., Frederix, G. W. J., Wu, O., Goettsch, W., Leufkens, H. G. M., Klungel, O. H., & Hoekman, J. (Accepted/In press). Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England. Value in Health. https://doi.org/10.1016/j.jval.2021.09.012

Komen, J. J., Pottegård, A., Mantel-Teeuwisse, A. K., Forslund, T., Hjemdahl, P., Wettermark, B., Hellfritzsch, M., Hallas, J., Olesen, M., Bennie, M., Mueller, T., Voss, A., Schink, T., Haug, U., Kollhorst, B., Karlstad, Ø., Kjerpeseth, L. J., & Klungel, O. H. (2021). Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries. Europace, 23(11), 1722-1730. https://doi.org/10.1093/europace/euab091

Komen, J. J., Belitser, S. V., Wyss, R., Schneeweiss, S., Taams, A. C., Pajouheshnia, R., Forslund, T., & Klungel, O. H. (2021). Greedy caliper propensity score matching can yield variable estimates of the treatment-outcome association—A simulation study. Pharmacoepidemiology and Drug Safety, 30(7), 934-951. https://doi.org/10.1002/pds.5232

Lo Re, V., Klungel, O. H., Chan, K. A., Panozzo, C. A., Zhou, W., & Winterstein, A. G. (2021). Global covid-19 vaccine rollout and safety surveillance - How to keep pace. The BMJ, 373, 1-4. [n1416]. https://doi.org/10.1136/bmj.n1416

Klungel, O. H., & Pottegård, A. (2021). Strengthening international surveillance of vaccine safety. The BMJ, 374, 1-2. [n1994]. https://doi.org/10.1136/bmj.n1994

Sabaté, M., Vidal, X., Ballarin, E., Rottenkolber, M., Schmiedl, S., Grave, B., Huerta, C., Martin-Merino, E., Montero, D., Leon-Muñoz, L. M., Gasse, C., Moore, N., Droz, C., Lassalle, R., Aakjær, M., Andersen, M., De Bruin, M. L., Souverein, P., Klungel, O. H., ... Ibáñez, L. (2021). Adherence to Direct Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation: A Cross-National Comparison in Six European Countries (2008-2015). Frontiers in Pharmacology, 12, 1-14. [682890]. https://doi.org/10.3389/fphar.2021.682890

Bloem, L. T., Bot, R. E., Mantel-Teeuwisse, A. K., van der Elst, M. E., Sonke, G. S., Klungel, O. H., Leufkens, H. G. M., & Hoekman, J. (2021). Pre-approval and post-approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: a comparison with standard approved cancer drugs. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15141

Røikjer, J., Werkman, N. C. C., Ejskjaer, N., van den Bergh, J. P. W., Vestergaard, P., Schaper, N. C., Jensen, M. H., Klungel, O., de Vries, F., Nielen, J. T. H., & Driessen, J. H. M. (2021). Incidence, hospitalization and mortality and their changes over time in people with a first ever diabetic foot ulcer. Diabetic Medicine, 1-10. [14725]. https://doi.org/10.1111/dme.14725

Komen, J. J., Forslund, T., Mantel-Teeuwisse, A. K., Klungel, O. H., Von Euler, M., Braunschweig, F., Wallén, H., & Hjemdahl, P. (2021). Response to: Kumar N, Ahmed M. Letter to the editor in response to Komen et al. 2021. European Heart Journal - Cardiovascular Pharmacotherapy, 7(3), E31. https://doi.org/10.1093/ehjcvp/pvab028

Komen, J., Pottegård, A., Hjemdahl, P., Mantel-Teeuwisse, A. K., Wettermark, B., Hellfritzsch, M., Hallas, J., Herings, R., Smits, L., Forslund, T., & Klungel, O. (2021). Non-vitamin K antagonist oral anticoagulants, proton pump inhibitors and gastrointestinal bleeds. Heart, 1-6. [319332]. https://doi.org/10.1136/heartjnl-2021-319332

Bloem, L. T., Karomi, M., Hoekman, J., van der Elst, M. E., Leufkens, H. G. M., Klungel, O. H., & Mantel-Teeuwisse, A. K. (2021). Comprehensive evaluation of post-approval regulatory actions during the drug lifecycle–a focus on benefits and risks. Expert Opinion on Drug Safety, 20(11), 1433-1442. https://doi.org/10.1080/14740338.2021.1952981

van Dalem, J., Driessen, J. H. M., Burden, A. M., Stehouwer, C. D. A., Klungel, O. H., de Vries, F., & Brouwers, M. C. G. J. (2021). Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study. Hepatology, 74(5), 2467-2477. https://doi.org/10.1002/hep.32012

van den Ham, H. A., Souverein, P. C., Klungel, O. H., Platt, R. W., Ernst, P., Dell'Aniello, S., Schmiedl, S., Grave, B., Rottenkolber, M., Huerta, C., Martín Merino, E., León-Muñoz, L. M., Montero, D., Andersen, M., Aakjær, M., De Bruin, M. L., & Gardarsdottir, H. (2021). Major bleeding in users of direct oral anticoagulants in atrial fibrillation: A pooled analysis of results from multiple population-based cohort studies. Pharmacoepidemiology and Drug Safety, 30(10), 1339-1352. https://doi.org/10.1002/pds.5317

Hempenius, M., Groenwold, R. H. H., de Boer, A., Klungel, O. H., & Gardarsdottir, H. (2021). Drug exposure misclassification in pharmacoepidemiology: sources and relative impact. Pharmacoepidemiology and Drug Safety, 30(12), 1703-1715. https://doi.org/10.1002/pds.5346

Bloem, L. T., Vreman, R. A., Peeters, N. W. L., Hoekman, J., van der Elst, M. E., Leufkens, H. G. M., Klungel, O. H., Goettsch, W. G., & Mantel-Teeuwisse, A. K. (2021). Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies. Clinical and Translational Science, 14(4), 1566-1577. https://doi.org/10.1111/cts.13027

van Dalem, J., Cgj Brouwers, M., Burden, A. M., DA Stehouwer, C., Klungel, O. H., de Vries, F., & Hm Driessen, J. (2021). Determinants of treatment modification before and after implementation of the updated 2015 NICE guideline on type 2 diabetes: A retrospective cohort study. Diabetes Research and Clinical Practice, 176, 1-14. [108828]. https://doi.org/10.1016/j.diabres.2021.108828

Hunt, N. B., Gardarsdottir, H., Bazelier, M. T., Klungel, O. H., & Pajouheshnia, R. (2021). A Systematic Review of How Missing Data are Handled and Reported in Multi-Database Pharmacoepidemiologic studies. Pharmacoepidemiology and Drug Safety, 30(7), 819-826. https://doi.org/10.1002/pds.5245

The Santeon NSCLC Study Group (2021). Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands. Scientific Reports, 11(1), [6306]. https://doi.org/10.1038/s41598-021-85696-3

Abedian, S., Abbasi, A., de Boer, A., Stricker, B. H., Bakker, S. J. L., van der Harst, P., Sedaghat, S., Darvishian, M., Ikram, M. A., Navis, G., Dehghan, A., Pen, I., Stolk, R. P., Snieder, H., Klungel, O. H., Souverein, P., & Alizadeh, B. Z. (2021). Effect of metabolic genetic variants on long-term disease comorbidity in patients with type 2 diabetes. Scientific Reports, 11(1), [2794]. https://doi.org/10.1038/s41598-021-82276-3

ten Ham, R. M. T., Nievaart, J. C., Hoekman, J., Cooper, R. S., Frederix, G. W. J., Leufkens, H. G. M., Klungel, O. H., Ovelgönne, H., Hoefnagel, M. H. N., Turner, M. L., & Mountford, J. C. (2021). Estimation of manufacturing development costs of cell-based therapies: a feasibility study. Cytotherapy, 23(8), 730-739. https://doi.org/10.1016/j.jcyt.2020.12.014

Hempenius, M., Groenwold, R. H. H., Souverein, P. C., de Boer, A., Klungel, O. H., & Gardarsdottir, H. (2021). Impact of anticoagulant exposure misclassification on the bleeding risk of direct oral anticoagulants. British Journal of Clinical Pharmacology, 87(9), 3508-3517. https://doi.org/10.1111/bcp.14764

Cramer-van der Welle, C. M., Schramel, F. M. N. H., Peters, B. J. M., van Putten, J. W. G., Klungel, O. H., Groen, H. J. M., & van de Garde, E. M. W. (2021). Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in extensive disease small cell lung cancer. Pharmacoepidemiology and Drug Safety, 30(4), 445-450. https://doi.org/10.1002/pds.5179

Werkman, N. C. C., Nielen, J. T. H., van den Bergh, J. P. W., Ejskjaer, N., Røikjer, J., Schaper, N. C., Rossi, B., Klungel, O., Vestergaard, P., de Vries, F., & Driessen, J. H. M. (2021). Use of Sodium-Glucose Co-Transporter-2-Inhibitors (SGLT2-Is) and Risk of Lower Limb Amputation. Current Drug Safety, 16(1), 62-72. https://doi.org/10.2174/1574886315666200805103053

Komen, J. J., Forslund, T., Mantel-Teeuwisse, A. K., Klungel, O. H., von Euler, M., Braunschweig, F., Wallén, H., & Hjemdahl, P. (2021). Association of preceding antithrombotic therapy in atrial fibrillation patients with ischaemic stroke, intracranial haemorrhage, or gastrointestinal bleed and mortality. European heart journal. Cardiovascular pharmacotherapy, 7(1), 3–10. https://doi.org/10.1093/ehjcvp/pvz063

2020

Wetenschappelijke publicaties

Werkman, N., van Dalem, J., Driessen, J., Rossi, B., Vestergaard, P., van den Bergh, J., Eastell, R., Burden, A., Rasmussen, N., Klungel, O., Brouwers, M., & de Vries, F. (2020). Use of Sodium-glucose Co-transporter-2 Inhibitors, Changes in Body Mass Index and Risk of Fracture in the United Kingdom (UK). Journal of Bone and Mineral Research, 35, 31-31.

Komen, J. J., Heerdink, E. R., Klungel, O. H., Mantel-Teeuwisse, A. K., Forslund, T., Wettermark, B., & Hjemdahl, P. (2020). Long-term persistence and adherence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk. European heart journal. Cardiovascular pharmacotherapy, 7(FI1), f72-f80. https://doi.org/10.1093/ehjcvp/pvaa017

Platt, R. W., Platt, R., Brown, J. S., Henry, D. A., Klungel, O. H., & Suissa, S. (2020). How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias. Pharmacoepidemiology and Drug Safety, 29(S1), 3-7. https://doi.org/10.1002/pds.4722

Pottegård, A., Kurz, X., Moore, N., Christiansen, C. F., & Klungel, O. (2020). Considerations for pharmacoepidemiological analyses in the SARS-CoV-2 pandemic. Pharmacoepidemiology and Drug Safety, 29(8), 825-831. https://doi.org/10.1002/pds.5029

Geenen, J. W., Belitser, S. V., Vreman, R. A., van Bloois, M., Klungel, O. H., Boersma, C., & Hövels, A. M. (2020). A novel method for predicting the budget impact of innovative medicines: validation study for oncolytics. European Journal of Health Economics, 21(6), 845-853. https://doi.org/10.1007/s10198-020-01176-x

Ilomäki, J., Bell, J. S., Chan, A. Y. L., Tolppanen, A. M., Luo, H., Wei, L., Lai, E. C. C., Shin, J. Y., De Paoli, G., Pajouheshnia, R., Ho, F. K., Reynolds, L., Lau, K. K., Crystal, S., Lau, W. C. Y., Man, K. K. C., Brauer, R., Chan, E. W., Shen, C. Y., ... Wong, I. C. K. (2020). Application of Healthcare ‘Big Data’ in CNS Drug Research: The Example of the Neurological and mental health Global Epidemiology Network (NeuroGEN). CNS Drugs, 34(9), 897-913. https://doi.org/10.1007/s40263-020-00742-4

Mahmoodi, B. K., Tragante, V., Kleber, M. E., Holmes, M. V., Schmidt, A. F., McCubrey, R. O., Howe, L. J., Direk, K., Allayee, H., Baranova, E. V., Braund, P. S., Delgado, G. E., Eriksson, N., Gijsberts, C. M., Gong, Y., Hartiala, J., Heydarpour, M., Pasterkamp, G., Kotti, S., ... Patel, R. S. (2020). Association of factor v leiden with subsequent atherothrombotic events: A GENIUS-CHD study of individual participant data. Circulation, 142(6), 546-555. https://doi.org/10.1161/CIRCULATIONAHA.119.045526

Padmasawitri, T. I. A., Saragih, S. M., Frederix, G. W., Klungel, O., & Hövels, A. M. (2020). Managing Uncertainties Due to Limited Evidence in Economic Evaluations of Novel Anti-Tuberculosis Regimens: A Systematic Review. PharmacoEconomics - Open, 4(2), 223-233. https://doi.org/10.1007/s41669-019-0162-z

Geenen, J. W., Vreman, R. A., Boersma, C., Klungel, O. H., & Hövels, A. M. (2020). Increasing the information provided by probabilistic sensitivity analysis: The relative density plot. Cost Effectiveness and Resource Allocation, 18(1), [54]. https://doi.org/10.1186/s12962-020-00251-7

Roeikjer, J., de Vries, F., Ejskjaer, N., van den Bergh, J. P. W., Vestergaard, P., Schaper, N. C., Hasselstrom, M., Klungel, O., & Driessen, J. H. M. (2020). Incidence of first diabetic foot ulcer, hospitalisation and mortality in people with diabetes from the primary care setting in the United Kingdom. Diabetologia, 63(SUPPL 1), S398-S398.

van Veelen, A., Abtahi, S., Souverein, P., Driessen, J. H. M., Klungel, O. H., Dingemans, A-M., van Geel, R., de Vries, F., & Croes, S. (2020). Characteristics and study eligibility of British lung cancer patients for clinical trials evaluating targeted therapies (TTS) or immune checkpoint inhibitors (ICIS). Pharmacoepidemiology and Drug Safety, 29(suppl. 3), 46. [4663]. https://doi.org/10.1002/pds.5113-2

Driessen, J. H. M., van Dalem, J., Burden, A. M., Stehouwer, C. D. A., Klungel, O. H., de Vries, F., & Brouwers, M. C. G. J. (2020). Use of thiazolidinediones and glucagon-like peptide-1 receptor agonists and the risk of non-alcoholic fatty liver disease. Pharmacoepidemiology and Drug Safety, 29, 128-128.

Werkman, N., Nielen, Y., van den Berg, J., Ejskjaer, N., Roikjer, J., Schaper, N., Klungel, O., Vestergaard, P., de Vries, F., & Driessen, A. (2020). Use of sodium-glucose co-transporter-2-inhibitors and risk of lower limb amputation. Pharmacoepidemiology and Drug Safety, 29, 593-594.

Vreman, R. A., Bloem, L. T., van Oirschot, S., Hoekman, J., van der Elst, M. E., Leufkens, H. G., Klungel, O. H., Goettsch, W. G., & Mantel-Teeuwisse, A. K. (2020). The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs. International Journal of Health Policy and Management. https://doi.org/10.34172/ijhpm.2020.198

PE, PV consortium H. Gardarsdottir (2020). Prescribers' compliance with Summary of Product Characteristics of dabigatran, rivaroxaban and apixaban - a European comparative drug utilization study. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.13517

Bergmeijer, T. O., Yasmina, A., Vos, G. J. A., Janssen, P. W. A., Hackeng, C. M., Kelder, J. C., Verma, S. S., Ritchie, M. D., Gong, L., Klein, T. E., de Boer, A., Klungel, O. H., Berg, J. M. T., & Deneer, V. H. M. (2020). Effect of CYP3A4*22 and PPAR-α genetic variants on platelet reactivity in patients treated with clopidogrel and lipid-lowering drugs undergoing elective percutaneous coronary intervention. Genes, 11(9), 1-13. [1068]. https://doi.org/10.3390/genes11091068

ten Ham, R. M. T., Klungel, O. H., Leufkens, H. G. M., & Frederix, G. W. J. (2020). A Review of Methodological Considerations for Economic Evaluations of Gene Therapies and Their Application in Literature. Value in Health, 23(9), 1268-1280. https://doi.org/10.1016/j.jval.2020.04.1833

Althunian, T. A., de Boer, A., Mantel-Teeuwisse, A. K., Groenwold, R. H. H., Gispen-de Wied, C. C., Leufkens, H. G. M., & Klungel, O. H. (2020). Assessment of the Regulatory Dialogue Between Pharmaceutical Companies and the European Medicines Agency on the Choice of Noninferiority Margins. Clinical Therapeutics, 42(8), 1588-1594. https://doi.org/10.1016/j.clinthera.2020.06.004

Souverein, P. C., van den Ham, H. A., Huerta, C., Merino, E. M., Montero, D., León-Muñoz, L. M., Schmiedl, S., Heeke, A., Rottenkolber, M., Andersen, M., Aakjaer, M., De Bruin, M. L., Klungel, O. H., & Gardarsdottir, H. (2020). Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.14450

Althunian, T. A., de Boer, A., Groenwold, R. H. H., Rengerink, K. O., Souverein, P. C., & Klungel, O. H. (2020). Rivaroxaban was found to be noninferior to warfarin in routine clinical care: A retrospective noninferiority cohort replication study. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5065

Ten Ham, R. M. T., Hövels, A. M., Hoekman, J., Frederix, G. W. J., Leufkens, H. G. M., Klungel, O. H., Jedema, I., Veld, S. A. J., Nikolic, T., Van Pel, M., Zwaginga, J. J., Lin, F., de Goede, A. L., Schreibelt, G., Budde, S., de Vries, I. J. M., Wilkie, G. M., Dolstra, H., Ovelgönne, H., ... Hoefnagel, M. H. N. (2020). What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings. Cytotherapy, 22(7), 388-397. https://doi.org/10.1016/j.jcyt.2020.03.432

Hempenius, M., Luijken, K., de Boer, A., Klungel, O., Groenwold, R., & Gardarsdottir, H. (2020). Quality of reporting of drug exposure in pharmacoepidemiological studies. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5020

Ten Ham, R. M. T., Hövels, A. M., Klungel, O. H., Leufkens, H. G. M., Broekmans, A. W., & Hoekman, J. (2020). Development and regulation of gene and cell-based therapies in Europe: a quantification and reflection. Trends in Pharmacological Sciences, 41(2), 67-71. https://doi.org/10.1016/j.tips.2019.11.007

Geenen, J. W., Jut, M., Boersma, C., Klungel, O. H., & Hövels, A. M. (2020). Affordability of oncology drugs: accuracy of budget impact estimations. Journal of market access & health policy, 8(1), [1697558]. https://doi.org/10.1080/20016689.2019.1697558

Komen, J. J., Hjemdahl, P., Mantel-Teeuwisse, A. K., Klungel, O. H., Wettermark, B., & Forslund, T. (2020). Concomitant Anticoagulant and Antidepressant Therapy in Atrial Fibrillation Patients and Risk of Stroke and Bleeding. Clinical Pharmacology and Therapeutics, 107(1), 287-294. https://doi.org/10.1002/cpt.1603

2019

Wetenschappelijke publicaties

Toh, S., Pratt, N., Klungel, O., Gagne, J. J., & Platt, R. W. (2019). Distributed networks of databases analyzed using common protocols and/or common data models. In Pharmacoepidemiology (pp. 617-638). Wiley-Blackwell. https://doi.org/10.1002/9781119413431.ch25

Langan, S. M., Schmidt, S. A. J., Wing, K., Ehrenstein, V., Nicholls, S. G., Filion, K. B., Klungel, O., Petersen, I., SØrensen, H. T., Dixon, W. G., Guttmann, A., Harron, K., Hemkens, L. G., Moher, D., Schneeweiss, S., Smeeth, L., Sturkenboom, M., Von Elm, E., Wang, S. V., & Benchimol, E. I. (2019). La déclaration RECORD-PE (Reporting of Studies Conducted Using Observational Routinely Collected Health Data Statement for Pharmacoepdemiology): directives pour la communication des études realisées à partir de données de santé observationelles collectées en routine en pharmacoépidémiologie. CMAJ, 191(25), E689-E708. https://doi.org/10.1503/cmaj.190347

Patel, R. S., Tragante, V., Schmidt, A. F., McCubrey, R. O., Holmes, M. V., Howe, L. J., Direk, K., Åkerblom, A., Leander, K., Virani, S. S., Kaminski, K. A., Muehlschlegel, J. D., Allayee, H., Almgren, P., Alver, M., Baranova, E. V., Behloui, H., Boeckx, B., Braund, P. S., ... Maitland-van der Zee, A. H. (2019). Subsequent Event Risk in Individuals With Established Coronary Heart Disease. Circulation. Genomic and precision medicine, 12(4), [e002470]. https://doi.org/10.1161/CIRCGEN.119.002470

CARDIoGRAMPlusC4D Consortium (2019). Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. Circulation. Genomic and precision medicine, 12(4), [e002471]. https://doi.org/10.1161/CIRCGEN.119.002471

Geenen, J. W., Boersma, C., Klungel, O. H., & Hövels, A. M. (2019). Accuracy of budget impact estimations and impact on patient access: a hepatitis C case study. European Journal of Health Economics, 20(6), 857-867. https://doi.org/10.1007/s10198-019-01048-z

Pottegård, A., Klungel, O., Winterstein, A., Huybrechts, K., Hallas, J., Schneeweiss, S., Evans, S., Bate, A., Pont, L., Trifirò, G., Smith, M., & Bourke, A. (2019). The International Society for Pharmacoepidemiology's Comments on the Core Recommendations in the Summary of the Heads of Medicines Agencies (HMA) - EMA Joint Big Data Task Force. Pharmacoepidemiology and Drug Safety, 28(12), 1640-1641. https://doi.org/10.1002/pds.4911

ten Ham, R., Leufkens, H. G., Klungel, O. H., & Fredrix, G. (2019). PBI75 Review of Economic Evaluations for gene therapies: are we ready for the future? Value in Health, 22(supplement 3), [S431]. https://doi.org/10.1016/j.jval.2019.09.179

Souverein, P. C., Van Den Ham, H. A., Huerta, C., Merino, E. M., Montero, D., León-Muñoz, L. M., Schmiedl, S., Rottenkolber, M., Andersen, M., Aakjær, M., De Bruin, M. L., Klungel, O. H., & Gardarsdottir, H. (2019). Risk of major bleeding associated with the use of direct oral anticoagulants compared to vitamin K antagonists in patients with atrial fibrillation: A European multicountry population-based cohort study. Pharmacoepidemiology and Drug Safety, 28(S2), 553-553. https://doi.org/10.1002/pds.4864

Pajouheshnia, R., Gardarsdottir, H., Platt, R., Toh, D., & Klungel, O. (2019). Analysis of data from distributed pharmacoepidemiologic networks. Pharmacoepidemiology and Drug Safety, 28(S2), 414. https://doi.org/10.1002/pds.4864

Van Den Ham, H., Souverein, P., Klungel, O., Platt, R., Ernst, P., Dell'Aniello, S., Schmiedl, S., Grave, B., Rottenkolber, M., Huerta, C., Merino, E. M., León-Muñoz, L., Montero, D., Andersen, M., Aakjær, M., De Bruin, M., & Gardarsdottir, H. (2019). Risk of major bleeding associated with the use of individual direct oral anticoagulants compared to vitamin K antagonists in patients with non-valvular atrial fibrillation: A metaanalysis of results from multiple population based cohort studies using a common protocol in Europe and Canada. Pharmacoepidemiology and Drug Safety, 28(S2), 410-411. https://doi.org/10.1002/pds.4864

Rottenkolber, M., Schmiedl, S., Ibanez, L., Sabaté, M., Ballarín, E., Vidal, X., Leon-Munoz, L. M., Huerta, C., Martin Merino, E., Montero, D., Gasse, C., Andersen, M., Aakjær, M., De Bruin, M. L., Gerlach, R., Tauscher, M., Souverein, P. C., Van Den Ham, R., Klungel, O., & Gardarsdottir, H. (2019). Prescribers' compliance with SmPC recommendations for dabigatran, rivaroxaban, and Apixaban: A European comparative drug utilization study. Pharmacoepidemiology and Drug Safety, 28(S2), 148-149. https://doi.org/10.1002/pds.4864

Ibanez, L., Sabaté, M., Vidal, X., Ballarín, E., Rottenkolber, M., Schmiedl, S., Heeke, A., Huerta, C., Merino, E. M., Montero, D., Leon-Muñoz, L. M., Gasse, C., Moore, N., Droz, C., Lassalle, R., Aakjaer, M., Andersen, M., De Bruin, M. L., Groenwold, R., ... Gardarsdottir, H. (2019). Incidence of direct oral anticoagulation use for non valvular atrial fibrillation and characteristics of users in six European countries (2008-2015): A cross-national drug utilization study. Pharmacoepidemiology and Drug Safety, 28(S2), 397. https://doi.org/10.1002/pds.4864

Sabaté Gallego, M., Ibáñez Mora, L., Vidal Guitart, X., Ballarin Alins, E., Rottenkolber, M., Schmiedl, S., Heeke, A., Huerta, C., Martin Merino, E., Montero, D., León-Muñoz, L. M., Gasse, C., Moore, N., Droz, C., Lassalle, R., Aakjaer, M., Andersen, M., De Briun, M., Groenwold, R., ... Gardarsdottir, H. (2019). Adherence to direct oral anticoagulants in patients with non-valvular atrial fibrillation cross-national comparison in six european countries. European Journal of Clinical Pharmacology, 75, 27-28. https://doi.org/10.1007/s00228-019-02685-2

Hempenius, M., Luijken, K., De Boer, A., Klungel, O. H., Groenwold, R. H. H., & Gardarsdottir, H. (2019). Current practice in reporting exposure in pharmacoepidemiological studies. 428. Abstract from 35th International conference on Pharmacoepidemiology & therapeutic risk management., Philapdelphia, Pennsylvania, United States. https://doi.org/10.1002/pds.4864

Althunian, T. A. I., De Boer, A., Groenwold, R. H. H., Rengerink, K. O., Souverein, P. C., & Klungel, O. H. (2019). Replication of rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation in a cohort study using electronic primary care database. Pharmacoepidemiology and Drug Safety, 28(S2), 57-58. https://doi.org/10.1002/pds.4864

Ibáñez, L., Sabaté, M., Vidal, X., Ballarin, E., Rottenkolber, M., Schmiedl, S., Heeke, A., Huerta, C., Martin Merino, E., Montero, D., Leon-Muñoz, L. M., Gasse, C., Moore, N., Droz, C., Lassalle, R., Aakjær, M., Andersen, M., De Bruin, M. L., Groenwold, R., ... Gardarsdottir, H. (2019). Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008–2015): A cross-national drug utilization study. British Journal of Clinical Pharmacology, 85(11), 2524-2539. https://doi.org/10.1111/bcp.14071

Bakhriansyah, M., Souverein, P. C., van den Hoogen, M. W. F., de Boer, A., & Klungel, O. H. (2019). Risk of Nephrotic Syndrome for Non-Steroidal Anti-Inflammatory Drug Users. Clinical journal of the American Society of Nephrology : CJASN, 14(9), 1355-1362. https://doi.org/10.2215/CJN.14331218

Hempenius, M., Groenwold, R. H. H., de Boer, A., Klungel, O. H., & Gardarsdottir, H. (2019). Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions. Pharmacoepidemiology and Drug Safety, 28(12), 1563-1571. https://doi.org/10.1002/pds.4851

Makady, A., van Acker, S., Nijmeijer, H., de Boer, A., Hillege, H., Klungel, O., & Goettsch, W. (2019). Conditional Financing of Drugs in the Netherlands: Past, Present, and Future-Results From Stakeholder Interviews. Value in Health, 22(4), 399-407. https://doi.org/10.1016/j.jval.2018.11.016

Bakhriansyah, M., Meyboom, R. H. B., Souverein, P. C., de Boer, A., & Klungel, O. H. (2019). Cyclooxygenase selectivity and chemical groups of non-steroidal anti-inflammatory drugs and the frequency of reporting hypersensitivity reactions: a case/non-case study in VigiBase. Fundamental and Clinical Pharmacology, 33(5), 589-600. https://doi.org/10.1111/fcp.12463

Bakhriansyah, M., Souverein, P. C., de Boer, A., & Klungel, O. H. (2019). Risk of myocardial infarction associated with non-steroidal anti-inflammatory drugs: Impact of additional confounding control for variables collected from self-reported data. Journal of Clinical Pharmacy and Therapeutics, 44(4), 623-631. https://doi.org/10.1111/jcpt.12836

Bloem, L. T., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., De Bruin, M. L., Klungel, O. H., & Hoekman, J. (2019). Postauthorization Changes to Specific Obligations of Conditionally Authorized Medicines in the European Union: A Retrospective Cohort Study. Clinical Pharmacology and Therapeutics, 105(2), 426-435. https://doi.org/10.1002/cpt.1169

Nielen, J. T. H., Dagnelie, P. C., Boonen, A., Klungel, O., van den Bemt, B., & de Vries, F. (2019). Impact of the definition of osteoarthritis and of the timing of its onset on the association between type 2 diabetes mellitus and osteoarthritis: Clinical Practice Research Datalink. Diabetes Research and Clinical Practice, 148, 240-248. https://doi.org/10.1016/j.diabres.2019.01.021

Makady, A., van Veelen, A., de Boer, A., Hillege, H., Klungel, O. H., & Goettsch, W. (2019). Implementing managed entry agreements in practice: The Dutch reality check. Health Policy, 123(3), 267-274. https://doi.org/10.1016/j.healthpol.2018.09.016

Bakhriansyah, M., Souverein, P. C., Klungel, O. H., de Boer, A., Blom, M. T., & Tan, H. L. (2019). Non-steroidal anti-inflammatory drugs and the risk of out-of-hospital cardiac arrest: a case-control study. Europace, 21(1), 99-105. https://doi.org/10.1093/europace/euy180

2018

Wetenschappelijke publicaties

De Jong, H. J. I., Tervaert, J. W. C., Lalmohamed, A., De Vries, F., Vandebriel, R. J., Van Loveren, H., Klungel, O. H., & Van Staa, T. P. (2018). Pattern of risks of rheumatoid arthritis among patients using statins: A cohort study with the clinical practice research datalink. PLoS One. https://doi.org/10.1371/journal.pone.0193297

Geenen, J. W., Vreman, R., ten Ham, R. M., Boersma, C., Klungel, O., & Hovels, A. M. (2018). A NEW GRAPHICAL REPRESENTATION OF PROBABILITY SENSITIVITY ANALYSIS RESULTS AS AN ALTERNATIVE FOR THE SCATTER-PLOT. Value in Health, 21(S3), 381. https://doi.org/10.1016/j.jval.2018.09.2265

Klungel, O. H. (2018). Pharmacoepidemiological approaches for population-based hypothesis testing. In Methods in Pharmacology and Toxicology (pp. 201-216). (Methods in Pharmacology and Toxicology). Humana Press. https://doi.org/10.1007/978-1-4939-8818-1_11

ten Ham, R. M., Hovels, A. M., Hoekman, J., Broekmans, A., Leufkens, H. G., & Klungel, O. (2018). CHALLENGES IN ACHIEVING MARKET ACCESS SUCCESS FOR ADVANCED THERAPIES IN EUROPE: A CASE STUDY. In ISPOR Europe 2018: New Perspectives for Improving 21st Century Health Systems (pp. 213) https://doi.org/10.1016/j.jval.2018.09.2868

Padmasawitri, T. I. A., Frederix, G. W., Alisjahbana, B., Klungel, O., & Hövels, A. M. (2018). Disparities in model-based cost-effectiveness analyses of tuberculosis diagnosis: A systematic review. PLoS One, 13(5), [e0193293]. https://doi.org/10.1371/journal.pone.0193293

Marees, A. T., Hammerschlag, A. R., Bastarache, L., de Kluiver, H., Vorspan, F., van den Brink, W., Smit, D. J., Denys, D., Gamazon, E. R., Li-Gao, R., Breetvelt, E. J., de Groot, M. C. H., Galesloot, T. E., Vermeulen, S. H., Poppelaars, J. L., Souverein, P. C., Keeman, R., de Mutsert, R., Noordam, R., ... Derks, E. M. (2018). Exploring the role of low-frequency and rare exonic variants in alcohol and tobacco use. Drug and Alcohol Dependence, 188, 94-101. https://doi.org/10.1016/j.drugalcdep.2018.03.026

Langan, S. M., Schmidt, S. A., Wing, K., Ehrenstein, V., Nicholls, S. G., Filion, K. B., Klungel, O., Petersen, I., Sorensen, H. T., Dixon, W. G., Guttmann, A., Harron, K., Hemkens, L. G., Moher, D., Schneeweiss, S., Smeeth, L., Sturkenboom, M., von Elm, E., Wang, S. V., & Benchimol, E. I. (2018). The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). British Medical Journal, 363, [k3532]. https://doi.org/10.1136/bmj.k3532

Makady, A., De Boer, A., Hillege, H., Klungel, O., & Goettsch, W. (2018). What is real-world data? A review of definitions based on literature and stakeholder interviews. 410. Abstract from 34th International conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague, Czech Republic. https://doi.org/10.1002/pds.4629

Santeon NSCLC Study Group (2018). Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer. European Respiratory Journal, 52(6), [1801100]. https://doi.org/10.1183/13993003.01100-2018

Makady, A., Kalf, R. R. J., Ryll, B., Spurrier, G., De Boer, A., Hillege, H., Klungel, O. H., & Goettsch, W. (2018). Social media as a tool for assessing patient perspectives on quality of life in metastatic melanoma: A feasibility study 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis. Health and Quality of Life Outcomes, 16(1), [222]. https://doi.org/10.1186/s12955-018-1047-z

Klungel, O., Bakhriansyah, M., Meijboom, R., Souverein, P., & De Boer, A. (2018). Cox selectivity and chemical subgroup of non-steroidal anti-inflammatory drugs and frequency of spontaneous reporting of hypersensitivity reactions. Drug Safety, 41(11), 1166. https://doi.org/10.1007/s40264-018-0719-2

Klungel, O., Alharbi, F., De Boer, A., & Kholod, A. (2018). The impact of sex on the associations between ace inhibitors and cough and angioedema: A systematic review and meta-analysis. Drug Safety, 41(11), 1165. https://doi.org/10.1007/s40264-018-0719-2

ten Ham, R. M. T., Hoekman, J., Hövels, A. M., Broekmans, A. W., Leufkens, H. G. M., & Klungel, O. H. (2018). Challenges in Advanced Therapy Medicinal Products Development: A survey amongst companies in Europe. Molecular Therapy - Methods & Clinical Development, 11, 121-130. https://doi.org/10.1016/j.omtm.2018.10.003

Makady, A., Kalf, R., Ryll, B., Spurrier, G., De Boer, A., Hillege, H., Klungel, O., & Goettsch, W. (2018). Using social media to collect patient perspectives on quality of life: A feasibility study. Pharmacoepidemiology and Drug Safety, 27, 56. https://doi.org/10.1002/pds.4629

Bakhriansyah, M., Meyboom, R. H. B., Souverein, P. C., De Boer, A., & Klungel, O. H. (2018). Cyclooxygenase selectivity and chemical subgroup of non-steroidal anti-inflammatory drugs and frequency of spontaneous reporting of hypersensitivity reactions: A case/non-case study in Vigibase. Pharmacoepidemiology and Drug Safety, 27(S2), 264. https://doi.org/10.1002/pds.4629

Hempenius, M., Gardarsdottir, H., De Boer, A., Klungel, O., & Groenwold, R. (2018). Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions on risk estimation. Pharmacoepidemiology and Drug Safety, 27, 7. https://doi.org/10.1002/pds.4629

Alharbi, F., Kholod, A., De Boer, A. A., & Klungel, O. (2018). The impact of sex on the associations between ace inhibitors and cough and angioedema: A systematic review and metaanalysis. Pharmacoepidemiology and Drug Safety, 27(S2), 466. https://doi.org/10.1002/pds.4629

Althunian, T., De Boer, A., Mantel-Teeuwisse, A. K., Groenwold, R. H. H., Gispen-De Wied, C. C., Leufkens, H. G. M., Elferink, A., & Klungel, O. H. (2018). Regulatory challenges in the design of non-inferiority trials: Evaluating scientific advice letters from the European Medicines Agency (EMA). Pharmacoepidemiology and Drug Safety, 27(S2), 149. https://doi.org/10.1002/pds.4629

Althunian, T., De Boer, A., Groenwold, R. H. H., & Klungel, O. H. (2018). Using a single non-inferiority margin or a single preserved fraction for an entire pharmacological class may be invalid for the analysis of non-inferiority: A case study of statin non-inferiority trials. Pharmacoepidemiology and Drug Safety, 27(S2), 149. https://doi.org/10.1002/pds.4629

Althunian, T. A., de Boer, A., Groenwold, R. H. H., & Klungel, O. H. (2018). Using a single non-inferiority margin or preserved fraction for an entire pharmacological class was found to be inappropriate. Journal of Clinical Epidemiology, 104, 15-23. https://doi.org/10.1016/j.jclinepi.2018.07.004

de Jong, H. J. I., Tervaert, J. W. C., Lalmohamed, A., de Vries, F., Vandebriel, R. J., Van Loveren, H., Klungel, O. H., & van Staa, T. P. (2018). Pattern of risks of rheumatoid arthritis among patients using statins: A cohort study with the clinical practice research datalink. PLoS One, 13(2), [e0193297]. https://doi.org/10.1371/journal.pone.0193297

Bezin, J., Klungel, O. H., Lassalle, R., Dureau-Pournin, C., Moore, N. M., & Pariente, A. (2018). Medications Recommended for Secondary Prevention After First Acute Coronary Syndrome: Effectiveness of Treatment Combinations in a Real-Life Setting. Clinical Pharmacology and Therapeutics, 103(6), 1038-1046. https://doi.org/10.1002/cpt.864

Broekman, M. M. T. J., Coenen, M. J. H., Wanten, G. J. A., van Marrewijk, C. J., Kievit, W., Klungel, O. H., Verbeek, A. L. M., Wong, D. R., Hooymans, P. M., Guchelaar, H-J., Scheffer, H., Derijks, L. J. J., Bouvy, M. L., & de Jong, D. J. (2018). Patients' beliefs about medicine are associated with early thiopurine discontinuation in patients with inflammatory bowel diseases. European Journal of Gastroenterology and Hepatology, 30(2), 167-173. https://doi.org/10.1097/MEG.0000000000001025

Makady, A., van Veelen, A., Jonsson, P., Moseley, O., d'Andon, A., de Boer, A., Hillege, H., Klungel, O., & Goettsch, W. (2018). Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies. PharmacoEconomics, 36(3), 359–368. https://doi.org/10.1007/s40273-017-0596-z

van Dalem, J., Brouwers, M. C., Stehouwer, C. DA., Krings, A., Klungel, O. H., Driessen, J. H., de Vries, F., & Burden, A. M. (2018). Risk of a first ever acute myocardial infarction and all-cause mortality with sulphonylurea treatment: a population-based cohort study. Diabetes, Obesity and Metabolism, 20(4), 1056-1060. https://doi.org/10.1111/dom.13168

Broekman, M. M. T. J., Wong, D. R., Wanten, G. J. A., Roelofs, H. M., van Marrewijk, C. J., Klungel, O. H., Verbeek, A. L. M., Hooymans, P. M., Guchelaar, H-J., Scheffer, H., Derijks, L. J. J., Coenen, M. J. H., & de Jong, D. J. (2018). The glutathione transferase Mu null genotype leads to lower 6-MMPR levels in patients treated with azathioprine but not with mercaptopurine. Pharmacogenomics Journal, 18, 160–166. https://doi.org/10.1038/tpj.2016.87

2017

Wetenschappelijke publicaties

Wang, S. V., Schneeweiss, S., Berger, M. L., Brown, J., de Vries, F., Douglas, I., Gagne, J. J., Gini, R., Klungel, O., Mullins, C. D., Nguyen, M. D., Rassen, J. A., Smeeth, L., & Sturkenboom, M. (2017). Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. Value in Health, 20(8), 1009-1022. https://doi.org/10.1016/j.jval.2017.08.3018

Nijmeijer, H., van Veelen, A., De Boer, A., Hillege, H., Klungel, O., Goettsch, W., & Makady, A. (2017). Conditional financing in health technology assessment practice: The Dutch experience. International Journal of Technology Assessment in Health Care, 33, 42-43. https://search.proquest.com/openview/aa071a295fbfb195bcda188c62313717/1?pq-origsite=gscholar&cbl=36708

Hu, Y. J., Schmidt, A. F., Dudbridge, F., Holmes, M. V., Brophy, J. M., Tragante, V., Li, Z., Liao, P., Quyyumi, A. A., McCubrey, R. O., Horne, B. D., Hingorani, A. D., Asselbergs, F. W., Patel, R. S., Long, Q., Åkerblom, A., Algra, A., Allayee, H., Almgren, P., ... on behalf of the GENIUS-CHD Consortium (2017). Impact of Selection Bias on Estimation of Subsequent Event Risk. Circulation: Cardiovascular Genetics, 10(5), [e001616]. https://doi.org/10.1161/CIRCGENETICS.116.001616

Ankarfeldt, M. Z., Thorsted, B. L., Groenwold, R. H., Adalsteinsson, E., Ali, M. S., & Klungel, O. H. (2017). Assessment of channeling bias among initiators of glucose-lowering drugs: A UK cohort study. Journal of Clinical Epidemiology, 9, 19-30. https://doi.org/10.2147/CLEP.S124054

Ankarfeldt, M. Z., Adalsteinsson, E., Groenwold, R. H., Ali, M. S., & Klungel, O. H. (2017). A systematic literature review on the efficacy-effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs. Journal of Clinical Epidemiology, 9, 41-51. https://doi.org/10.2147/CLEP.S121991

Wing, K., Bhaskaran, K., Pealing, L., Root, A., Smeeth, L., van Staa, T. P., Klungel, O. H., Reynolds, R. F., & Douglas, I. (2017). Quantification of the risk of liver injury associated with flucloxacillin: a UK population-based cohort study. Journal of Antimicrobial Chemotherapy, 72(9), 2636-2646. https://doi.org/10.1093/jac/dkx183

Broekman, M. M. T. J., Coenen, M. J. H., van Marrewijk, C. J., Wanten, G. J. A., Wong, D. R., Verbeek, A. L. M., Klungel, O. H., Hooymans, P. M., Guchelaar, H-J., Scheffer, H., Derijks, L. J. J., & De Jong, D. J. (2017). More Dose-dependent Side Effects with Mercaptopurine over Azathioprine in IBD Treatment Due to Relatively Higher Dosing. Inflammatory Bowel Diseases, 23(10), 1873-1881. https://doi.org/10.1097/MIB.0000000000001163

Broekman, M. M. T. J., Coenen, M. J. H., Wanten, G. J. A., van Marrewijk, C. J., Klungel, O. H., Verbeek, A. L. M., Hooymans, P. M., Guchelaar, H. J., Scheffer, H., Derijks, L. J. J., Wong, D. R., & de Jong, D. J. (2017). Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype. Alimentary Pharmacology and Therapeutics, 46(10), 953-963. https://doi.org/10.1111/apt.14323

Yasmina, A., Bergmeijer, T. O., Janssen, P. W. A., Vos, G. J. A., Hackeng, C. M., De Boer, A., Klungel, O. H., Ten Berg, J. M., & Deneer, V. H. M. (2017). PPAR-α genetic variants influence on-treatment platelet reactivity in patients treated with clopidogrel and lipid-lowering drugs and undergoing non-urgent percutaneous coronary intervention with stent implantation. Pharmacoepidemiology and Drug Safety, 26(S2), 261-262. https://doi.org/10.1002/pds.4275

Bakhriansyah, M., Souverein, P., De Boer, A., & Klungel, O. H. (2017). The risk of acute myocardial infarction associated with non-steroidal anti-inflammatory drugs users: Impact of additional confounding control for variables collected from self-reported data. Pharmacoepidemiology and Drug Safety, 26(S2), 89. https://doi.org/10.1002/pds.4275

Rahman, N. A. B., Yasmina, A., De Boer, A., Deneer, V. H. M., Souverein, P. C., & Klungel, O. H. (2017). Patterns of antiplatelet therapy in patients with ischaemic stroke or transient ischaemic attack. Pharmacoepidemiology and Drug Safety, 26, 495. https://doi.org/10.1002/pds.4275

Makady, A., van Veelen, P. A., Jonsson, P. V., Moseley, O., d'Andon, A., De Boer, A., Hillege, J. L., Klungel, O., & Goettsch, W. (2017). Using real-world data (RWD) in health technology assessment (HTA) practice: A comparative study of 5 HTA agencies. Value in Health, 20(9), 401. https://doi.org/10.1016/j.jval.2017.08.017

Alharbi, F. F., Kholod, A. A. V., Souverein, P. C., Meijboom, R., de Groot, M. C. H., de Boer, A., & Klungel, O. H. (2017). The impact of age and sex on the reporting of cough and angioedema with renin-angiotensin system inhibitors: a case/noncase study in VigiBase. Fundamental and Clinical Pharmacology, 31(6), 676-684. https://doi.org/10.1111/fcp.12313

Wang, S. V., Schneeweiss, S., Berger, M. L., Brown, J., de Vries, F., Douglas, I., Gagne, J. J., Gini, R., Klungel, O., Mullins, C. D., Nguyen, M. D., Rassen, J. A., Smeeth, L., Sturkenboom, M. C. J. M., & on behalf of the joint ISPE‐ISPOR Special Task Force on Real World Evidence in Health Care Decision Making (2017). Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. Value in Health, 20(8), 1009-1022. https://doi.org/10.1016/j.jval.2017.08.3018

Wang, S. V., Schneeweiss, S., Berger, M. L., Brown, J., de Vries, F., Douglas, I., Gagne, J. J., Gini, R., Klungel, O., Mullins, C. D., Nguyen, M. D., Rassen, J. A., Smeeth, L., Sturkenboom, M. C. J. M., & on behalf of the joint ISPE-ISPOR Special Task Force on Real World Evidence in Health Care Decision Making (2017). Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. Pharmacoepidemiology and Drug Safety, 26(9), 1018-1032. https://doi.org/10.1002/pds.4295

De Jong, H. J. I., van Staa, T. P., Lalmohamed, A., de Vries, F., Vandebriel, R. J., Van Loveren, H., Klungel, O. H., & Cohen Tervaert, J. W. (2017). Pattern of risks of systemic lupus erythematosus among statin users: a population-based cohort study. Annals of the Rheumatic Diseases, 76(10), 1723–1730. https://doi.org/10.1136/annrheumdis-2016-210936

Alharbi, F. F., Souverein, P. C., de Groot, M. C. H., Blom, M. T., de Boer, A., Klungel, O. H., & Tan, H. L. (2017). The Impact of Serum Potassium-Influencing Antihypertensive Drugs on the Risk of Out-of-Hospital Cardiac Arrest: A Case Control Study. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.13356

Makady, A., de Boer, A., Hillege, H., Klungel, O., & Goettsch, W. (2017). What Is Real-World Data (RWD)? A Review of Definitions Based on Literature and Stakeholder Interviews. Value in Health, 20(7), 858-865. https://doi.org/10.1016/j.jval.2017.03.008

Makady, A., Ham, R. T., de Boer, A., Hillege, H., Klungel, O., Goettsch, W., & GetReal Workpackage 1 (2017). Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies. Value in Health, 20(4), 520-532. https://doi.org/10.1016/j.jval.2016.12.003

Bakhriansyah, M., Souverein, P. C., de Boer, A., & Klungel, O. H. (2017). Gastrointestinal toxicity among patients taking selective COX-2 inhibitors or conventional NSAIDs, alone or combined with proton pump inhibitors: a case-control study. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.4183

Alharbi, F. F., Souverein, P. C., de Groot, M. C., Maitland-van der Zee, A. H., de Boer, A., & Klungel, O. H. (2017). Risk of acute myocardial infarction after discontinuation of antihypertensive agents: a case-control study. Journal of Human Hypertension. https://doi.org/10.1038/jhh.2017.1

Althunian, T. A., de Boer, A., Groenwold, R. H. H., & Klungel, O. H. (2017). Defining the non-inferiority margin and analyzing non-inferiority: An overview. British Journal of Clinical Pharmacology, 83(8), 1636-1642. https://doi.org/10.1111/bcp.13280

Althunian, T. A., de Boer, A., Klungel, O. H., Insani, W. N., & Groenwold, R. H. H. (2017). Methods of defining the non-inferiority margin in randomized, double-blind controlled trials: a systematic review. Trials, 18(107), 1-9. https://doi.org/10.1186/s13063-017-1859-x

Bezin, J., Groenwold, R., Ali, M. S., Lassalle, R., Robinson, P., de Boer, A., Moore, N., Klungel, O. H., & Pariente, A. (2017). Comparative effectiveness of recommended versus less intensive drug combinations in secondary prevention of acute coronary syndrome. Pharmacoepidemiology and Drug Safety, 26(3), 285-293. https://doi.org/10.1002/pds.4171

Wong, D. R., Coenen, M. J. H., Derijks, L. J. J., Vermeulen, S. H., van Marrewijk, C. J., Klungel, O. H., Scheffer, H., Franke, B., Guchelaar, H-J., de Jong, D. J., Engels, L. G. J. B., Verbeek, A. L., Hooymans, P. M., & TOPIC Recruitment Team (2017). Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 45(3), 391-402. https://doi.org/10.1111/apt.13879

Yasmina, A., de Boer, A., Deneer, V. H. M., Souverein, P. C., & Klungel, O. H. (2017). Patterns of antiplatelet drug use after a first myocardial infarction during a 10-years period. British Journal of Clinical Pharmacology, 83(3), 632-641. https://doi.org/10.1111/bcp.13139

Wong, D. R., Coenen, M. J. H., Vermeulen, S. H., Derijks, L. J. J., van Marrewijk, C. J., Klungel, O. H., Scheffer, H., Franke, B., Guchelaar, H-J., de Jong, D. J., Engels, L. G. J. B., Verbeek, A. L. M., & Hooymans, P. M. (2017). Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-Induced Leukopenia in Inflammatory Bowel Disease. Journal of Crohn's & Colitis, 11(2), 175-184. https://doi.org/10.1093/ecco-jcc/jjw130

Overige resultaten

Yasmina, A., De Boer, A., Deneer, V. H. M., Ten Berg, J. M., Groenwold, R. H. H., Souverein, P. C., & Klungel, O. H. (2017). Comparative effectiveness and safety of antiplatelet drug regimens as secondary prevention after ischemic stroke or transient ischemic attack. 490-491. Abstract from 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management. https://doi.org/10.1002/pds.4275

Bloem, L. T., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., De Bruin, M. L., Klungel, O. H., & Hoekman, J. (2017). Risk factors associated with post-marketing changes in specific obligations of conditionally authorised products in the EU. Pharmacoepidemiology and Drug Safety, 26, 605. https://doi.org/10.1002/pds.4275

2016

Wetenschappelijke publicaties

Van Den Ham, H. A., Klungel, O. H., Singer, D. E., Leufkens, H. G. M., & Van Staa, T. P. (2016). Reply Comparing the ATRIA, CHADS2, and CHA2DS2-VASc Scores for Stroke Prediction in Atrial Fibrillation. Journal of the American College of Cardiology, 67(19), 2317-2318. https://doi.org/10.1016/j.jacc.2016.01.085

Althunian, T. A. I., De Boer, A., Klungel, O. H., Insani, W. N., & Groenwold, R. H. H. (2016). Methods of defining the noninferiority margin: A systematic review. Pharmacoepidemiology and Drug Safety, 25, 139-140. https://doi.org/10.1002/pds.4070

Alharbi, F. F., Kholod, A. A. V., Souverein, P. C., Meyboom, R. H., de Groot, M., De Boer, A., & Klungel, O. H. (2016). A novel approach to study the impact of ethnicity on reporting of cough/angioedema with RAS inhibitors in VigiBase. Pharmacoepidemiology and Drug Safety, 25(S3), 443-44. [763]. https://doi.org/10.1002/pds.4070

Alharbi, F. F., Kholod, A. A. V., Souverein, P. C., Meyboom, R. H., de Groot, M., De Boer, A., & Klungel, O. H. (2016). The impact of age and gender on reporting of cough and angioedema with RAS inhibitors: A case/non-case in VigiBase. Pharmacoepidemiology and Drug Safety, 25, 442. [762]. https://doi.org/10.1002/pds.4070

Ali, M. S., Groenwold, R. H., & Klungel, O. H. (2016). Best (but oft-forgotten) practices: propensity score methods in clinical nutrition research. American Journal of Clinical Nutrition, 104(2), 247-58. https://doi.org/10.3945/ajcn.115.125914

Wing, K., Bhaskaran, K., Smeeth, L., van Staa, T. P., Klungel, O. H., Reynolds, R. F., & Douglas, I. (2016). Optimising case detection within UK electronic health records: use of multiple linked databases for detecting liver injury. BMJ Open, 6(9), 1-12. [e012102]. https://doi.org/10.1136/bmjopen-2016-012102

Klungel, O. H., Kurz, X., de Groot, M. C. H., Schlienger, R. G., Tcherny-Lessenot, S., Grimaldi, L., Ibáñez, L., Groenwold, R. H. H., Reynolds, R. F., Alvarez, Y., Candore, G., Durand, J., Slattery, J., Hasford, J., Rottenkolber, M., Schmiedl, S., de Abajo Iglesias, F., Gil, M., Gonzalez, R., ... On behalf of the members of work-package 2 of PROTECT (2016). Multi-centre, multi-database studies with common protocols: Lessons learnt from the IMI PROTECT project. Pharmacoepidemiology and Drug Safety, 25(supplement S1), 156-165. https://doi.org/10.1002/pds.3968

De Groot, M. C. H., Candore, G., Uddin, J., Souverein, P., Ali, M. S., Belitser, S., Huerta, C., Groenwold, R. H. H., Alvarez, Y., Slattery, J., Korevaar, J., Hoes, A. W., Roes, K. C. B., de Boer, A., Douglas, I. J., Schlienger, R. G., Reynolds, R., Klungel, O. H., & Gardarsdottir, H. (2016). Case-only designs for studying the association of antidepressants and hip or femur fracture. Pharmacoepidemiology and Drug Safety, 25(Supplement S1), 103-113. https://doi.org/10.1002/pds.3850

Maciel Afonso, A., Schmiedl, S., Becker, C., Tcherny-Lessenot, S., Primatesta, P., Plana, E., Souverein, P., Wang, Y., Korevaar, J. C., Hasford, J., Reynolds, R., de Groot, M. C. H., Schlienger, R., Klungel, O., & Rottenkolber, M. (2016). A methodological comparison of two European primary care databases and replication in a US claims database: inhaled long-acting beta-2-agonists and the risk of acute myocardial infarction. European Journal of Clinical Pharmacology, 72(9), 1105–1116. https://doi.org/10.1007/s00228-016-2071-8

Ali, M. S., Groenwold, R. H. H., Belitser, S., Souverein, P. C., Martín, E., Gatto, N. M., Huerta, C., Gardarsdottir, H., Roes, K. C. B., Hoes, A. W., de Boer, A., & Klungel, O. H. (2016). Methodological comparison of marginal structural model, time-varying Cox regression, and propensity score methods: the example of antidepressant use and the risk of hip fracture. Pharmacoepidemiology and Drug Safety, 25(Suppl 1), 114-121. https://doi.org/10.1002/pds.3864

Brauer, R., Douglas, I., Garcia Rodriguez, L. A., Downey, G., Huerta, C., de Abajo, F., Bate, A., Feudjo Tepie, M., de Groot, M. C. H., Schlienger, R., Reynolds, R., Smeeth, L., Klungel, O., & Ruigómez, A. (2016). Risk of acute liver injury associated with use of antibiotics. Comparative cohort and nested case-control studies using two primary care databases in Europe. Pharmacoepidemiology and Drug Safety, 25(Supplement S1), 29-38. https://doi.org/10.1002/pds.3861

Uddin, M. J., Groenwold, R. H. H., de Boer, A., Afonso, A. S. M., Primatesta, P., Becker, C., Belitser, S., Hoes, A. W., Roes, K. C. B., & Klungel, O. H. (2016). Evaluating different physician's prescribing preference based instrumental variables in two primary care databases: A study of inhaled long-acting beta2-agonist use and the risk of myocardial infarction. Pharmacoepidemiology and Drug Safety, 25(Supplement 1), 132-141. https://doi.org/10.1002/pds.3860

Uddin, M. J., Groenwold, R. H. H., de Boer, A., Gardarsdottir, H., Martin, E., Candore, G., Belitser, S. V., Hoes, A. W., Roes, K. C. B., & Klungel, O. H. (2016). Instrumental variables analysis using multiple databases: An example of antidepressant use and risk of hip fracture. Pharmacoepidemiology and Drug Safety, 25(Supplement S1), 122-131. https://doi.org/10.1002/pds.3863

Uddin, M. J., Groenwold, R. H. H., Ali, M. S., de Boer, A., Roes, K. C. B., Chowdhury, M. A. B., & Klungel, O. H. (2016). Methods to control for unmeasured confounding in pharmacoepidemiology: an overview. International Journal of Clinical Pharmacy, 38(3), 714-723. https://doi.org/10.1007/s11096-016-0299-0

Souverein, P. C., Abbing-Karahagopian, V., Martin, E., Huerta, C., de Abajo, F., Leufkens, H. G. M., Candore, G., Alvarez, Y., Slattery, J., Miret, M., Requena, G., Gil, M. J., Groenwold, R. H. H., Reynolds, R., Schlienger, R. G., Logie, J. W., de Groot, M. C. H., Klungel, O. H., van Staa, T. P., ... Gardarsdottir, H. (2016). Understanding inconsistency in the results from observational pharmacoepidemiological studies: the case of antidepressant use and risk of hip/femur fractures. Pharmacoepidemiology and Drug Safety, 25 (Suppl 1), 88-102. https://doi.org/10.1002/pds.3862

Reynolds, R. F., Kurz, X., de Groot, M. C. H., Schlienger, R. G., Grimaldi-Bensouda, L., Tcherny-Lessenot, S., & Klungel, O. H. (2016). The IMI PROTECT project: purpose, organizational structure, and procedures. Pharmacoepidemiology and Drug Safety, 25 Suppl 1, 5-10. https://doi.org/10.1002/pds.3933

Schuerch, M., Gasse, C., Robinson, N. J., Alvarez, Y., Walls, R., Mors, O., Christensen, J., Hesse, U., de Groot, M., Schlienger, R., Reynolds, R., Klungel, O., & de Vries, F. (2016). Impact of varying outcomes and definitions of suicidality on the associations of antiepileptic drugs and suicidality: comparisons from UK Clinical Practice Research Datalink (CPRD) and Danish national registries (DNR). Pharmacoepidemiology and Drug Safety, 25 (S1), 142-155. https://doi.org/10.1002/pds.3928

Schmidt, A. F., Klungel, O. H., Nielen, M., de Boer, A., Groenwold, R. H. H., & Hoes, A. W. (2016). Tailoring treatments using treatment effect modification. Pharmacoepidemiology and Drug Safety, 25(4), 355-362. https://doi.org/10.1002/pds.3965

Grimaldi-Bensouda, L., Klungel, O., Kurz, X., de Groot, M. C. H., Maciel Afonso, A. S., de Bruin, M. L., Reynolds, R., & Rossignol, M. (2016). Calcium channel blockers and cancer: a risk analysis using the UK Clinical Practice Research Datalink (CPRD). BMJ Open, 6(1). https://doi.org/10.1136/bmjopen-2015-009147

Schmidt, A. F., Groenwold, R. H. H., Amsellem, P., Bacon, N., Klungel, O. H., Hoes, A. W., de Boer, A., Kow, K., Maritato, K., Kirpensteijn, J., & Nielen, M. (2016). Which dogs with appendicular osteosarcoma benefit most from chemotherapy after surgery? Results from an individual patient data meta-analysis. Preventive Veterinary Medicine, 125, 116–125. https://doi.org/10.1016/j.prevetmed.2015.10.016

Schmidt, A. F., Nielen, M., Withrow, S. J., Selmic, L. E., Burton, J. H., Klungel, O. H., Groenwold, R. H. H., & Kirpensteijn, J. (2016). Chemotherapy effectiveness and mortality prediction in surgically treated osteosarcoma dogs: A validation study. Preventive Veterinary Medicine, 125, 126-134. https://doi.org/10.1016/j.prevetmed.2016.01.004

Brauer, R., Ruigómez, A., Klungel, O., Reynolds, R., Feudjo Tepie, M., Smeeth, L., & Douglas, I. (2016). The risk of acute liver injury among users of antibiotic medications: a comparison of case-only studies. Pharmacoepidemiology and Drug Safety, 25(Suppl. S1), 39-46. https://doi.org/10.1002/pds.3846

Schmidt, A. F., Klungel, O. H., Groenwold, R. H. H., & GetReal Consortium (2016). Adjusting for Confounding in Early Postlaunch Settings: Going Beyond Logistic Regression Models. Epidemiology, 27(1), 133-42. https://doi.org/10.1097/EDE.0000000000000388

Groenwold, R. H. H., de Groot, M. C. H., Ramamoorthy, D., Souverein, P. C., & Klungel, O. H. (2016). Unmeasured confounding in pharmacoepidemiology. Annals of Epidemiology, 26(1), 85-86. https://doi.org/10.1016/j.annepidem.2015.10.007

Requena, G., Logie, J., Martin, E., Boudiaf, N., González González, R., Huerta, C., Alvarez, A., Webb, D., Bate, A., García Rodríguez, L. A., Reynolds, R., Schlienger, R., Gardarsdottir, H., de Groot, M., Klungel, O. H., de Abajo, F., & Douglas, I. J. (2016). Do case-only designs yield consistent results across design and different databases? A case study of hip fractures and benzodiazepines. Pharmacoepidemiology and Drug Safety, 25(Suppl. S1), 79–87. https://doi.org/10.1002/pds.3822

Requena, G., Huerta, C., Gardarsdottir, H., Logie, J., González-González, R., Abbing-Karahagopian, V., Miret, M., Schneider, C., Souverein, P. C., Webb, D., Afonso, A., Boudiaf, N., Martin, E., Oliva, B., Alvarez, A., De Groot, M. C. H., Bate, A., Johansson, S., Schlienger, R., ... de Abajo, F. J. (2016). Hip/femur fractures associated with the use of benzodiazepines (anxiolytics, hypnotics and related drugs): a methodological approach to assess consistencies across databases from the PROTECT-EU project. Pharmacoepidemiology and Drug Safety, 25(Suppl. S1), 66–78. https://doi.org/10.1002/pds.3816

Huerta, C., Abbing-Karahagopian, V., Requena, G., Oliva, B., Alvarez, Y., Gardarsdottir, H., Miret, M., Schneider, C., Gil, M., Souverein, P. C., De Bruin, M. L., Slattery, J., De Groot, M. C. H., Hesse, U., Rottenkolber, M., Schmiedl, S., Montero, D., Bate, A., Ruigomez, A., ... de Abajo, F. J. (2016). Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project. Pharmacoepidemiology and Drug Safety, 25(S1), 56–65. https://doi.org/10.1002/pds.3825

Brauer, R., Ruigómez, A., Downey, G., Bate, A., Garcia Rodriguez, L. A., Huerta, C., Gil, M., de Abajo, F., Requena, G., Alvarez, Y., Slattery, J., de Groot, M., Souverein, P., Hesse, U., Rottenkolber, M., Schmiedl, S., de Vries, F., Tepie, M. F., Schlienger, R., ... Klungel, O. (2016). Prevalence of antibiotic use: a comparison across various European health care data sources. Pharmacoepidemiology and Drug Safety, 25(Suppl. S1), 11-20. https://doi.org/10.1002/pds.3831

Vakpublicaties

Klungel, O. H. (2016). Farmaco-epidemiologie: Let op methodologische valkuilen. Pharmaceutisch Weekblad, 151(3), 14-16.

Overige resultaten

Noorsyahdy, A., De Boer, A., Deneer, V. H. M., Ten Berg, J. M., Souverein, P. C., & Klungel, O. H. (2016). Population-based effectiveness and safety of different antiplatelet regimens as secondary prevention for ischemic stroke/Transient ischemic attack. Pharmacoepidemiology and Drug Safety, 25(S3), 570. https://doi.org/10.1002/pds.4070

Bezin, J., Groenwold, R., Ali, S., Lassalle, R., De Boer, A., Moore, N., Klungel, O., & Pariente, A. (2016). Effectiveness of recommended drug classes in secondary prevention of acute coronary syndrome in France. Pharmacoepidemiology and Drug Safety, 25(S3), 258-259. https://doi.org/10.1002/pds.4070

Makady, A., Nijmeijer, H., De Boer, A., Hillege, J. L., Klungel, O., & Goettsch, W. (2016). Implementation of conditional reimbursement schemes in HTA practice: Experiences from the Netherlands. Value in Health, 19(7), A348. https://doi.org/10.1016/j.jval.2016.09.011

Makady, A. A. M. A., ten Ham, R. M. T., de Boer, A., Hillege, H., Klungel, O. H., & Goettsch, W. G. (2016). Policies for use of Real-World Data in Health Technology Assessment: A comparative study of 6 HTA agencies. https://doi.org/10.1016/j.jval.2016.12.003

2015

Wetenschappelijke publicaties

De Jong, H. J., Van Staa, T. P., Lalmohamed, A., Vandebriel, R. J., Van Loveren, H., De Vries, F., Klungel, O. H., & Tervaert, J. W. C. (2015). Pattern of Risks of Systemic Lupus Erythematosus among Statin Users: A Population-based Retrospective Cohort Study. Pharmacoepidemiology and Drug Safety, 24, 319-320.

Ali, S., Groenwold, R. H. H., Belitser, S., Roes, K. C. B., Hoes, A. W., De Boer, A., & Klungel, O. H. (2015). Covariate balance assessment, model selection and bias in propensity score matching: A simulation study. Pharmacoepidemiology and Drug Safety, 24, 22. https://doi.org/10.1002/pds.3838

Uddin, J., Groenwold, R. H. H., Ali, M. S., Candore, G., De Groot, M. C. H., Souverein, P. C., Alvarez, Y., Belitser, S., Hoes, A. W., De Boer, A., Roes, K. C. B., Klungel, O. H., & Gardarsdottir, H. (2015). Application of the self-controlled case series design in pharmacoepidemiological studies: A cautionary note. European Journal of Epidemiology, 30(8), 903. https://doi.org/10.1007/s10654-015-0072-z

Alharbi, F. F., Souverein, P. C., Blom, M. T., Tan, H. L., De Boer, A., & Klungel, O. H. (2015). Use of antihypertensive agents and the risk of out-of-hospital cardiac arrest: A case control study. Pharmacoepidemiology and Drug Safety, 24, 200. https://doi.org/10.1002/pds.3838

Yasmina, A., De Boer, A., Klungel, O. H., & Souverein, P. C. (2015). Patterns of antiplatelet use in patients with myocardial infarction and subsequent acute coronary syndrome events. Pharmacoepidemiology and Drug Safety, 24, 119. https://doi.org/10.1002/pds.3838

Alharbi, F. F., Souverein, P. C., De Groot, M. C. H., Der Zee, A. H. M-V., De Boer, A., & Klungel, O. H. (2015). The risk of acute myocardial infarction after discontinuation of antihypertensive agents. Pharmacoepidemiology and Drug Safety, 24, 199-200. https://doi.org/10.1002/pds.3838

Uddin, M. J., Groenwold, R. H. H., Ali, M. S., Candore, G., De Groot, M. C. H., Souverein, P. C., Alvarez, Y., Belitser, S., Hoes, A. W., De Boer, A., Roes, K. C. B., Klungel, O., & Gardarsdottir, H. (2015). Impact of violations of the assumptions of the self-controlled case series design in pharmacoepidemiological studies: An example of antidepressants use and the risk of hip fracture. Pharmacoepidemiology and Drug Safety, 24, 2-3. https://doi.org/10.1002/pds.3838

Ali, M. S., Groenwold, R. H. H., Belitser, S., Pestman, W. R., Hoes, A. W., Roes, K. C. B., Boer, A. D., & Klungel, O. H. (2015). Reporting of covariate selection and balance assessment in propensity score analysis is suboptimal: A systematic review. Journal of Clinical Epidemiology, 68(2), 112-121. https://doi.org/10.1016/j.jclinepi.2014.08.011

Broekman, M. M., Coenen, M. J., Franke, B., Derijks, L. J., Vermeulen, S. H., Wong, D. R., Klungel, O. H., Verbeek, A. L., Hooymans, P., Scheffer, H., Guchelaar, H-J., Van Marrewijk, C. J., & De Jong, D. J. (2015). Azathioprine and 6-mercaptopurine are equally effective in thiopurine naïve IBD patients. Gastroenterology, 148(4), 269. https://doi.org/10.1016/S0016-5085(15)30889-1

Hazelbag, C. M., Klungel, O. H., van Staa, T. P., de Boer, A., & Groenwold, R. H. H. (2015). Left truncation results in substantial bias of the relation between time-dependent exposures and adverse events. International Journal of Epidemiology, 25(8), 590-6. https://doi.org/10.1016/j.annepidem.2015.03.019

Coenen, M. J. H., de Jong, D. J., van Marrewijk, C. J., Derijks, L. J. J., Vermeulen, S. H., Wong, D. R., Klungel, O. H., Verbeek, A. L. M., Hooymans, P. M., Peters, W. H. M., te Morsche, R. H. M., Newman, W. G., Scheffer, H., Guchelaar, H-J., Franke, B., & TOPIC Recruitment Team (2015). Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease. Gastroenterology, 149(4), 907-17.e7. https://doi.org/10.1053/j.gastro.2015.06.002

Ng, E. S-W., Klungel, O. H., Groenwold, R. H. H., & van Staa, T-P. (2015). Risk patterns in drug safety study using relative times by accelerated failure time models when proportional hazards assumption is questionable: an illustrative case study of cancer risk of patients on glucose-lowering therapies. Pharmaceutical Statistics, 14(5), 382-94. https://doi.org/10.1002/pst.1697

van den Ham, H. A., Klungel, O. H., Singer, D. E., Leufkens, H. G. M., & van Staa, T. P. (2015). Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation: Results From a National Primary Care Database. Journal of the American College of Cardiology, 66(17), 1851-9. https://doi.org/10.1016/j.jacc.2015.08.033

Ferrer, P., Sabaté, M., Ballarín, E., Rottenkolber, M., Schmiedl, S., Amelio, J., De Abajo, F., Ruigómez, A., Gil, M., Huerta, C., Gardarsdottir, H., Afonso, A., Klungel, O., De Groot, M., Schlinger, R., Reynolds, R., & Ibáñez, L. (2015). Measuring drug use: Differences between medical records and healthcare utilisation data bases. Clinical Therapeutics, 37(8), 75.

Sabaté, M., Ferrer, P., Ballarín, E., Rottenkolber, M., Amelio, J., Schmiedl, S., Reynolds, R., Klungel, O., Ibáñez, L., PROTECT Work Package 2, & de Vries, F. (2015). Inpatient drug utilization in Europe: nationwide data sources and a review of publications on a selected group of medicines (PROTECT project). Basic & Clinical Pharmacology & Toxicology, 116(3), 201-211. https://doi.org/10.1111/bcpt.12358

Rottenkolber, M., Voogd, E., van Dijk, L., Primatesta, P., Becker, C., Schlienger, R., de Groot, M. C. H., Alvarez, Y., Durand, J., Slattery, J., Afonso, A., Requena, G., Gil, M., Alvarez, A., Hesse, U., Gerlach, R., Hasford, J., Fischer, R., Klungel, O. H., & Schmiedl, S. (2015). Time trends of period prevalence rates of patients with inhaled long-acting beta-2-agonists-containing prescriptions: a European comparative database study. PLoS One, 10(2), [e0117628]. https://doi.org/10.1371/journal.pone.0117628

Uddin, M. J., Groenwold, R. H. H., van Staa, T. P., de Boer, A., Belitser, S. V., Hoes, A. W., Roes, K. C. B., & Klungel, O. H. (2015). Performance of prior event rate ratio adjustment method in pharmacoepidemiology: a simulation study. Pharmacoepidemiology and Drug Safety, 24(5), 468-477. https://doi.org/10.1002/pds.3724

Rañopa, M., Douglas, I., van Staa, T., Smeeth, L., Klungel, O., Reynolds, R., & Bhaskaran, K. (2015). The identification of incident cancers in UK primary care databases: a systematic review. Pharmacoepidemiology and Drug Safety, 24, 11-18. https://doi.org/10.1002/pds.3729

2014

Wetenschappelijke publicaties

De Jong, H. J. I., Meijboom, R., Helle, M. J., Klungel, O. H., Niskanen, L., & Tervaert, J. W. C. (2014). Giant cell arteritis and polymyalgia rheumatica after reexposure to a statin: A case report. Annals of Internal Medicine, 161(8), 614-615.

Schmiedl, S., Fischer, R., Ibáñez, L., Fortuny, J., Klungel, O., Reynolds, R., Gerlach, R., Tauscher, M., Thuermann, P., Hasford, J., & Rottenkolber, M. (2014). Long-acting beta-2-adrenoceptor agonists and anticholinergic drugs: Drug utilisation and off-label use in paediatric patients living in Bavaria (Germany). Basic & Clinical Pharmacology & Toxicology, 115, 74.

Abbing-Karahagopian, V., Huerta, C., Souverein, P. C., De Abajo, F., Leufkens, H. G. M., Slattery, J., Alvarez, Y., Miret, M., Gil, M., Oliva, B., Hesse, U., Requena, G., De Vries, F., Rottenkolber, M., Schmiedl, S., Reynolds, R., Schlienger, R. G., De Groot, M. C. H., Klungel, O. H., ... De Bruin, M. L. (2014). Antidepressant prescribing in five European countries: Application of common definitions to assess the prevalence, clinical observations, and methodological implications. European Journal of Clinical Pharmacology, 70(7), 849-857. https://doi.org/10.1007/s00228-014-1676-z

Ali, MS., De Groot, M., Candore, G., Groenwold, R. H. H., Souverein, P. C., Alvarez, Y., Uddin, M. J., Hoes, A. W., De Boer, A., Klungel, O. H., & Gardarsdottir, H. (2014). Antidepressantuse and the risk of hip fracture: A self-controlled case series approach in two primary care databases. Pharmacoepidemiology and Drug Safety, 23, 385. https://doi.org/10.1002/pds.3701

Schmiedl, S., Fischer, R., Ibáñez, L., Fortuny, J., Klungel, O. H., Reynolds, R., Gerlach, R., Tauscher, M., Thürmann, P., Hasford, J., & Rottenkolber, M. (2014). Utilisation and off-label prescriptions of respiratory drugs in children. PLoS One, 9(9), [e105110]. https://doi.org/10.1371/journal.pone.0105110

Requena, G., Abbing-Karahagopian, V., Huerta, C., De Bruin, M. L., Alvarez, Y., Miret, M., Hesse, U., Gardarsdottir, H., Souverein, P. C., Slattery, J., Schneider, C., Rottenkolber, M., Schmiedl, S., Gil, M., De Groot, M. C. H., Bate, A., Ruigómez, A., García Rodríguez, L. A., Johansson, S., ... De Abajo, F. J. (2014). Incidence rates and trends of hip/femur fractures in five European countries: Comparison using e-healthcare records databases. Calcified Tissue International, 94(6), 580-589. https://doi.org/10.1007/s00223-014-9850-y

Schmidt, A. F., Groenwold, R. H. H., Knol, M. J., Hoes, A. W., Nielen, M., Roes, K. C. B., De Boer, A., & Klungel, O. H. (2014). Exploring interaction effects in small samples increases rates of false-positive and false-negative findings: Results from a systematic review and simulation study. Journal of Clinical Epidemiology, 67(7), 821-829. https://doi.org/10.1016/j.jclinepi.2014.02.008

Coenen, M., Van Marrewijk, C., Derijks, L., Vermeulen, S., Wong, D., Klungel, O., Verbeek, A., Hooymans, P., Scheffer, H., Guchelaar, H-J., Franke, B., & De Jong, D. (2014). Personalized thiopurine dosing based on TPMT genotyping reduces leucopenia occurrence and results in cost-savings in IBD patients. Results from a randomized trial in the Netherlands. Journal of Crohn's & Colitis, 8, 4. [OP006]. https://doi.org/10.1002/cpt.56
https://dspace.library.uu.nl/bitstream/handle/1874/304282/pdf.pdf?sequence=1

Van Staa, T-P., Klungel, O., & Smeeth, L. (2014). Use of electronic healthcare records in large-scale simple randomized trials at the point of care for the documentation of value-based medicine. Journal of Internal Medicine, 275(6), 562-569. https://doi.org/10.1111/joim.12211

de Groot, M. C. H., Klungel, O. H., Leufkens, H. G. M., van Dijk, L., Grobbee, D. E., & van de Garde, E. M. W. (2014). Sources of heterogeneity in case–control studies on associations between statins, ACE-inhibitors, and proton pump inhibitors and risk of pneumonia. European Journal of Epidemiology, 29(10), 767-775. https://doi.org/10.1007/s10654-014-9941-0

Ali, M. S., Groenwold, R. H. H., & Klungel, O. H. (2014). Propensity score methods and unobserved covariate imbalance: Comments on "squeezing the balloon". Health Services Research, 49(3), 1074-1082. https://doi.org/10.1111/1475-6773.12152

Schmidt, A. F., Groenwold, R. H. H., Van Delden, J. J. M., Van Der Does, Y., Klungel, O. H., Roes, K. C. B., Hoes, A. W., & Van Der Graaf, R. (2014). Justification of exclusion criteria was underreported in a review of cardiovascular trials. Journal of Clinical Epidemiology, 67(6), 635-644. https://doi.org/10.1016/j.jclinepi.2013.12.005

Prieto-Alhambra, D., Petri, H., Goldenberg, J. S. B., Khong, T. P., Klungel, O. H., Robinson, N. J., & De Vries, F. (2014). Excess risk of hip fractures attributable to the use of antidepressants in five European countries and the USA. Osteoporosis International, 25(3), 847-855. https://doi.org/10.1007/s00198-013-2612-2

Holmes, M. V., Dale, C. E., Zuccolo, L., Silverwood, R. J., Guo, Y., Ye, Z., Prieto-Merino, D., Dehghan, A., Trompet, S., Wong, A., Cavadino, A., Drogan, D., Padmanabhan, S., Li, S., Yesupriya, A., Leusink, M., Sundstrom, J., Hubacek, J. A., Pikhart, H., ... Casas, J. P. (2014). Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ - Clinical research, 349, [g4164]. https://doi.org/10.1136/bmj.g4164

Abbing-Karahagopian, V., Kurz, X., de Vries, F., van Staa, T. P., Alvarez, Y., Hesse, U., Hasford, J., Dijk, L. V., de Abajo, F. J., Weil, J. G., Grimaldi-Bensouda, L., Egberts, A. C. G., Reynolds, R. F., & Klungel, O. H. (2014). Bridging differences in outcomes of pharmacoepidemiological studies: design and first results of the PROTECT project. Current Clinical Pharmacology, 9(2), 130-138.

de Groot, M. C. H., Schuerch, M., de Vries, F., Hesse, U., Oliva, B., Gil, M., Huerta, C., Requena, G., de Abajo, F., Afonso, A. S., Souverein, P. C., Alvarez, Y., Slattery, J., Rottenkolber, M., Schmiedl, S., Van Dijk, L., Schlienger, R. G., Reynolds, R., & Klungel, O. H. (2014). Antiepileptic drug use in seven electronic health record databases in Europe: a methodologic comparison. Epilepsia, 55(5), 666-673. https://doi.org/10.1111/epi.12557

Yasmina Noorsyahdy, A., de Boer, A., Klungel, O. H., & Deneer, V. H. M. (2014). Pharmacogenomics of oral antiplatelet drugs. Pharmacogenomics, 15(4), 509-28. https://doi.org/10.2217/pgs.14.16

Leusink, M., Onland-Moret, N. C., Asselbergs, F. W., Ding, B., Kotti, S., Van Zuydam, N. R., Papp, A. C., Danchin, N., Donnelly, L., Morris, A. D., Chasman, D. I., Doevendans, P. A. F. M., Klungel, O. H., Ridker, P. M., Van Gilst, W. H., Simon, T., Nyberg, F., Palmer, C. N. A., Sadee, W., ... Maitland-Van Der Zee, A. H. (2014). Cholesteryl ester transfer protein polymorphisms, statin use, and their impact on cholesterol levels and cardiovascular events. Clinical Pharmacology and Therapeutics, 95(3), 314-320.

Swerdlow, D. I., Preiss, D., Kuchenbaecker, K. B., Holmes, M. V., Engmann, J. E. L., Shah, T., Sofat, R., Stender, S., Johnson, P. C. D., Scott, R. A., Leusink, M., Verweij, N., Sharp, S. J., Guo, Y., Giambartolomei, C., Chung, C., Peasey, A., Amuzu, A., Li, K., ... DIAGRAM Consortium, MAGIC Consortium, InterAct Consortium (2014). HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. The Lancet. https://doi.org/10.1016/S0140-6736(14)61183-1

Schmidt, A. F., Klugkist, I., Klungel, O. H., Nielen, M., de Boer, A., Hoes, A. W., & Groenwold, R. H. H. (2014). Bayesian methods including nonrandomized study data increased the efficiency of postlaunch RCTs. Journal of Clinical Epidemiology, 68(4), 387-396. [8758]. https://doi.org/10.1016/j.jclinepi.2014.11.015

Wing, K., Douglas, I., Bhaskaran, K., Klungel, O. H., Reynolds, R. F., Pirmohamed, M., Smeeth, L., & van Staa, T. P. (2014). Development of predictive genetic tests for improving the safety of new medicines: the utilization of routinely collected electronic health records. Drug Discovery Today, 19(4), 361-6. https://doi.org/10.1016/j.drudis.2013.11.003

Yasmina, A., Deneer, V. H. M., Maitland-van der Zee, A. H., van Staa, T. P., de Boer, A., & Klungel, O. H. (2014). Application of routine electronic health record databases for pharmacogenetic research. Journal of Internal Medicine, 275(6), 590-604. https://doi.org/10.1111/joim.12226

Ruigómez, A., Brauer, R., Rodríguez, L. A. G., Huerta, C., Requena, G., Gil, M., de Abajo, F., Downey, G., Bate, A., Tepie, M. F., de Groot, M. C. H., Schlienger, R., Reynolds, R., & Klungel, O. (2014). Ascertainment of acute liver injury in two European primary care databases. European Journal of Clinical Pharmacology, 70(10), 1227-1235. https://doi.org/10.1007/s00228-014-1721-y

de Keyser, C. E., Peters, B. J. M., Becker, M. L., Visser, L. E., Uitterlinden, A. G., Klungel, O. H., Verstuyft, C., Hofman, A., Maitlan d-van der Zee, A. H., & Stricker, B. H. C. (2014). The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharmacogenetics and Genomics, 24(1), 43-51. https://doi.org/10.1097/FPC.0000000000000018

Ali, M. S., Uddin, M. J., Groenwold, R. H. H., Pestman, W. R., Belitser, S. V., Hoes, A. W., de Boer, A., Roes, K. C. B., & Klungel, O. H. (2014). Quantitative falsification of instrumental variables assumption using balance measures. Epidemiology, 25(5), 770-772. https://doi.org/10.1097/EDE.0000000000000152

Fournier, J. P., Duijnhoven, R. G., Renoux, C., Dell'Aniello, S., Klungel, O. H., & Suissa, S. (2014). Concurrent use of statins and hormone therapy and risk of venous thromboembolism in postmenopausal women: a population-based case-control study. Menopause, 21(9).

Ali, M. S., Groenwold, R. H. H., Pestman, W. R., Belitser, S. V., Roes, K. C. B., Hoes, A. W., de Boer, A., & Klungel, O. H. (2014). Propensity score balance measures in pharmacoepidemiology: A simulation study. Pharmacoepidemiology and Drug Safety, 23(8), 802-811. https://doi.org/10.1002/pds.3574

Uddin, M. J., Groenwold, R. H. H., de Boer, A., Belitser, S. V., Roes, K. C. B., Hoes, A. W., & Klungel, O. H. (2014). Performance of instrumental variable methods in cohort and nested case-control studies: A simulation study. Pharmacoepidemiology and Drug Safety, 23(2), 165-177. https://doi.org/10.1002/pds.3555

Overige resultaten

De Jong, H. J., Tervaert, J. W. C., Lalmohamed, A., De Vries, F., Vandebriel, R. J., Van Loveren, H., Klungel, O. H., & Van Staa, T. (2014). Pattern of Risks of Rheumatoid Arthritis among Patients Using Statins: a Cohort Study with the Clinical Practice Research Datalink. Pharmacoepidemiology and Drug Safety, 23(S1), 2-2.

Ali, M. S., De Groot, M., Candore, G., Groenwold, R. H. H., Souverein, P. C., Alvarez, Y., Uddin, M. J., Hoes, A. W., de Boer, A., Klungel, O. H., & Gardarsdottir, H. (2014). Antidepressant Use and the Risk of Hip Fracture: A Self-Controlled Case Series Approach in Two Primary Care Databases. Pharmacoepidemiology and Drug Safety, 23, 385-385.

Requena, G., Huerta, C., Gardarsdottir, H., Miret, M., Martin, E., Souverein, P. C., Schneider, C., Gonzalez-Gonzalez, R., Bate, A., Alvarez, Y., Montero, D., Garcia-Rodriguez, L. A., Reynolds, R., Schlienger, R. G., de Groot, M. C. H., Klungel, O. H., & de Abajo, F. J. (2014). Risk of Hip Fractures Associated with Benzodiazepines: Common Methodology But Different Results in a Multi-Site Cohort Study. The PROTECT Project. Pharmacoepidemiology and Drug Safety, 23(S1), 383-384. [715].
https://dspace.library.uu.nl/bitstream/handle/1874/304517/715xx.pdf?sequence=1

Abbing-Karahagopian, V., Souverein, P., Martin, E., Huerta, C., de Abajo, F., Leufkens, H., Candore, G., Alvarez, Y., Slattery, J., Miret, M., Requena, G., Gil, M., Groenwold, R., Reynolds, R., Schlienger, R., de Groot, M., Klungel, O. H., van Staa, T., Egberts, T., ... Gardarsdottir, H. (2014). Understanding Inconsistent Results from Observational Pharmacoepidemiological Studies: the Case of Antidepressant Use and Risk of Hip Fracture. Pharmacoepidemiology and Drug Safety, 23, 36-36.

Van Den Ham, H. A., Klungel, O. H., Singer, D. E., Leufkens, H. G. M., & Van Staa, T. P. (2014). Comparison of ATRIA and CHA2DS2-VASc risk stratification schemes for the prediction of stroke in the individual patient with atrial fibrillation and the impact on treatment decisions. European Heart Journal, 35(S1), 1032. [5833 ]. https://doi.org/10.1093/eurheartj/ehu325

Brauer, R., Douglas, I., Rodriguez, L. A. G., Bate, A., Smeeth, L., Reynolds, R., Klungel, O., & Ruigomez, A. (2014). The risk of acute liver injury among users of antibiotic medications in the protect project: The results of a nested case-control study using european outpatient healthcare data. Pharmacoepidemiology and Drug Safety, 23(S1), 372-373. [695]. https://doi.org/10.1002/pds.3701

Grimaldi-Bensouda, L., De Groot, M., Reynolds, R., Klungel, O., & Rossignol, M. (2014). Calcium channel blockers and cancer risk using the UK CPRD. Pharmacoepidemiology and Drug Safety, 23(S1), 353. [660]. https://doi.org/10.1002/pds.3701

Klungel, O., De Groot, M., Gardarsdottir, H., Brauer, R., Grimaldi-Bensouda, L., Kurz, X., Gasse, C., & Reynolds, R. (2014). Impact of methodological choices on findings from pharmacoepidemiological studies: Final results of the IMI-protect (pharmacoepidemiological research on outcomes of therapeutics by a European consortium) project. Pharmacoepidemiology and Drug Safety, 23(S1), 43. [78]. https://doi.org/10.1002/pds.3701

De Jong, H. J., Tervaert, J. W. C., Lalmohamed, A., De Vries, F., Vandebriel, R. J., Van Loveren, H., Klungel, O. H., & Van Staa, T. (2014). Pattern of risks of rheumatoid arthritis among patients using statins: A cohort study with the clinical practice research datalink. Pharmacoepidemiology and Drug Safety, 23(S1), 2. [3]. https://doi.org/10.1002/pds.3701

De Groot, M. C. H., Belitser, S. V., Souverein, P. C., Groenwold, R. H. H., Candore, G., Alvarez, Y., Schlienger, R. G., Reynolds, R., Klungel, O. H., & Gardarsdottir, H. (2014). Impact of varying control moment selection in a case-crossover (CCO) study on antidepressant drug (AD) use and hip/femur fracture (HFF) in protect. Pharmacoepidemiology and Drug Safety, 23(S1), 407-408. [758]. https://doi.org/10.1002/pds.3701

Souverein, P. C., De Groot, M. C. H., Martin, E., Huerta, C., Candore, G., Alvarez, Y., Slattery, J., Schlienger, R. G., Reynolds, R., Klungel, O. H., & Gardarsdottir, H. (2014). No impact of adjusting for lifestyle factors or general practice on risk estimates for the association between antidepressants and hip/femur fracture. Pharmacoepidemiology and Drug Safety, 23(S1), 384-385. [716]. https://doi.org/10.1002/pds.3701

Requena, G., Logie, J., Martin, E., Huerta, C., González-González, R., Boudiaf, N., Álvarez, A., Bate, A., García-Rodríguez, L. A., Reynolds, R., Schlienger, R. G., De Groot, M. C. H., Klungel, O. H., De Abajo, F. J., & Douglas, I. (2014). Do case-only designs yield consistent results between them and across different databases (DB)? Hip fractures associated with Benzodiazepines (BZD) as a case study. Pharmacoepidemiology and Drug Safety, 23(S1), 61-62. [112]. https://doi.org/10.1002/pds.3701

Requena, G., Logie, J., González-González, R., Gardarsdottir, H., Afonso, A., Souverein, P. C., Merino, E. M., Boudiaf, N., Huerta, C., Bate, A., Alvarez, Y., García-Rodríguez, L. A., Reynolds, R., Schlienger, R. G., De Groot, M. C. H., Klungel, O. H., & De Abajo, F. J. (2014). Risk of hip fractures associated with benzodiazepines: Applying common protocol to a multi-database nested case-control study. The protect project. Pharmacoepidemiology and Drug Safety, 23, 44. [80]. https://doi.org/10.1002/pds.3701

Shakir, S. A. W., Layton, D., Klungel, O. H., & Van Staa, T. (2014). Comparisons in pharmacoepidemiology: New challenges and limitations of current approaches. Pharmacoepidemiology and Drug Safety, 23(S1), 362. [676]. https://doi.org/10.1002/pds.3701

Van Den Ham, H. A., Klungel, O. H., Singer, D. E., Leufkens, H. G. M., & Van Staa, T. P. (2014). Comparison of atria and CHA2DS2-vasc risk stratification schemes for the prediction of stroke in the individual patient with atrial fibrillation and the impact on treatment decisions. Pharmacoepidemiology and Drug Safety, 23(S1), 359-360. [672]. https://doi.org/10.1002/pds.3701

Uddin, M. J., Groenwold, R. H. H., Van Staa, T. P., De Boer, A., Belitser, S. V., Hoes, A. W., Roes, K. C. B., & Klungel, O. H. (2014). The use of prior event rate ratio adjustment method for controlling unmeasured confounding in pharmacoepidemiologic studies: A cautionary note. Pharmacoepidemiology and Drug Safety, 23(S1), 182. [345]. https://doi.org/10.1002/pds.3701

Ali, M. S., Groenwold, R. H. H., Belitser, S. V., Hoes, A. W., De Boer, A., & Klungel, O. H. (2014). Propensity score matching and unmeasured covariate imbalance: A simulation study. Pharmacoepidemiology and Drug Safety, 23(S1), 12-13. [22]. https://doi.org/10.1002/pds.3701

Uddin, M. J., Groenwold, R. H. H., De Boer, A., Afonso, A., Primatesta, P., Becker, C., Belitser, S. V., Hoes, A. W., Roes, K. C. B., & Klungel, O. H. (2014). Evaluating different physician's prescribing preference based instrumental variables in the study of beta2-agonist use and the risk of acute myocardial infarction. Pharmacoepidemiology and Drug Safety, 23(S1), 32. [58]. https://doi.org/10.1002/pds.3701

Uddin, M. J., Groenwold, R. H. H., De Boer, A., Gardarsdottir, H., Martin, E., Candore, G., Belitser, S. V., Hoes, A. W., Roes, K. C. B., & Klungel, O. H. (2014). Instrumental variable analysis using multiple databases: An example of antidepressant use and risk of hip/femur fracture. Pharmacoepidemiology and Drug Safety, 23(S1), 30-31. [55]. https://doi.org/10.1002/pds.3701

Ali, M. S., Groenwold, R. H. H., Belitser, S. V., Souverein, P. C., Gardarsdottir, H., Hoes, A. W., De Boer, A., & Klungel, O. H. (2014). Antidepressant use and risk of hip fracture: A comparison of marginal structural models, conventional regression and propensity score methods. Pharmacoepidemiology and Drug Safety, 23(S1), 199. [377]. https://doi.org/10.1002/pds.3701

Afonso, A. S. M., Schmiedl, S., Becker, C., Primatesta, P., Plana, E., Souverein, P. C., Korevaar, J. C., Hasford, J., Reynolds, R., De Groot, M. C. H., Schlienger, R. G., Klungel, O. H., & Rottenkolber, M. (2014). Association between inhaled long-acting beta-2-agonists and the risk of acutemyocardial infarction: A methodological comparison of two databases. Pharmacoepidemiology and Drug Safety, 23(S1), 390-391. [727]. https://doi.org/10.1002/pds.3701

2013

Wetenschappelijke publicaties

Abbing-Karahagopian, V., Huerta, C., Souverein, P. C., de Abajo, F., Leufkens, H. G. M., Slattery, J., Alvarez, Y., Montserrat, M., Gil, M., Hesse, U., Requena, G., de Vries, F., Rottenkolber, M., Schmiedl, S., Reynolds, R., Schlinger, R., de Groot, M., Klungel, O. H., van Staa, T. P., ... De Bruin, M. L. (2013). Antidepressant Prescribing in Five European Countries: Application of Common Methods to Assess the Variation in Prevalence. Pharmacoepidemiology and Drug Safety.

De Groot, M. C. H., Schuerch, M., De Vries, F., Hesse, U., Oliva, B., Huerta Alvarez, C., Gil, M., Requena, G., Abajo, F., Afonso, A., Souverein, P. C., Alvarez, Y., Slattery, J., Rottenkolber, M., Schmiedl, S., Van Dijk, L., Schlienger, R. G., Reynolds, R., & Klungel, O. (2013). Antiepileptic Drug Use in Seven Electronic Health Record Databases in Europe: A Methodological Comparison. Pharmacoepidemiology and Drug Safety, 22, 289-290.

Requena, G., Abbing-Karahagopian, V., Huerta, C., De Bruin, M. L., Alvarez, Y., Miret, M., Hesse, U., Gardarsdottir, H., Souverein, P., Slattery, J., Schneider, C., Rottenkolber, M., Schmiedl, S., Gil, M., De Groot, M. C. H., Bate, A., Ruigomez, A., Garcia, L. A., Johanson, S., ... De Abajo, F. J. (2013). Trends in Incidence Rates (IR) of Hip/Femur Fractures in Five European Countries: A Comparison Using Electronic Health Care Records (e-HCR). Pharmacoepidemiology and Drug Safety, 22, 408-409.

Ali, S., Groenwold, R. H. H., Pestman, W. R., Belitser, S., Hoes, A. W., De Boer, A., & Klungel, O. H. (2013). Time-dependent propensity score and collider-stratification bias: An example of beta2-agonist use and the risk of coronary heart disease. European Journal of Epidemiology, 28(4), 291-299. https://doi.org/10.1007/s10654-013-9766-2

Abbing-Karahagopian, V., Huerta, C., Souverein, P. C., De Abajo, F., Leufkens, H. G. M., Slattery, J., Alvarez, Y., Montserrat, M., Gil, M., Hesse, U., Requena, G., De Vries, F., Rottenkolber, M., Schmiedl, S., Reynolds, R., Schlinger, R., De Groot, M. C. H., Klungel, O. H., Van Staa, T. P., ... De Bruin, M. L. (2013). Antidepressant prescribing in five european countries: Application of common methods to assess the variation in prevalence. Pharmacoepidemiology and Drug Safety, 22, 279-280. https://doi.org/10.1002/pds.3512

Vandebriel, R. J., De Jong, H. J. I., Gremmer, E. R., Klungel, O. H., Tervaert, J-W. C., Slob, W., Van Der Laan, J. W., & Van Loveren, H. (2013). Response to 'Statins accelerate the onset of collagen type II-induced arthritis in mice'-authors' reply. Arthritis Research & Therapy, 15(2), [403]. https://doi.org/10.1186/ar4170

Wangge, G., De Boer, A., Klungel, O. H., Hoes, A. W., & Knol, M. J. (2013). Expert-opinion on non-inferiority margin: A case study of oral anti-coagulant agents for prophylaxis of venous thromboembolic events after orthopedic surgery. Thrombosis Research, 131(4), 368-371. https://doi.org/10.1016/j.thromres.2013.01.013

Wangge, G., Klungel, O. H., Roes, K. C. B., De Boer, A., Hoes, A. W., & Knol, M. J. (2013). Should non-inferiority drug trials be banned altogether? Drug Discovery Today, 18(11-12), 601-604. https://doi.org/10.1016/j.drudis.2013.01.003

Schmidt, A. F., Rovers, M. M., Klungel, O. H., Hoes, A. W., Knol, M. J., Nielen, M., De Boer, A., & Groenwold, R. H. H. (2013). Differences in interaction and subgroup-specific effects were observed between randomized and nonrandomized studies in three empirical examples. Journal of Clinical Epidemiology, 66(6), 599-607. https://doi.org/10.1016/j.jclinepi.2012.08.008

Uddin, M. J., Ali, M. S., Groenwold, R. H. H., Pestman, W. R., Belitser, S. V., Hoes, A. W., De Boer, A., Roes, K. C. B., & Klungel, O. H. (2013). Quantitative verification of instrumental variables assumption using balance measures. American Journal of Epidemiology, 177, 102. https://doi.org/10.1093/aje/kwt103

Van Der Baan, F. H., Knol, M. J., Maitland-Van Der Zee, A. H., Regieli, J. J., Van Iperen, E. P. A., Egberts, A. C. G., Klungel, O. H., Grobbee, D. E., & Jukema, J. W. (2013). Added value of pharmacogenetic testing in predicting statin response: Results from the REGRESS trial. The Pharmacogenomics Journal, 13(4), 318-324. https://doi.org/10.1038/tpj.2012.12

Schmidt, A. F., Groenwold, R. H. H., Pocock, S., Gueyffier, F., Hoes, A. W., De Boer, A., Nielen, M., & Klungel, O. H. (2013). Comparing effectiveness estimates from randomized and nonrandomized studies, using subgroup analyses and individual patient data. Pharmacoepidemiology and Drug Safety, 22, 29-30.

Wangge, G., de Boer, A., Klungel, O. H., Hoes, A. W., & Knol, M. J. (2013). Expert-opinion on non-inferiority margin: a case study of oral anti-coagulant agents for prophylaxis of venous thromboembolic events after orthopedic surgery. Thrombosis Research, 131(4), 368-71. https://doi.org/10.1016/j.thromres.2013.01.013

Wangge, G., Putzeist, M., Knol, M. J., Klungel, O. H., Gispen-De Wied, C. C., de Boer, A., Hoes, A. W., Leufkens, H. G., & Mantel-Teeuwisse, A. K. (2013). Regulatory Scientific Advice on Non-Inferiority Drug Trials. PLoS One, 8(9), [e74818]. https://doi.org/10.1371/journal.pone.0074818

Groenwold, R. H. H., Klungel, O. H., Altman, D. G., van der Graaf, Y., Hoes, A. W., Moons, K. G. M., PROTECT WP2 (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium, Work Programme 2 [Framework for pharmacoepidemiology studies]), & van Staa, T. (2013). Adjustment for continuous confounders: an example of how to prevent residual confounding. Canadian Medical Association Journal, 185(5), 401-406. https://doi.org/10.1503/cmaj.120592

Donnelly, L. A., Van Zuydam, N. R., Zhou, K., Tavendale, R., Carr, F., Maitland-Van Der Zee, A. H., Leusink, M., De Boer, A., Doevendans, P. A., Asselbergs, F. W., Morris, A. D., Pearson, E. R., Klungel, O. H., Doney, A. S. F., & Palmer, C. N. A. (2013). Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment. Pharmacogenetics and Genomics, 23(10), 518-525. https://doi.org/10.1097/FPC.0b013e3283642fd6

Ali, M. S., Groenwold, R. H. H., Pestman, W. R., Belitser, S. V., Hoes, A. W., de Boer, A., & Klungel, O. H. (2013). Time-dependent propensity score and collider-stratification bias: an example of beta(2)-agonist use and the risk of coronary heart disease. European Journal of Epidemiology, 28(4), 291-299.

van den Ham, H. A., Klungel, O. H., Leufkens, H. G. M., & van Staa, T. P. (2013). The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation. Journal of Thrombosis and Haemostasis, 11(1), 107-15.

for the V.S.S.O. Investigators (2013). Prognostic factors of early metastasis and mortality in dogs with appendicular osteosarcoma after receiving surgery: an individual patient data meta-analysis. Preventive Veterinary Medicine, 112(3-4), 414-422. https://doi.org/10.1016/j.prevetmed.2013.08.011

Boessen, R., van der Baan, F. H., Groenwold, R. H. H., Egberts, A. C. G., Klungel, O. H., Grobbee, D. E., Knol, M. J., & Roes, K. C. B. (2013). Optimizing trial design in pharmacogenetics research: comparing a fixed parallel group, group sequential, and adaptive selection design on sample size requirements. Pharmaceutical Statistics, 12, 366-374.

Bernabe, R. D. L. C., Wangge, G., Knol, M. J., Klungel, O. H., van Delden, J. J. M., de Boer, A., Hoes, A. W., Raaijmakers, J. A. M., & van Thiel, G. J. M. W. (2013). Phase IV non-inferiority trials and additional claims of benefit. BMC Medical Research Methodology [E], 13, 70. https://doi.org/10.1186/1471-2288-13-70

Holmes, M. V., Simon, T., Exeter, H. J., Folkersen, L., Asselbergs, F. W., Guardiola, M., Cooper, J. A., Palmen, J., Hubacek, J. A., Carruthers, K. F., Horne, B. D., Brunisholz, K. D., Mega, J. L., Van Iperen, E. P. A., Li, M., Leusink, M., Trompet, S., Verschuren, J. J. W., Hovingh, G. K., ... Talmud, P. J. (2013). Secretory phospholipase A2-IIA and cardiovascular disease: A mendelian randomization study. Journal of the American College of Cardiology, 62(21), 1966-1976. https://doi.org/10.1016/j.jacc.2013.06.044

de Jong, H. J. I., Damoiseaux, J. G., Vandebriel, R. J., Souverein, P. C., Gremmer, E. R., Wolfs, M., Klungel, O. H., van Loveren, H., Cohen Tervaert, J. W., & Verschuren, W. M. (2013). Statin use and markers of immunity in the doetinchem cohort study. PLoS One, 8(10).

Overige resultaten

De Groot, M. C. H., Schuerch, M., De Vries, F., Hesse, U., Oliva, B., Alvarez, C. H., Gil, M., Requena, G., Abajo, F., Afonso, A., Souverein, P. C., Alvarez, Y., Slattery, J., Rottenkolber, M., Schmiedl, S., Van Dijk, L., Schlienger, R. G., Reynolds, R., & Klungel, O. (2013). Antiepileptic drug use in seven electronic health record databases in europe: A methodological comparison. Pharmacoepidemiology and Drug Safety, 22(s1), 289-290. [585]. https://doi.org/10.1002/pds.3512

Brauer, R., Ruigómez, A., Downey, G., Bate, A., Rodriguez, L. A. G., Huerta, C., Oliva, B., Gil, M., Abajo, F., Requena, G., Alvarez, Y., Slattery, J., de Groot, M., Souverein, P., Hesse, U., Rottenkolber, M., Schmiedl, S., de Vries, F., Tepie, M. F., ... Klungel, O. (2013). Prevalence of antibiotic use: A methodological comparison across various European health care data sources. Pharmacoepidemiology and Drug Safety, 22(s1), 457. [912]. https://doi.org/10.1002/pds.3512

Rottenkolber, M., Voogd, E., Van Dijk, L., Primatesta, P., Schlienger, R. G., De Groot, M. C. H., Hortoneda, E. P., Alvarez, Y., Durand, J., Slattery, J., Afonso, A. S., Requena, G., Gil, M., Huerta, C., Alvarez, A., De Abajo, F., Hesse, U., Fischer, R., Hasford, J., ... Schmiedl, S. (2013). Time trends in prevalence of inhaled long-acting beta-2-adrenoceptor agonist prescribing-a comparison of seven european electronic health record databases. Pharmacoepidemiology and Drug Safety, 22(s1), 304. [611]. https://doi.org/10.1002/pds.3512

De Groot, M. C. H., Van Den Ham, R., De Bruin, M., Alvarez, C. H., Gill, M., Afonso, A., Requena, G., Hesse, U., Rønn, P. F., Souverein, P. C., Alvarez, Y., Slattery, J., Rottenkolber, M., Schmiedl, S., Van Dijk, L., Schlienger, R. G., Reynolds, R., Klungel, O. H., & Grimaldi-Bensouda, L. (2013). Comparison of seven electronic healthcare databases in eu countries using a standardized methodology; a descriptive study on the exposure to calcium-channel blockers (CCBS). Pharmacoepidemiology and Drug Safety, 22(s1), 290-291. [586]. https://doi.org/10.1002/pds.3512

De Groot, M. C. H., Klungel, O. H., Leufkens, H. G. M., Van Dijk, L., Grobbee, D. E., & Van De Garde, E. M. W. (2013). Multiple database approach for study of associations between frequently used drugs and community-acquired pneumonia. Pharmacoepidemiology and Drug Safety, 22(s1), 289. [584]. https://doi.org/10.1002/pds.3512

Afonso, A. S., De Groot, M. C. H., Van Den Ham, R., Bruin, M. L., Alvarez, C. H., Gil, M., Hesse, U., Rønn, P. F., Souverein, P. C., Alvarez, Y., Slattery, J., Rottenkolber, M., Van Dijk, L., Schlienger, R. G., Reynolds, R., Klungel, O. H., & Grimaldi-Bensouda, L. (2013). Comparison of six electronic healthcare databases in Europe using standardized protocols: A descriptive study on the incidence of cancer. Pharmacoepidemiology and Drug Safety, 22(s1), 285. [576]. https://doi.org/10.1002/pds.3512

Leusink, M., Onland, N. C., Asselbergs, F. W., Ding, B., Kotti, S., Van Zuydam, N. R., Papp, A. C., Danchin, N., Donnelly, L., Morris, A. D., Chasman, D. I., Klungel, O. H., Ridker, P. M., Van Gilst, W. H., Simon, T., Nyberg, F., Palmer, C. N. A., Sadee, W., Van Der Harst, P., ... Maitland-Van Der Zee, A-H. (2013). Cholesteryl ester transfer protein (CETP) polymorphisms, statin use, and their impact on cholesterol levels and cardiovascular events. Pharmacoepidemiology and Drug Safety, 22(s1), 323-324. [648]. https://doi.org/10.1002/pds.3512

Van Den Ham, R., Klungel, O. H., Leufkens, H. G. M., & Van Staa, T. P. (2013). Balancing individual benefits and risks of warfarin in patients with atrial fibrillation. Pharmacoepidemiology and Drug Safety, 22(s1), 247-248. [504]. https://doi.org/10.1002/pds.3512

De Groot, M. C. H., Schlienger, R., Reynolds, R., Gardarsdottir, H., Juhaeri, J., Hesse, U., Gasse, C., Rottenkolber, M., Schuerch, M., Kurz, X., & Klungel, O. H. (2013). Improving consistency in findings from pharmacoepidemiological studies: The IMI-protect (Pharmacoepidemiological research on outcomes of therapeutics by a European consortium) project. Pharmacoepidemiology and Drug Safety, 22(s1), 370. [738]. https://doi.org/10.1002/pds.3512

Jamal Uddin, M., Groenwold, R. H. H., De Boer, A., Belitser, S. V., Hoes, A. W., Roes, K. C. B., & Klungel, O. H. (2013). Application of instrumental variables method in pharmacoepidemiology: An example of beta2-agonist use and myocardial infarction. Pharmacoepidemiology and Drug Safety, 22(s1), 32-33. [61]. https://doi.org/10.1002/pds.3512

Groenwold, R. H., Van Staa, T. P., De Boer, A., & Klungel, O. H. (2013). Impact of censoring on estimates of adverse drug effects: A simulation study. Pharmacoepidemiology and Drug Safety, 22(s1), 219. [445]. https://doi.org/10.1002/pds.3512

Uddin, M. J., Ali, M. S., Groenwold, R. H. H., Pestman, W. R., Belitser, S. V., Hoes, A. W., Boer, A., Roes, K. C. B., & Klungel, O. H. (2013). Quantitative verification of instrumental variables assumption using balance measures. Pharmacoepidemiology and Drug Safety, 22(s1), 138. [287]. https://doi.org/10.1002/pds.3512

Ali, M. S., Groenwold, R. H. H., Belitser, S. V., Pestman, W. R., Hoes, A. W., Roes, K. C. B., Boer, A., & Klungel, O. H. (2013). Balance measures for determining optimal caliper width in propensity score matching: A simulation study. Pharmacoepidemiology and Drug Safety, 22(s1), 133-134. [277]. https://doi.org/10.1002/pds.3512

Ali, M. S., Groenwold, R. H. H., Belitser, S. V., Pestman, W. R., Hoes, A. W., Roes, K. C. B., Boer, A., & Klungel, O. H. (2013). Assessment of balance in propensity score analysis in the medical literature: A systematic review. Pharmacoepidemiology and Drug Safety, 22(s1), 133. [276]. https://doi.org/10.1002/pds.3512

Requena, G., Abbing-Karahagopian, V., Huerta, C., De Bruin, M. L., Alvarez, Y., Miret, M., Hesse, U., Gardarsdottir, H., Souverein, P., Slattery, J., Schneider, C., Rottenkolber, M., Schmiedl, S., Gil, M., De Groot, M. C. H., Bate, A., Ruigómez, A., García, L. A., Johanson, S., ... De Abajo, F. J. (2013). Trends in incidence rates (IR) of hip/femur fractures in five european countries: A comparison using electronic health care records (E-HCR). Pharmacoepidemiology and Drug Safety, 22(s1), 408-409. [811]. https://doi.org/10.1002/pds.3512

2012

Wetenschappelijke publicaties

Peters, B. J. M., de Boer, A., Schalekamp, T., Klungel, O. H., & Maitland-van der Zee, A. H. (2012). Cardiovascular Pharmacogenetics. In Pharmacogenetics and Individualized Therapy (pp. 183-213). John Wiley and Sons Ltd. https://doi.org/10.1002/9781118116494.ch6

Harmsze, A. M., van Werkum, J. W., Hackeng, C. M., Ruven, H. J. T., Kelder, J. C., Bouman, H. J., Breet, N. J., Ten Berg, J. M., Klungel, O. H., de Boer, A., & Deneer, V. H. M. (2012). The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenetics and Genomics, 22(3), 169-75. https://doi.org/10.1097/FPC.0b013e32834ff6e3

Voight, B. F., Peloso, G. M., Orho-Melander, M., Frikke-Schmidt, R., Barbalic, M., Jensen, M. K., Hindy, G., Hólm, H., Ding, E. L., Johnson, T., Schunkert, H., Samani, N. J., Clarke, R., Hopewell, J. C., Thompson, J. F., Li, M., Thorleifsson, G., Newton-Cheh, C., Musunuru, K., ... de Boer, A. (2012). Erratum: Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study (The Lancet (2012) DOI:10.1016/S0140-6736(12) 60312-2). The Lancet, 380(9841).

Swerdlow, D. I., Holmes, M. V., Kuchenbaecker, K. B., Engmann, J. E. L., Shah, T., Sofat, R., Guo, Y., Chung, C., Peasey, A., Pfister, R., Mooijaart, S. P., Ireland, H. A., Leusink, M., Langenberg, C., Li, K., Palmen, J., Howard, P., Cooper, J. A., Drenos, F., ... Casas, J. P. (2012). The interleukin-6 receptor as a target for prevention of coronary heart disease: A mendelian randomisation analysis. The Lancet, 379(9822), 1214-1224. https://doi.org/10.1016/S0140-6736(12)60110-X

Saxena, R., Elbers, C. C., Guo, Y., Peter, I., Gaunt, T. R., Mega, J. L., Lanktree, M. B., Tare, A., Castillo, B. A., Li, Y. R., Johnson, T., Bruinenberg, M., Gilbert-Diamond, D., Rajagopalan, R., Voight, B. F., Balasubramanyam, A., Barnard, J., Bauer, F., Baumert, J., ... Keating, B. J. (2012). Erratum: Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci (American Journal of Human Genetics (2012) 90 (410-425)). American Journal of Human Genetics, 90(4), 753. https://doi.org/10.1016/j.ajhg.2012.03.001

Harmsze, A. M., van Werkum, J. W., Hackeng, C. M., Ruven, H. J. T., Kelder, J. C., Bouman, H. J., Breet, N. J., ten Berg, J. M., Klungel, O. H., de Boer, A., & Deneer, V. H. M. (2012). The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenetics and Genomics, 22(3), 169-175. https://doi.org/10.1097/FPC.0b013e32834ff6e3

Saxena, R., Elbers, C. C., Guo, Y., Peter, I., Gaunt, T. R., Mega, J. L., Lanktree, M. B., Tare, A., Castillo, B. A., Li, Y. R., Johnson, T., Bruinenberg, M., Gilbert-Diamond, D., Rajagopalan, R., Voight, B. F., Balasubramanyam, A., Barnard, J., Bauer, F., Baumert, J., ... Keating, B. J. (2012). Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. American Journal of Human Genetics, 90(3), 410-425. https://doi.org/10.1016/j.ajhg.2011.12.022

Lanktree, M. B., Guo, Y., Murtaza, M., Glessner, J. T., Bailey, S. D., Onland-Moret, N. C., Lettre, G., Ongen, H., Rajagopalan, R., Johnson, T., Shen, H., Nelson, C. P., Klopp, N., Baumert, J., Padmanabhan, S., Pankratz, N., Pankow, J. S., Shah, S., Taylor, K., ... Keating, B. J. (2012). Erratum: Meta-analysis of dense genecentric association studies reveals common and uncommon variants associated with height ((The American Journal of Human Genetics (2010) 88 (6-18)). American Journal of Human Genetics, 90(6), 1116-1117. https://doi.org/10.1016/j.ajhg.2012.05.017

Eussen, S. R. B. M., Geleijnse, J. M., Giltay, E. J., Rompelberg, C. J. M., Klungel, O. H., & Kromhout, D. (2012). Effects of n-3 fatty acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction. European Heart Journal, 33(13), 1582-1588. https://doi.org/10.1093/eurheartj/ehr499

de Jong, H. J. I., Vandebriel, R. J., Saldi, S. R. F., van Dijk, L., van Loveren, H., Cohen Tervaert, J. W., & Klungel, O. H. (2012). Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and the risk of developing rheumatoid arthritis in antihypertensive drug users. Pharmacoepidemiology and Drug Safety, 21(8), 835-843. https://doi.org/10.1002/pds.3291

Voight, B. F., Peloso, G. M., Orho-Melander, M., Frikke-Schmidt, R., Barbalic, M., Jensen, M. K., Hindy, G., Hólm, H., Ding, E. L., Johnson, T., Schunkert, H., Samani, N. J., Clarke, R., Hopewell, J. C., Thompson, J. F., Li, M., Thorleifsson, G., Newton-Cheh, C., Musunuru, K., ... Kathiresan, S. (2012). Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. The Lancet, 380(9841), 572-80. https://doi.org/10.1016/S0140-6736(12)60312-2

de Jong, H. J. I., Vandebriel, R. J., Saldi, S. R. F., van Dijk, L., van Loveren, H., Cohen Tervaert, J. W., & Klungel, O. H. (2012). Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and risk of developing rheumatoid arthritis in antihypertensive drug users. Pharmacoepidemiology and Drug Safety, 21, 835-843. http://www.ncbi.nlm.nih.gov/pubmed/22674737

Eussen, S. R. B. M., Geleijnse, J. M., Giltay, E. J., Rompelberg, C. J. M., Klungel, O. H., & Kromhout, D. (2012). Effects on n-3 fatty acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction. European Heart Journal, 33, 1582-1588.

Khong, T. P., de Vries, F., Goldenberg, J. S. B., Klungel, O. H., Robinson, N. J., Ibáñez, L., & Petri, H. (2012). Potential impact of benzodiazepine use on the rate of hip fractures in five large European countries and the United States. Calcified Tissue International, 91(1), 24-31. https://doi.org/10.1007/s00223-012-9603-8

van der Baan, F. H., Knol, M. J., Klungel, O. H., Egberts, A. C. G., Grobbee, D. E., & Roes, C. B. (2012). Potential of adaptive clinical trial designs in pharmacogenetic research. Pharmacogenomics, 13(5), 571-578. http://www.ncbi.nlm.nih.gov/pubmed/22462749

de Jong, H. J. I., Saldi, S. R. F., Klungel, O. H., Vandebriel, R. J., Souverein, P. C., Meyboom, R. H. B., Passier, J. L. M., van Loveren, H., & Tervaert, J. W. C. (2012). Statin-associated polymyalgia rheumatica. An analysis using WHO global individual case safety database: A case/non-case approach. PLoS One, 7(7), e41289. [e41289]. https://doi.org/10.1371/journal.pone.0041289

de Groot, M. C. H., & Klungel, O. H. (2012). Pharmacogenetics of Diabetes. In R. B. Altman, D. Flockhart, & D. B. Goldstein (Eds.), Principles of Pharmacogenetics and Pharmacogenomics (pp. 145-153). Cambridge University Press.

Brandsma, M., Baas, F., de Bakker, P. I. W., Beem, E. P., Boomsma, D. I., Bovenberg, J., Bueno-de-Mesquita, B., van Duijn, C., Kiemeney, L. A., Klungel, O., de Leeuw, P. W., van Leeuwen, F. E., Ridder-Numan, J., Stolk, R. P., Slagboom, P. E., Swertz, M., Wijmenga, C., & van Ommen, G. J. B. (2012). How to kickstart a national biobanking infrastructure - experiences and prospects of BBMRI-NL. Norsk Epidemiologi, 21(2), 143-148.

Clarke, R., Bennett, D. A., Parish, S., Verhoef, P., Dotsch-Klerk, M., Lathrop, M., Xu, P., Nordestgaard, B. G., Holm, H., Hopewell, J. C., Saleheen, D., Tanaka, T., Anand, S. S., Chambers, J. C., Kleber, M. E., Ouwehand, W. H., Elbers, C. C., Peters, B. J. M., et al., X., ... Peto, R. (2012). Homocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication bias. PLoS Medicine, 9(2), e1001177. http://www.ncbi.nlm.nih.gov/pubmed/22363213

van Vliet-Ostaptchouk, J. V., van Haeften, T. W., Landman, G. W. D., Reiling, E., Kleefstra, N., Bilo, H. J. G., Klungel, O. H., de Boer, A., van Diemen, C. C., Wijmenga, C., Boezen, H. M., Dekker, J. M., van 't Riet, E., Nijpels, G., Welschen, L. M. C., Zavrelova, H., Bruin, E. J., Elbers, C. C., Bauer, F., ... 't Hart, L. M. (2012). Common variants in the type 2 diabetes KCNQ1 gene are associated with impairments in insulin secretion during hyperglycaemic glucose clamp. PLoS One, 7(3), e32148. https://doi.org/10.1371/journal.pone.0032148

Vandebriel, R. J., de Jong, H. J. I., Gremmer, E. R., Klungel, O. H., Tervaert, J. W., Slob, W., van der Laan, J. W., & van Loveren, H. (2012). Statins accelerate the onset of collagen type II-induced arthritis in mice. Arthritis Research & Therapy, 14(2), R90. http://www.ncbi.nlm.nih.gov/pubmed/22537858

de Jong, H. J. I., Klungel, O. H., van Dijk, L., Vandebriel, R. J., Leufkens, H. G. M., van der Laan, J. W., Cohen Tervaert, J. W., & van Loveren, H. (2012). Use of statins is associated with an increased risk of rheumatoid arthritis. Annals of the Rheumatic Diseases, 71(5), 648-54. http://www.ncbi.nlm.nih.gov/pubmed/21979000

Overige resultaten

Gardarsdottir, H., Sauer, B. C., Liang, H., Ryan, P., Klungel, O., & Reynolds, R. (2012). Transparent, reproducible and reusable research in pharmacoepidemiology. Pharmacoepidemiology and Drug Safety, 21(S3), 197. [416]. https://doi.org/10.1002/pds.3324

Abbing-Karahagopian, V., Gardarsdottir, H., Souverein, P. C., Klungel, O. H., Leufkens, B. G. M., Egberts, T. C. G., & De Bruin, M. L. (2012). Timing of concomitant drug use in pharmacoepidemiological studies. Pharmacoepidemiology and Drug Safety, 21(S3), 423. [914]. https://doi.org/10.1002/pds.3324

Schmidt, A. F., Rovers, M. M., Klungel, O. H., Hoes, A. W., Knol, M. J., Nielen, M., De Boer, A., & Groenwold, R. H. H. (2012). Comparison of interaction and subgroup effects in observational studies and randomized clinical trials: Three empirical examples. Pharmacoepidemiology and Drug Safety, 21(S3), 127. [270]. https://doi.org/10.1002/pds.3324

Ali, M. S., Groenwold, R. H. H., Pestman, W. R., Belitser, S., Hoes, A. W., Roes, K. C. B., De Boer, A., & Klungel, O. H. (2012). Evaluating propensity score balance measures in typical pharmacoepidemiological settings. Pharmacoepidemiology and Drug Safety, 21(S3), 36-37. [72]. https://doi.org/10.1002/pds.3324

Ali, M. S., Groenwold, R. H. H., Pestman, W. R., Belitser, S. V., Hoes, A. W., De Boer, A., & Klungel, O. H. (2012). Time-dependent propensity score and collider-stratification bias: Inhaled beta2-agonist and risk of coronary heart disease. Pharmacoepidemiology and Drug Safety, 21(S3), 252. [537]. https://doi.org/10.1002/pds.3324

2011

Wetenschappelijke publicaties

Goldenberg, J. S. B., Petri, H., Khong, P. T., Klungel, O. H., & De Vries, F. (2011). Potential Population Impact of Antidepressant Use on Hip Fractures Rate in Denmark (DK), Norway (NO) and the Netherlands (NL). Pharmacoepidemiology and Drug Safety, 20, S30-S30.

Khong, P. T., de Vries, F., Goldenberg, J. S. B., Klungel, O. H., & Petri, H. (2011). Potential Impact of Benzodiazepine Use on the Rate of Hip Fractures in Denmark (DK), the Netherlands (NL) and Norway (NO). Pharmacoepidemiology and Drug Safety, 20, S30-S31.

Abbing-Karahagopian, V., Kurtz, X., de Vries, F., Reynolds, R., & Klungel, O. (2011). Bridging Differences in Findings from Observational Pharmacoepidemiological Studies: The Design and Rationale of Work-Package 2 of the PROTECT Project. Pharmacoepidemiology and Drug Safety, 20, S34-S34.

Harmsze, A. M., Van Werkum, J. W., Moral, F., Ten Berg, J. N. M., Hackeng, C. M., Klungel, O. H., De Boer, A., & Deneer, V. H. M. (2011). Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients. Platelets, 22(2), 98-102. https://doi.org/10.3109/09537104.2010.530359

Butterworth, A. S., Braund, P., Farrall, M., Hardwick, R. J., Saleheen, D., Peden, J., Soranzo, N., Chambers, J. C., Sivapalaratnam, S., Kleber, M. E., Keating, B., Qasim, A., Klopp, N., Erdmann, J., Assimes, T. L., Ball, S. G., Balmforth, A. J., Barnes, T., Basart, H., ... Wallace, C. (2011). Large-scale gene-centric analysis identifies novel variants for coronary artery disease. PLoS Genetics, 7(9). https://doi.org/10.1371/journal.pgen.1002260

Eiriksdottir, G., Harris, T. B., Launer, L. J., Gudnason, V., Folsom, A. R., Andrews, G., Ballantyne, C. M., Samani, N. J., Hall, A. S., Braund, P. S., Balmforth, A. J., Whincup, P. H., Morris, R., Lawlor, D. A., Lowe, G. D. O., Timpson, N., Ebrahim, S., Ben-Shlomo, Y., Davey-Smith, G., ... Packard, C. J. (2011). Association between C reactive protein and coronary heart disease: Mendelian randomisation analysis based on individual participant data. BMJ Open, 342(7794), 425. [d548]. https://doi.org/10.1136/bmj.d548

Harmsze, A. M., VanWerkum, J. W., Souverein, P. C., Bouman, H. J., Hackeng, C. M., Ruven, H. J. T., Ten Berg, J. M., Klungel, O. H., de Boer, A., & Deneer, V. H. M. (2011). Combined influence of PPIs, CCBs and CYP2C19∗2 on on-treatment platelet reactivitiy and on the occurrence of atherothrombotic events in patients undergoing coronary stent implantation. European Heart Journal, 32, 239-240. https://doi.org/10.1093/eurheartj/ehr322

Belitser, S., Martens, E. P., Pestman, W. R., Groenwold, R. H. H., De Boer, A., & Klungel, O. H. (2011). Measuring balance and model selection in propensity score methods. Pharmacoepidemiology and Drug Safety, 20(11), 1115-1129. https://doi.org/10.1002/pds.2188

Eussen, S. R. B. M., De Jong, N., Rompelberg, C. J. M., Garssen, J., Verschuren, W. M. M., & Klungel, O. H. (2011). Dose-dependent cholesterol-lowering effects of phytosterol/-stanol-enriched margarine in statin users and non-statin users under free-living conditions. European Journal of Pharmacology, 668, 5-6. https://doi.org/10.1016/j.ejphar.2011.09.204

Eussen, S. R. B. M., Rompelberg, C. J. M., Andersson, K. E., Klungel, O. H., Hellstrand, P., & Öste, R. (2011). Simultaneous intake of oat bran and atorvastatin reduces their efficacy to lower lipid levels and atherosclerosis in LDLr-deficient mice. European Journal of Pharmacology, 668, 35-36. https://doi.org/10.1016/j.ejphar.2011.09.276

Maitland-Van Der Zee, A-H., Van Wieren-De Wijer, D. B. M. A., De Boer, A., Kroon, A. A., De Leeuw, P. W., Schiffers, P., Janssen, R. G. J. H., Psaty, B. M., Van Duijn, C. M., Stricker, B. H. C., & Klungel, O. H. (2011). Genetic variation in the renin-angiotensin system, use of renin-angiotensin system inhibitors and the risk of myocardial infarction. Journal of the renin-angiotensin-aldosterone system, 12(3), 208-214. https://doi.org/10.1177/1470320310391834

Klungel, O. (2011). Mondriaan: A dutch 'population' laboratory. Value in Health, 14(7), 423. https://doi.org/10.1016/j.jval.2011.08.1045

de Jong, H. J. I., Cohen Tervaert, J. W., Saldi, S. R. F., Vandebriel, R. J., Souverein, P. C., Meyboom, R. H. B., van Loveren, H., & Klungel, O. H. (2011). Association Between Statin Use and Lupus-Like Syndrome Using Spontaneous Reports. Seminars in Arthritis & Rheumatism, 41(3), 373-381. https://doi.org/10.1016/j.semarthrit.2011.06.002

Eussen, S. R., Rompelberg, C. J., Klungel, O. H., & Van Eijkeren, J. C. (2011). Modelling approach to simulate reductions in LDL cholesterol levels after combined intake of statins and phytosterols/-stanols in humans. Lipids in Health and Disease, 10, [187]. https://doi.org/10.1186/1476-511X-10-187

de Peuter, O. R., Souverein, P. C., Klungel, O. H., Büller, H. R., de Boer, A., & Kamphuisen, P. W. (2011). Non-selective vs. selective beta-blocker treatment and the risk of thrombo-embolic events in patients with heart failure. European Journal of Heart Failure, 13(2), 220-6. https://doi.org/10.1093/eurjhf/hfq176

Groenwold, R. H. H., de Vries, F., de Boer, A., Pestman, W. R., Rutten, F. H., Hoes, A. W., & Klungel, O. H. (2011). Balance measures for propensity score methods: a clinical example on beta-agonist use and the risk of myocardial infarction. Pharmacoepidemiology and Drug Safety, 20(11), 1130-1137. https://doi.org/10.1002/pds.2251

Peters, B. J. M., Pett, H., Klungel, O. H., Stricker, B. H. C., Psaty, B. M., Glazer, N. L., Wiggins, K. L., Bis, J. C., de Boer, A., & Maitland-van der Zee, A-H. (2011). Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI. Atherosclerosis, 217(2), 458-464. https://doi.org/10.1016/j.atherosclerosis.2011.06.023

Groenwold, R. H. H., Klungel, O. H., Grobbee, D. E., & Hoes, A. W. (2011). Selection of confounding variables should not be based on observed associations with exposure. European Journal of Epidemiology, 26(8), 589-593. http://www.ncbi.nlm.nih.gov/pubmed/21796419

Eussen, S. R. B. M., Feenstra, T. L., Toxopeus, I. B., Hoekstra, J., Klungel, O. H., Verhagen, H., van Kranen, H. J., & Rompelberg, C. J. M. (2011). Costs and health effects of adding functional foods containing phytosterols/-stanols to statin therapy in the prevention of cardiovascular disease. European Journal of Pharmacology, 668, S91-S100.

Eussen, S. R. B. M., Bouvy, M. L., Rompelberg, C. J. M., van der Elst, M. E., Garssen, J., Oosterveld, M. H., de Boer, A., de Gier, J. J., van Kranen, H. J., & Klungel, O. H. (2011). Influence of the use of functional foods enriched with phytosterols/-stanols on adherence to statin therapy. Pharmacoepidemiology and Drug Safety, 20(8), 830-7. https://doi.org/10.1002/pds.2168

Wangge, G., Klungel, O. H., Roes, K. C. B., De Boer, A., Hoes, A. W., & Knol, M. J. (2011). Challenges of defining a non-inferiority margin: A case study of non-inferiority randomized controlled trials of oral anti-thrombolytic agents for prophylaxis of venous thromboembolic events after orthopedic surgery. Trials, 12(suppl 1), A32-A32. https://doi.org/10.1186/1745-6215-12-S1-A32

Eussen, S. R. B. M., de Jong, N., Rompelberg, C. J. M., Garssen, J., Verschuren, W. M. M., & Klungel, O. H. (2011). Dose-dependent cholesterol-lowering effects of phytosterol/phytostanol-enriched margarine in statin users and statin non-users under free-living conditions. Public Health Nutrition, 14(10), 1823-1832.

Eussen, S. R. B. M., Verhagen, H., Klungel, O. H., Garssen, J., van Loveren, H., van Kranen, H. J., & Rompelberg, C. J. M. (2011). Functional foods and dietary supplements: Products at the interface between pharma and nutrition. European Journal of Pharmacology, 688, S2-S9. https://doi.org/10.1016/j.ejphar.2011.07.008

De Peuter, O. R., Lip, G. Y., Souverein, P. C., Klungel, O. H., de Boer, A., Buller, H. R., & Kamphuisen, P. W. (2011). Time-trends in treatment and cardiovascular events in patients with heart failure: a pharmacosurveillance study. European Journal of Heart Failure, 13(5), 489-495.

Harmsze, A. M., Van Werkum, J. W., Souverein, P. C., Breet, N. J., Bouman, H. J., Hackeng, C. M., Ruven, H. J. T., Ten Berg, J. M., Klungel, O. H., De Boer, A., & Deneer, V. H. M. (2011). Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention. Journal of Thrombosis and Haemostasis, 9(10), 1892-1901. https://doi.org/10.1111/j.1538-7836.2011.04483.x

van der Baan, F. H., Klungel, O. H., Egberts, A. C. G., Leufkens, H. G. M., Grobbee, D. E., Roes, K. C. B., & Knol, M. J. (2011). Pharmacogenetics in randomized controlled trials: considerations for trial design. Pharmacogenomics, 12(10), 1485-1492. http://www.ncbi.nlm.nih.gov/pubmed/22008051

Knol, M. J., Vanderweele, T. J., Groenwold, R. H. H., Klungel, O. H., Rovers, M. M., & Grobbee, D. E. (2011). Estimating measures of interaction on an additive scale for preventive exposures. European Journal of Epidemiology, 26(6), 433-438. https://doi.org/10.1007/s10654-011-9554-9

Harmsze, A. M., van Werkum, J. W., Moral, F., Ten Berg, J. N., Hackeng, C. M., Klungel, O. H., de Boer, A., & Deneer, V. H. M. (2011). Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients. Platelets, 22(2), 98-102.

Lanktree, M. B., Guo, Y., Murtaza, M., Glessner, J. T., Bailey, S. D., Onland-Moret, N. C., Lettre, G., Ongen, H., Rajagopalan, R., Johnson, T., Shen, H., Nelson, C. P., Klopp, N., Baumert, J., Padmanabhan, S., Pankratz, N., Pankow, J. S., Shah, S., Taylor, K., ... van der Schouw, Y. T. (2011). Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. American Journal of Human Genetics, 88(1), 6-18. http://www.ncbi.nlm.nih.gov/pubmed/21194676

Belitser, S. V., Martens, E. P., Pestman, W. R., Groenwold, R. H. H., de Boer, A., & Klungel, O. H. (2011). Measuring balance and model selection in propensity score methods. Pharmacoepidemiology and Drug Safety, 20(11), 1115-1129. https://doi.org/10.1002/pds.2188

Eussen, S. R. B. M., Rompelberg, C. J. M., Andersson, K. E., Klungel, O. H., Hellstrand, P., Oste, R., van Kranen, H., & Garssen, J. (2011). Simultaneous intake of oat bran and atorvastatin reduces their efficacy to lower lipid levels and atherosclerosis in LDLr-/- mice. Pharmacological Research, 64(1), 36-43.

Vakpublicaties

Harmsze, A. M., van Werkum, J. W., ten Berg, J. M., Ruven, H. J. T., Hackeng, C. M., Tjoeng, M. M., Klungel, O. H., de Boer, A., & Deneer, V. H. M. (2011). Effect van genetische variaties op de effectiviteit van clopidogrel. Pharmaceutisch Weekblad Scientific edition, 5(5), a1111.

Overige resultaten

Groenwold, R. H. H., De Vries, F., De Boer, A., Pestman, W. R., Rutten, F. H., Hoes, A. W., & Klungel, O. H. (2011). Balance measures for propensity score methods: A clinical example on beta-agonist use and the risk of myocardial infarction. Pharmacoepidemiology and Drug Safety, 20, 310. https://doi.org/10.1002/pds.2206

de Boer, A., Harmsze, A. M., Deneer, V. H. M., Maitland - van der Zee, A-H., Peters, B. J. M., Souverein, P. C., Van Werkum, J. W., ten Berg, J. M., Tjoeng, M. M., & Klungel, O. (2011). Interactions between CES2, CYP2C9, UGT1A6 and COX1 genetic variants and acetylsalicylic acid modify the risk of myocardial infarction. Basic & Clinical Pharmacology & Toxicology, 109, 102. https://doi.org/10.1111/j.1742-7843.2011.00722.x

Duijnhoven, R., Dell'Aniello, S., Renoux, C., Tagalakis, V., Knol, M., Klungel, O., & Suissa, S. (2011). Effect of simultaneous use of oestrogens and statins on the risk for venous thromboembolism in post-menopausal women. Pharmacoepidemiology and Drug Safety, 20, 131-132. https://doi.org/10.1002/pds.2206

Abbing-Karahagopian, V., Kurtz, X., De Vries, F., Reynolds, R., & Klungel, O. (2011). Bridging differences in findings from observational pharmacoepidemiological studies: The design and rationale of work-package 2 of the protect project. Pharmacoepidemiology and Drug Safety, 20, 34. https://doi.org/10.1002/pds.2206

Eussen, S., Rompelberg, C. J. M., Andersson, K., Klungel, O., Hellstrand, P., Öste, R., & Garssen, J. (2011). Simultaneous intake of oat bran and atorvastatin reduces their efficacy to lower total cholesterol and atherosclerosis in ldl-receptor-deficient mice. Atherosclerosis Supplements, 12(1), 139.

De Jong, H. J., Vandebriel, R. J., Saldi, S. R., Van Dijk, L., Van Loveren, H., Tervaert, J. W. C., & Klungel, O. H. (2011). Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and the risk of developing rheumatoid arthritis in antihypertensive patients. Pharmacoepidemiology and Drug Safety, 20(S1), S68. [157]. https://doi.org/10.1002/pds.2206

De Jong, H. J., Saldi, S. R., Klungel, O. H., Vandebriel, R. J., Souverein, P. C., Meyboom, R. H., Passier, A., Van Loveren, H., & Tervaert, J. W. C. (2011). The association between statin use and polymyalgia rheumatica/arteritis temporalis: Demonstrated by spontaneous reports and self-described case-reports. Pharmacoepidemiology and Drug Safety, 20(S1), S67. [155]. https://doi.org/10.1002/pds.2206

Khong, P. T., De Vries, F., Goldenberg, J. S. B., Klungel, O. H., & Petri, H. (2011). Potential impact of benzodiazepine use on the rate of hip fractures in Denmark (DK), the Netherlands (NL) and Norway (NO). Pharmacoepidemiology and Drug Safety, 20(S1), 30-31. [69]. https://doi.org/10.1002/pds.2206

Goldenberg, J. S. B., Petri, H., Khong, P. T., Klungel, O. H., & De Vries, F. (2011). Potential population impact of antidepressant use on hip fractures rate in Denmark (DK), Norway (NO) and the Netherlands (NL). Pharmacoepidemiology and Drug Safety, 20(S1), S30. [67]. https://doi.org/10.1002/pds.2206

Van Der Baan, F. H., Knol, M. J., Klungel, O. H., Egberts, T. C. G., Grobbee, D. E., & Roes, K. C. B. (2011). Potential of adaptive clinical trial designs in pharmacogenetic research, A simulation based on the IPASS trial. Pharmacoepidemiology and Drug Safety, 20(18), S8-S9. [18]. https://doi.org/10.1002/pds.2206

Van Der Baan, F. H., Gregoor, J. G., Loovers, H. M., Klungel, O. H., Egberts, T. C. G., Grobbee, D. E., Knol, M. J., & Van Der Weide, J. (2011). Cytochrome P-450 2D6 and 2C19 polymorphisms and consumption of care in psychiatric practice. Pharmacoepidemiology and Drug Safety, 20(S1), S6-S7. [14]. https://doi.org/10.1002/pds.2206

2010

Wetenschappelijke publicaties

Eussen, S., Klungel, O., & Bouvy, M. (2010). Weten en cholesterol meten. Pharmaceutisch Weekblad, 145(13), 35.

Harmsze, A. M., Deneer, V. H., Maitland-van Der Zee, A. H., De Boer, A., & Klungel, O. H. (2010). Genetische variaties beïnvloeden effectiviteit en veiligheid van geneesmiddelen. Nederlands Tijdschrift voor Geneeskunde, 154(28), 1329-1333.

Eussen, S., Van Der Elst, M., Klungel, O., Rompelberg, C., Garssen, J., Oosterveld, M., De Boer, A., De Gier, J., & Bouvy, M. (2010). A randomized controlled trial of the effect of a pharmaceutical care program on improving adherence to statin therapy: The statin intervention research project (STIPT). 35-36. https://doi.org/10.1002/pds.2019

Harmsze, A. M., Robijns, K., Van Werkum, J. W., Breet, N. J., Hackeng, C. M., Ten Berg, J. M., Ruven, H. J. T., Klungel, O. H., De Boer, A., & Deneer, V. H. M. (2010). The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thrombosis and Haemostasis, 103(5), 920-925. https://doi.org/10.1160/TH09-08-0516

Eussen, S. R. B. M., Van Der Elst, M. E., Klungel, O. H., Rompelberg, C. J. M., Garssen, J., Oosterveld, M. H., De Boer, A., De Gier, J. J., & Bouvy, M. L. (2010). A pharmaceutical care program to improve adherence to statin therapy: A randomized controlled trial. Annals of Pharmacotherapy, 44(12), 1905-1913. https://doi.org/10.1345/aph.1P281

Milder, I. E. J., Klungel, O. H., Mantel-Teeuwisse, A. K., Verschuren, W. M. M., & Bemelmans, W. J. E. (2010). Relation between body mass index, physical inactivity and use of prescription drugs: the Doetinchem Cohort Study. International Journal of Obesity, 34(6), 1060-9. https://doi.org/10.1038/ijo.2010.2

Taverne, K., de Groot, M., de Boer, A., & Klungel, O. (2010). Genetic polymorphisms related to the renin-angiotensin-aldosterone system and response to antihypertensive drugs. Expert Opinion on Drug Metabolism and Toxicology, 6(4), 439-60. https://doi.org/10.1517/17425250903571670

Wangge, G., Klungel, O. H., Roes, K. C. B., de Boer, A., Hoes, A. W., & Knol, M. J. (2010). Room for improvement in conducting and reporting non-inferiority randomized controlled trials on drugs: a systematic review. PLoS One, 5(10), e13550. https://doi.org/10.1371/journal.pone.0013550

Harmsze, A. M., van Werkum, J. W., ten Berg, J. M., Zwart, B., Bouman, H. J., Breet, N. J., van 't Hof, A. W., Ruven, H. J., Hackeng, C. M., Klungel, O. H., de Boer, A., & Deneer, V. H. M. (2010). CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. European Heart Journal, 31(24), 3046-3053. https://doi.org/10.1093/eurheartj/ehq321

Harmsze, A. M., Deneer, V. H., Maitland-van der Zee, A. H., de Boer, A., & Klungel, O. H. (2010). Genetische variaties beïnvloeden effectiviteit en veiligheid van geneesmiddelen. Nederlands Tijdschrift voor Geneeskunde, 154(A1503), A1503.

Eussen, S. R. B. M., Klungel, O. H., Garssen, J., Verhagen, H., van Kranen, H., van Loveren, H., & Rompelberg, C. J. (2010). Support of drug therapy using functional foods and dietary supplements: focus on statin therapy. British Journal of Nutrition, 103, 1260-1277.

Peters, B. J. M., Rodin, A. S., Klungel, O. H., van Duijn, C. M., Stricker, B. H. C., van't Slot, R., de Boer, A., & Maitland-van der Zee, A-H. (2010). Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction. Pharmacogenomics, 11(8), 1065-1076. https://doi.org/10.2217/pgs.10.81

Groenwold, R. H. H., Hak, E., Klungel, O. H., & Hoes, A. W. (2010). Instrumental variables in influenza vaccination studies: mission impossible?! Value in Health, 13(1), 132-137. http://www.ncbi.nlm.nih.gov/pubmed/19695007

Eussen, S. R. B. M., de Jong, N., Rompelberg, C. J., Garssen, J., Verschuren, W. M., & Klungel, O. H. (2010). Effects of the use of phytosterol/-stanol-enriched margarines on adherence to statin therapy. Pharmacoepidemiology and Drug Safety, 19(12), 1225-1232.

Peters, B. J. M., Rodin, A. S., Klungel, O. H., Stricker, B. H. C., Bruno, H. C., de Boer, A., & Maitland-van der Zee, A. H. (2010). Variants of ADAMTS1 modify the effectiveness of statins in reducing the risk of myocardial infarction. Pharmacogenetics and Genomics, 20(12), 766-774.

Harmsze, A., van Werkum, J. W., Bouman, H. J., Ruven, H. J., Breet, N. J., Ten Berg, J. M., Hackeng, C. M., Tjoeng, M. M., Klungel, O. H., de Boer, A., & Deneer, V. H. (2010). Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. Pharmacogenetics and Genomics, 20(1), 18-25. https://doi.org/10.1097/FPC.0b013e328333dafe

Wangge, G., Klungel, O. H., Roes, K. C. B., de Boer, A., Hoes, A. W., & Knol, M. J. (2010). Interpretation and inference in noninferiority randomized controlled trials in drug research. Clinical Pharmacology and Therapeutics, 88(3), 420-423. https://doi.org/10.1038/clpt.2010.134

Overige resultaten

De Peuter, O., Lip, G. Y. H., Souverein, P. C., Klungel, O. H., de Boer, A., Büller, H. R., & Kamphuisen, P. W. (2010). Time-trends in treatment and cardiovascular events in patients with heart failure: A pharmacosurveillance study. 39. https://doi.org/10.1159/000318096

Wangge, G., Klungel, O. H., Roes, K. C. B., De Boer, A., Hoes, A. W., & Knol, M. J. (2010). Room for improvements in conducting and reporting non-inferiority randomized controlled trials on drugs. 73-74. Abstract from 26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. https://doi.org/10.1002/pds.2019

De Peuter, O. R., Souverein, P. C., Klungel, O. H., Lip, G. Y., Buller, H. R., De Boer, A., & Kamphuisen, P. W. (2010). Non-selective beta-blockers decrease thrombotic events in patients with heart failure. 268. https://doi.org/10.1016/S0735-1097(10)60269-0

De Peuter, O. R., Lip, G. Y. H., Souverein, P. C., Klungel, O. H., De Boer, A., Buller, H. R., & Kamphuisen, P. W. (2010). Time-trends in treatment and cardiovascular events in patients with heart failure: A pharmacosurveillance study. 1052-1053. https://doi.org/10.1093/eurheartj/ehq290

Harmsze, A. M., Van Werkum, J. W., Taubert, D., Hackeng, C. M., Ruven, H. J., Ten Berg, J. M., Klungel, O. H., de Boer, A., & Deneer, V. H. M. (2010). Concomitant use of esomeprazole, but not pantoprazole, is associated with lower plasma concentrations of clopidogrel's active thiol metabolite and higher on-clopidogrel platelet aggregation. European Heart Journal, 31(S1), 968. https://doi.org/10.1093/eurheartj/ehq290

van der Baan, F. H., Klungel, O. H., Grobbee, D. E., Egberts, A. C. G., & Knol, M. J. (2010). Suitable Study Designs for Pharmacogenetic Research. S90, 210. Abstract from Abstracts of the 26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 19-22 August 2010, Brighton, UK.

Peters, B. J. M., Pett, H., de Boer, A., Klungel, O. H., & Maitland-van der Zee, A. H. (2010). The PCSK9 E670G Polymorphism Modifies the Effectiveness of Statins in Reducing the Risk of Myocardial Infarction. S114. Abstract from Abstracts of the 26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 19-22 August 2010, Brighton, UK.

Klungel, O. H., Rietveld, M., de Groot, M. C. H., Stolk, R. P., Postma, M. J., Leufkens, H. G. M., Egberts, A. C. G., Hövels, A. M., van de Langerijt, L., de Bruijn, W., Hoes, A. W., & Grobbee, D. E. (2010). The Mondriaan Project: The Dutch Healthcare Landscape as a Population Laboratory. S177, 418. Abstract from Abstracts of the 26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 19-22 August 2010, Brighton, UK.

Eussen, S. R. B. M., van der Elst, M. E., Klungel, O. H., Rompelberg, C. J., Garssen, J., Oosterveld, M., de Boer, A., de Gier, J. J., & Bouvy, M. L. (2010). A Randomized Controlled Trial of the Effect of a Pharmaceutical Care Program on Improving Adherence to Statin Therapy: The STatin Intervention Research ProjecT (STIPT). S35. Abstract from Abstracts of the 26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 19-22 August 2010, Brighton, UK.

2009

Wetenschappelijke publicaties

Plat, A. W., Stoffers, H. E. J. H., Klungel, O. H., van Schayck, C. P., de Leeuw, P. W., Soomers, F. L., Schiffers, P. M., Kester, A. D. M., & Kroon, A. A. (2009). The contribution of six polymorphisms to cardiovascular risk in a Dutch high-risk primary care population: The HIPPOCRATES project. Journal of Human Hypertension, 23(10), 659-667. https://doi.org/10.1038/jhh.2009.6

Van Der Zee, A. H. M., Van Wieren-De Wijer, D. B. M. A., Stricker, B. H. C., De Boer, A., Kroon, A. A., Psaty, B. M., & Klungel, O. H. (2009). Reply. Journal of Hypertension, 27(6), 1328-1329. https://doi.org/10.1097/HJH.0b013e32832bb882

Klungel, O. H., & De Boer, A. (2009). Verdere studie nodig naar rol staties bij diabetes. Pharmaceutisch Weekblad, 144(7), 16-19.

Klungel, O. H., Rietveld, A. C. M., De Groot, M. C., Stolk, R. P., Postma, M. J., Leufkens, H. G., Egberts, T. C., Hövels, A. M., van de Langerijt, L., Hoes, A. W., & Grobbee, D. E. (2009). The mondriaan project: The dutch health care landscape as a population laboratory. Value in Health, 12(7), 392.

De Peuter, O. R., Souverein, P. C., Klungel, O. H., De Boer, A., Büller, H. R., & Kamphuisen, P. W. (2009). Non-selective beta-blockers decrease thrombotic events in patients with heart failure. Journal of Thrombosis and Haemostasis, 7(S2), 215. http://hdl.handle.net/11370/9ad01c77-c6e3-4f17-a179-d48877bc82b2

Bozkurt, O., De Boer, A., Grobbee, D. E., De Leeuw, P. W., Kroon, A. A., Schiffers, P., & Klungel, O. H. (2009). Variation in renin-angiotensin system and salt-sensitivity genes and the risk of diabetes mellitus associated with the use of thiazide diuretics. American Journal of Hypertension, 22(5), 545-551. https://doi.org/10.1038/ajh.2009.38

Peters, B. J. M., Klungel, O. H., de Boer, A., Ch Stricker, B. H., & Maitland-van der Zee, A-H. (2009). Pharmacogenetics of cardiovascular drug therapy. Clinical Cases in Mineral and Bone Metabolism, 6(1), 55-65.

van Wieren-de Wijer, D. B. M. A., Maitland-van der Zee, A-H., de Boer, A., Kroon, A. A., de Leeuw, P. W., Schiffers, P., Janssen, R. G. J. H., Psaty, B. M., van Duijn, C. M., Stricker, B. H. C., & Klungel, O. H. (2009). Interaction between the Gly460Trp alpha-adducin gene variant and diuretics on the risk of myocardial infarction. Journal of Hypertension, 27(1), 61-8. https://doi.org/10.1097/HJH.0b013e328317a74d

van Wieren-de Wijer, D. B. M. A., Maitland-van der Zee, A-H., de Boer, A., Kroon, A. A., de Leeuw, P. W., Schiffers, P., Janssen, R. G. J. H., Psaty, B. M., van Duijn, C. M., Stricker, B. H. C., & Klungel, O. H. (2009). Reasons for non-response in observational pharmacogenetic research. Pharmacoepidemiology and Drug Safety, 18(8), 665-71. https://doi.org/10.1002/pds.1764

Bozkurt, Ö., de Boer, A., Grobbee, D. E., Kroon, A. A., Schiffers, P., de Leeuw, P., & Klungel, O. H. (2009). Renin-angiotensin system polymorphisms and the association between use of angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors and the risk of diabetes. Journal of the renin-angiotensin-aldosterone system, 10(2), 101-108. https://doi.org/10.1177/1470320309104877

van Wieren-de Wijer, D. B. M. A., Maitland-van der Zee, A. H., de Boer, A., Belitser, S. V., Kroon, A. A., de Leeuw, P. W., Schiffers, P., Janssen, R. G. J. H., van Duijn, C. M., Stricker, B. H. C. H., & Klungel, O. H. (2009). Determinants of DNA yield and purity collected with buccal cell samples. European Journal of Epidemiology, 24(11), 677-82. https://doi.org/10.1007/s10654-009-9388-x

Peters, B. J. M., Klungel, O. H., de Boer, A., & Maitland-van der Zee, A-H. (2009). Genetic determinants of response to statins. Expert Review of Cardiovascular Therapy, 7(8), 977-983. https://doi.org/10.1586/erc.09.83

Peters, B. J., Klungel, O. H., Visseren, F. L., de Boer, A., & Maitland-van der Zee, A-H. (2009). Pharmacogenomic insights into treatment and management of statin-induced myopathy. Genome Medicine, 1(12), 120. https://doi.org/10.1186/gm120

van Bruggen, J. A. R., Gorter, K. J., Stolk, R. P., Zuithoff, P., Klungel, O. H., & Rutten, G. E. H. M. (2009). Refill adherence and polypharmacy among patients with type 2 diabetes in general practice. Pharmacoepidemiology and Drug Safety, 18(11), 983-991. http://www3.interscience.wiley.com/journal/122518283/abstract?CRETRY=1&SRETRY=0

van Bruggen, J. A. R., Gorter, K. J., Stolk, R. P., Klungel, O. H., & Rutten, G. E. H. M. (2009). Clinical inertia in general practice: widespread and related to the outcome of diabetes care. Family Practice, 26(4), 428-436.

van Wieren-de Wijer, D. B. M. A., Maitland-van der Zee, A-H., de Boer, A., Stricker, B. H. C., Kroon, A. A., de Leeuw, P. W., Bozkurt, O., & Klungel, O. H. (2009). Recruitment of participants through community pharmacies for a pharmacogenetic study of antihypertensive drug treatment. Pharmacy World & Science, 31(2), 158-164. https://doi.org/10.1007/s11096-008-9264-x

van Wieren-de Wijer, B. M. A., Maitland-van der Zee, A. H., de Boer, A., Kroon, A. A., de Leeuw, P. W., Schiffers, P. M., Janssen, R. G. J. H., Psaty, B. M., van Duijn, C. M., Stricker, B. H. C., & Klungel, O. H. (2009). Interaction between the Fly460Trp α-adducin gene variant and diuretics on the risk of myocardial infarction. Journal of Hypertension, 27, 61-68.

Vink, N. M., Klungel, O. H., Stolk, P., & Denig, P. (2009). Comparison of various measures for assessing medication refill adherence using prescription data. Pharmacoepidemiology and Drug Safety, 18, 159-165.

Vakpublicaties

Klungel, O. H., & de Boer, A. (2009). Wel nadere studie nodig rol statines bij diabetes. Visie op statines blijft overeind. Pharmaceutisch Weekblad, februari, 16-20.

Overige resultaten

Bozkurt, O., De Boer, A., Grobbee, D. E., Leeuw, P. W. D., Kroon, A. A., Schiffers, P., & Klungel, O. H. (2009). Variation in renin-angiotensin system and salt sensitivity genes and the risk of diabetes mellitus associated with the use of thiazide diuretics. 23. Abstract from 25th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, United States. https://doi.org/10.1002/pds.1806

Van Wieren-De Wijer, D. B. M. A., Maitland-Van Der Zee, A. H., De Boer, A., Kroon, A. A., De Leeuw, P. W., Schiffers, P., Janssen, R. G. J. H., Psaty, B. M., Van Duijn, C. M., Stricker, B. H. C., & Klungel, O. H. (2009). Interaction between the G894TeNOS gene variant and calcium antagonists on the risk of myocardial infarction. 162-163. https://doi.org/10.1002/pds.1806

De Boer, A., Harmsze, A. M., Van Werkum, J. W., Deneer, V. D., Ruven, H. J., Klungel, O. H., Hackeng, C. M., & Ten Berg, J. M. (2009). Influence of proton pump inhibitors on the antiplatelet properties of two clopidogrel dosing regimens and the role of CYP2C19 genotype. 28. https://doi.org/10.1111/j.1742-7843.2009.00436.x

Eussen, S., Van Der Elst, M., Rompelberg, C., Garssen, J., Van Loveren, H., Bouvy, M., Oosterveld, M., De Boer, A., De Gier, J., & Klungel, O. (2009). Effects of phytosterols on pattern and effectiveness of statin use: Preliminary results of a post-marketing study. 128-129. https://doi.org/10.1002/pds.1806

De Peuter, O. R., Souverein, P. C., Klungel, O. H., de Boer, A., Büller, H. R., & Kamphuisen, P. W. (2009). Non-Selective ß-Blockers Decrease Thrombotic Events in Patients with Heart Failure. Pharmacoepidemiology and Drug Safety, 18, S114.

Eussen, S. R. B. M., van der Elst, M. E., Rompelberg, C. J., Garssen, J., Bouvy, M. L., Oostervelt, M. H., de Boer, A., de Gier, J. J., & Klungel, O. H. (2009). Effects of functional foods enriched with plant sterols/-stanols on effectiveness and pattern of statin therapy. Poster session presented at Internl Conf. on Pharmacoepidemiology and Therapeutic Risk Management, Rhode Island, USA.

van Wieren-de Wijer, B. M. A., Maitland-van der Zee, A. H., de Boer, A., Kroon, A. A., de Leeuw, P. W., Schiffers, P. M. H., Janssen, R. G. J. H., Psaty, B. M., van Duijn, C. M., Stricker, B. H. C., & Klungel, O. H. (2009). Interaction between the G894T eNOS Gene Variant and Calcium Antagonists on the Risk of Myocardial Infarction. Pharmacoepidemiology and Drug Safety, 18, S162.

Harmsze, A. M., van Werkum, J. W., Deneer, V. H. M., Ruven, H. J., Klungel, O. H., Hackeng, C. M., ten Berg, J. M., & de Boer, A. (2009). Influence of Proton Pump Inhibitors on the Anti-platelet Properties of Two Clopidogrel Dosing regimens and the Role of CYP2C19 Genotype. Pharmacoepidemiology and Drug Safety, 18, S131.

van der Baan, F. H., Knol, M. J., de Bruin, M. L., Leufkens, H. G. M., Klungel, O. H., & Egberts, A. C. G. (2009). Impact of a Safety Issue on the Number and Type of Publications: The Example of Sertindole. Pharmacoepidemiology and Drug Safety, 18, S170.

de Jong, H. J. I., Klungel, O. H., van Dijk, C. E. M. J., Vandebriel, R. J., Leufkens, H. G. M., Cohen Tervaert, J. W., & van Loveren, H. (2009). Use of Statins and the Risk of Rheumatoid Arthritis. Pharmacoepidemiology and Drug Safety, 18, S126.

Eussen, S. R. B. M., van der Elst, M. E., Rompelberg, C. J., Garssen, J., van Loveren, H., Oosterveld, M., de Boer, A., Bouvy, M. L., de Gier, J. J., & Klungel, O. H. (2009). Effects of Phytosterols on Pattern and Effectiveness of Statin Use: Prreliminary Results of a Post-Marketing Study. Pharmacoepidemiology and Drug Safety, 18, S128.

2008

Wetenschappelijke publicaties

Breekveldt-Postma, N. S., Penning-Van Beest, F. J. A., Siiskonen, S. J., Falvey, H., Vincze, G., Klungel, O. H., & Herings, R. M. C. (2008). The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. Current Medical Research and Opinion, 24(1), 121-127. https://doi.org/10.1185/030079908X253843

Breekveldt-Postma, N. S., Penningvan Beest, F. J. A., Siiskonen, S. J., Koerselman, J., Klungel, O. H., Falvey, H., Vincze, G., & Herings, R. M. C. (2008). Effect of persistent use of antihypertensives on blood pressure goal attainment. Current Medical Research and Opinion, 24(4), 1025-1031. https://doi.org/10.1185/030079908X280554

Swen, J. J., Wilting, I., De Goede, A. L., Grandia, L., Mulder, H., Touw, D. J., De Boer, A., Conemans, J. M. H., Egberts, T. C. G., Klungel, O. H., Koopmans, R., Van Der Weide, J., Wilffert, B., Guchelaar, H-J., & Deneer, V. H. M. (2008). Corrigendum: Pharmacogenetics: From bench to byte (Clinical Pharmacology and Therapeutics (2008) 83, 5, (781-787) DOI: 10.1038/sj.clpt.6100507). Clinical Pharmacology and Therapeutics, 84(1), 175. https://doi.org/10.1038/clpt.6100624

de Vries, F., Pouwels, S., Bracke, M., Lammers, J-W., Leufkens, B., Klungel, O., & van Staa, T. (2008). Use of inhaled corticosteroids and the risk of non-fatal acute myocardial infarction. Journal of Hypertension, 26(1), 124-129. https://doi.org/10.1097/HJH.0b013e3282f0ab4a

de Vries, F., Pouwels, S., Bracke, M., Lammers, J-W., Klungel, O., Leufkens, H., & van Staa, T. (2008). Use of β2 agonists and risk of acute myocardial infarction in patients with hypertension. British Journal of Clinical Pharmacology, 65(4), 580-586. https://doi.org/10.1111/j.1365-2125.2007.03077.x

Swen, J. J., Wilting, I., de Goede, A. L., Grandia, L., Mulder, H., Touw, D. J., de Boer, A., Conemans, J. M. H., Egberts, T. C. G., Klungel, O. H., Koopmans, R., van der Weide, J., Wilffert, B., Guchelaar, H-J., & Deneer, V. H. M. (2008). Pharmacogenetics: from bench to byte. Clinical Pharmacology and Therapeutics, 83(5), 781-787. https://doi.org/10.1038/sj.clpt.6100507

Schelleman, H., Klungel, O. H., Witteman, J. C. M., Breteler, M. M. B., Hofman, A., van Duijn, C. M., de Boer, A., & Stricker, B. H. C. (2008). Interaction between polymorphisms in the renin-angiotensin-system and angiotensin-converting enzyme inhibitor or beta-blocker use and the risk of myocardial infarction and stroke. The Pharmacogenomics Journal, 8(6), 400-7. https://doi.org/10.1038/sj.tpj.6500493

Schalekamp, T., Klungel, O. H., Souverein, P. C., & de Boer, A. (2008). Increased Bleeding Risk With Concurrent Use of Selective Serotonin Reuptake inhibitors and Coumarins. Archives of Internal Medicine, 168(2), 180-185. https://doi.org/10.1001/archinternmed.2007.32

Schalekamp, T., Klungel, O. H., Souverein, P. C., & de Boer, A. (2008). Effect of oral antiplatelet agents on major bleeding in users of coumarins. Thrombosis and Haemostasis, 100(6), 1076-1083.

Bozkurt, O., Verschuren, W. M. M., van Wieren-de Wijer, B. M. A., Knol, M. J., de Boer, A., Grobbee, D. E., Geerlings, M. I., Heerdink, E. R., & Klungel, O. H. (2008). Genetic variation in the renin-angiotensin system modifies the beneficial effects of ACE inhibitors on the risk of diabetes mellitus among hypertensives. Journal of Human Hypertension, 22(11), 774-780. https://doi.org/10.1038/jhh.2008.62

van Wijk, B. L. G., Shrank, W. H., Klungel, O. H., Schneeweiss, S., Brookhart, A. M., & Avorn, J. (2008). A cross-national study of the persistence of antihypertensive medication use in the elderly. Journal of Hypertension, 26, 145-153.
https://dspace.library.uu.nl/bitstream/handle/1874/32597/wijk_08_across-nationalstudyofthepersistence.pdf?sequence=2

Peters, B. J. M., Maitland-van der Zee, A-H., Stricker, B. H. C., van Wieren-de Wijer, D. B. M. A., de Boer, A., Kroon, A. A., de Leeuw, P. W., Schiffers, P., Janssen, R. G. J. H., van Duijn, C. M., & Klungel, O. H. (2008). Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variant. Pharmacogenetics and Genomics, 18(7), 631-636. https://doi.org/10.1097/FPC.0b013e3283023fb2

van Wieren-de Wijer, B. M. A., Klungel, O. H., & Maitland-van der Zee, A. H. (2008). Are there interactions between the Gly460Trp alpha-adducin gene variant and the use of diuretics? Personalized Medicine, 5(2), 117-121.

Derijks, H. J., Heerdink, E. R., de Koning, F. H., Janknegt, R., Klungel, O. H., & Egberts, A. C. G. (2008). The association between antidepressant use and hypoglycaemia in diabetic patients: a nested case-control study. Pharmacoepidemiology and Drug Safety, 2008(17), 336-344.

Schelleman, H., Klungel, O. H., Witteman, J. C. M., Breteler, M. M. B., Hofman, A., van Duijn, C. M., de Boer, A., & Stricker, B. H. C. (2008). Interaction between polymorphisms in the renin-angiotensin-system and angiotensin-converting enzyme inhibitor or β-blocker use and the risk of myocardial infarction and stroke. The Pharmacogenomics Journal, 6(1), 22-26.

Martens, E. P., de Boer, A., Pestman, W. R., Belitser, S. V., Stricker, B. H. C., & Klungel, O. H. (2008). Comparing treatment effects after adjustment with multivariable Cox proportional hazards regression and propensity score methods. Pharmacoepidemiology and Drug Safety, 17(1), 1-8. https://doi.org/10.1002/pds.1520

Klungel, O. H., Storimans, M. J., Floor-Schreudering, A., Talsma, H., Rutten, G. E. H. M., & de Blaey, C. J. (2008). Perceived diabetes status is independently associated with glucose monitoring behaviour among type 2 diabetes mellitus patients. Primary Care Diabetes, 2, 25-30.
https://dspace.library.uu.nl/bitstream/handle/1874/32214/klungel_08_perceiveddiabetesstatus.pdf?sequence=1

Martens, E. P., Pestman, W. R., de Boer, A., Belitser, S., & Klungel, O. H. (2008). Systematic differences in treatment effect estimates between propensity score methods and logistic regression. International Journal of Epidemiology, 37, 1142-1147.

Vakpublicaties

Klungel, O., & De Boer, A. (2008). Primaire preventie met statines is zinvoller dan gerapporteerd. Pharmaceutisch Weekblad, 143(7), 14-15.

Klungel, O. H., & de Boer, A. (2008). Reacties Onderwaardering. Pharmaceutisch Weekblad, 16, 10.

Klungel, O. H., & de Boer, A. (2008). Publieksmedia zaaien nieuwe onrust onder statinegebruikers. Primaire preventie zinvoller dan gemeld. Pharmaceutisch Weekblad, 7, 14-16.

Overige resultaten

Klungel, O. H., van Wieren-de Wijer, B. M. A., de Boer, A., Kroon, A. A., Psaty, B. M., van Duijn, C., Stricker, B. H. C., & Maitland-van der Zee, A. H. (2008). Renin-Angiotensin System Polymorphisms, Use of ACE Inhibitors and the Risk of Myocardial Infarction. S4. Abstract from 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management.

Bozkurt, O., de Boer, A., Grobbee, D. E., Kroon, A. A., Schiffers, P. M., de Leeuw, P. W., & Klungel, O. H. (2008). Renin-Angiotensin-System Polymorphisms, Use of Angiotensin Receptor Blockers and the Risk of Diabetes. S264. Abstract from 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management.

Eijgelsheim, M., Klungel, O. H., & Stricker, B. H. C. (2008). ACE-Inhibitors and Angiotensionogen M235T Variant Interact in Type 2 Diabetes Mellitus Risk. S119. Abstract from 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management.

Harmsze, A. M., van Werkum, J. W., Deneer, V. H. M., Ruven, H. J., Klungel, O. H., Hackeng, C. M., ten Berg, J. M., & de Boer, A. (2008). The Effect of Seven Genetic Variants on the Response to Clopidogrel. S5. Abstract from 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management.

van Wieren-de Wijer, B. M. A., Maitland-van der Zee, A. H., de Boer, A., Kroon, A. A., de Leeuw, P. W., Schiffers, P. M., Janssen, R. J., van Duijn, C. M., Stricker, B. H. C., & Klungel, O. H. (2008). Interactions between the Gly460Trp alpha-adducin gene variant and diuretics and the risk of myocardial infarction among treated hypertensive patients. 296. Abstract from Dutch Society of Clinical Pharmacology an Biopharmacy Meeting.

Peters, B. J. M., Maitland-van der Zee, A. H., Stricker, B. H. C., van Wieren-de Wijer, B. M. A., de Boer, A., Kroon, A. A., de Leeuw, P. W., Schiffers, P. M., Janssen, R. G. J. H., van Duijn, C. M., & Klungel, O. H. (2008). Effectiveness of Statins in the Reduction of the Risk of Myocardial Infarction Is Modified by the GNB3 C825T Variant. S263. Abstract from 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management.

2007

Wetenschappelijke publicaties

Penning-Van Beest, F. J. A., Termorshuizen, F., Goettsch, W. G., Klungel, O. H., Kastelein, J. J. P., & Herings, R. M. C. (2007). Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: A cohort study. European Heart Journal, 28(2), 154-159. https://doi.org/10.1093/eurheartj/ehl391

de Vries, F., Pouwels, S., Bracke, M., Klungel, O., Lammers, J-W., Leufkens, H., & van Staa, T. (2007). Evidence for no association between use of beta-2-agonists and risk of acute myocardial infarction in patients with hypertension. Pharmacoepidemiology and Drug Safety.

Van Wijk, B. L. G., Avorn, J., Solomon, D. H., Klungel, O. H., Heerdink, E. R., de Boer, A., & Brookhart, A. M. (2007). Herstarten van antihypertensiva. Pharmaceutisch Weekblad, 142(38), 118-120.

Schelleman, H., Klungel, O. H., Witteman, J. C. M., Breteler, M. M. B., Hofman, A., van Duijn, C. M., de Boer, A., & Stricker, B. H. C. (2007). Diuretic-gene interaction and the risk of myocardial infarction and stroke. The Pharmacogenomics Journal, 7(5), 346-52. https://doi.org/10.1038/sj.tpj.6500428

van Wijk, B. L. G., Avorn, J., Solomon, D. H., Klungel, O. H., Heerdink, E. R., de Boer, A., & Brookhart, A. M. (2007). Rates and determinants of reinitiating antihypertensive therapy after prolonged stoppage: a population-based study. Journal of Hypertension, 25(3), 689-697. https://doi.org/10.1097/HJH.0b013e3280148a58

Schelleman, H., Klungel, O. H., Witteman, J. C. M., Hofman, A., van Duijn, C. M., de Boer, A., & Stricker, B. H. C. (2007). Pharmacogenetic interactions of three candidate gene polymorphisms with ACE-inhibitors or β-blockers and the risk of atherosclerosis. British Journal of Clinical Pharmacology, 64(1), 57-66. https://doi.org/10.1111/j.1365-2125.2007.02848.x

Schelleman, H., Klungel, O. H., Witteman, J. C. M., Breteler, M. M. B., Yazdanpanah, M., Danser, A. H. J., Hofman, A., van Duijn, C. M., de Boer, A., & Stricker, B. H. C. (2007). Angiotensinogen M235T polymorphism and the risk of myocardial infarction and stroke among hypertensive patients on ACE-inhibitors or beta-blockers. European Journal of Human Genetics, 15(4), 478-484. https://doi.org/10.1038/sj.ejhg.5201789

Gumbs, P. D., Verschuren, W. M. M., Souverein, P. C., Mantel-Teeuwisse, A. K., de Wit, G. A., de Boer, A., & Klungel, O. H. (2007). Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution. British Journal of Clinical Pharmacology, 64(5), 680-685. https://doi.org/10.1111/j.1365-2125.2007.02958.x

Maitland-van der Zee, A. H., Boerwinkle, E., Arnett, D. K., Davis, B. R., Leiendecker-Foster, C., Miller, M. B., Klungel, O. H., Ford, C. E., & Eckfeldt, J. H. (2007). Absence of an interaction between the angiotensinconverting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: The Genetics of Hypertension-Associated Treatment (GenHAT) study. American Heart Journal, 153, 54-58.
https://dspace.library.uu.nl/bitstream/handle/1874/27365/maitland_07_absenceofaninteractionbetween.pdf?sequence=2

Isaacs, A., Aulchenko, YS., Hofman, A., Sijbrands, E. J., A Sayed-Tabatabaei, F., Klungel, O. H., Maitland-van der Zee, A. H., Stricker, B. H. C., Oostra, B. A., Witteman, J. C., & van Duijn, C. M. (2007). The CETP 1405V Polymorphism Is Associated with Increased HDL Levels and Decreased Risk of Myocardial Infarction: The Rotterdam Study. European Journal of Cardiovascular Prevention and Rehabilitation, 14(3), 419-421.

Yazdanpanah, M., Aulchenko, YS., Hofman, A., Janssen, J. A., A Sayed-Tabatabaei, F., van Schaik, R. H., Klungel, O. H., Stricker, B. H. C., Pols, H. A., Witteman, J. C., Lamberts, S. W. J., Oostra, B. A., & van Duijn, C. M. (2007). Effects of the renin-angiotensin system genes and salt sensitivity genes on bloodpressure and atherosclerosis in the total population and patients with type 2 diabetes. Diabetes, 56(7), 1905-1912.

de Jong, N., Klungel, O. H., Verhagen, H., Wolfs, M. C. J., Ocké, M. C., & Leufkens, H. G. M. (2007). Functional foods: the case for closer evaluation. BMJ (International edition), 334, 1037-1039.
https://dspace.library.uu.nl/bitstream/handle/1874/27387/klungel_07_functionalfoods.pdf?sequence=1

Knol, M. J., Heerdink, E. R., Egberts, A. C. G., Geerlings, M. I., Gorter, K. J., Numans, M. E., Grobbee, D. E., Klungel, O. H., & Burger, H. (2007). Depressive symptoms in subjects with diagnosed and undiagnosed Type 2 diabetes. Psychosomatic Medicine, 69(4), 300-305.
https://dspace.library.uu.nl/bitstream/handle/1874/27104/knol_07_depressivesymptomsinsubjects.pdf?sequence=1

Isaacs, A., Aulchenko, YS., Hofman, A., Sijbrands, E. J., A Sayed-Tabatabaei, F., Klungel, O. H., Maitland-van der Zee, A. H., Stricker, B. H. C., Oostra, B. A., Witteman, J. C., & van Duijn, C. M. (2007). Epistatic Effect of CEPT and LIPC on Serum HDL Levels: The Rotterdam Study. Journal of Clinical Endocrinology and Metabolism, 92, 2680-2687.

Bozkurt, O., de Boer, A., Grobbee, D. E., Heerdink, E. R., Burger, H., & Klungel, O. H. (2007). Pharmacogenetics of glucose-lowering drug treatment: a systematic review. Molecular Diagnosis & Therapy, 11(8), 291-302.
https://dspace.library.uu.nl/bitstream/handle/1874/27324/bozkurt_07_pharmacogeneticsofglucoselowering.pdf?sequence=1

Storimans, M. J., Klungel, O. H., Talsma, H., & de Blaey, C. J. (2007). Differences in the association between structural factors and diabetes self-monitoring support. Pharmacy World & Science, 29(6), 676-682.
https://dspace.library.uu.nl/bitstream/handle/1874/27390/storimans_07_differencesintheassociation.pdf?sequence=2

Gumbs, P. D., Verschuren, M. W. M., Mantel-Teeuwisse, A. K., de Wit, A. G., de Boer, A., & Klungel, O. H. (2007). Economic evaluations of cholesterol-lowering drugs: a critical and systematic review. PharmacoEconomics, 25(3), 187-199.
https://dspace.library.uu.nl/bitstream/handle/1874/396837/gumbs_07_economicevaluationsofcholesterol.pdf?sequence=1

van Rijn, MJ., Bos, M. J., Isaacs, A., Yazdanpanah, M., Arias-Vásquez, A., Stricker, B. H. C., Klungel, O. H., Oostra, B. A., Koudstaal, P. J., Witteman, J. C., Hofman, A., Breteler, M. M. B., & van Duijn, C. M. (2007). Polymorphisms of the renin-angiotensin system are associated with blood pressure, atherosclerosis and cerebral white matter pathology. Journal of Neurology, Neurosurgery and Psychiatry, 78(10), 1083-1087.

Dobre, D., van Veldhuisen, D. J., DeJongste, M. J., van Sonderen, E., Klungel, O. H., Sanderman, R., Ranchor, A. V., & Haaijer-Ruskamp, F. (2007). The contribution of observational studies to the knowledge of drug effectiveness in heart failure. British Journal of Clinical Pharmacology, 64(4), 406-414.

Martens, E. P., Pestman, W. R., & Klungel, O. H. (2007). Conditioning on the propensity score can result in biased estimation of common measures of treatment effect: a Monte Carlo study (p n/a) by Austin PC et al. Statistics in Medicine, 26, 3208-3210.
https://dspace.library.uu.nl/bitstream/handle/1874/27375/martens_07_conditioningonthepropensityscore.pdf?sequence=2

Overige resultaten

de Vries, F., Pouwels, S., Bracke, M., Klungel, O., Lammers, J-W., Leufkens, H., & van Staa, T. (2007). Evidence for no association between use of beta-2-agonists and risk of acute myocardial infarction in patients with hypertension. S40-S40. Abstract from 23rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management.

van Wijk, B. L. G., Shrank, W. H., Klungel, O. H., Dhall, J., Levin, R., & Avorn, J. (2007). A Cross-National Study of Persistence of Antihypertensive Medication Use in the Elderly. S200. Abstract from 23rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management.

van Wieren-de Wijer, B. M. A., Maitland-van der Zee, A. H., de Boer, A., Stricker, B. H. C., & Klungel, O. H. (2007). Interactions between the Gly460Trp Alpha-Adducin Gene Variant and Diuretics and the Risk of Myocardial Infarction among Treated Hypertensive Patients. S24. Abstract from 23rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management.

van Wijk, B. L. G., Avorn, J., Solomon, D. H., Klungel, O. H., Heerdink, E. R., de Boer, A., & Brookhart, A. M. (2007). Rates and Determinants of Reinitiating Antihypertensive Therapy after Prolonged Stoppage. S199. Abstract from 23rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management.

Schalekamp, T., Klungel, O. H., Souverein, P. C., & de Boer, A. (2007). Effect of Oral Antiplatelet Drugs on Major Bleeding among Users of Coumarin Anticoagulants. S50. Abstract from 23rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management.

Martens, E. P., Pestman, W. R., de Boer, A., Belitser, S., & Klungel, O. H. (2007). An Important Advantage of Propensity Score Methods Compared to Logistic Regression Analysis. S114. Abstract from 23rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management.

Peters, B. J. M., Maitland-van der Zee, A. H., Stricker, B. H. C., van Wieren-de Wijer, B. M. A., de Boer, A., Kroon, A. A., de Leeuw, P. W., Schiffers, P. M., Janssen, R., van Duijn, C. M., & Klungel, O. H. (2007). Effectiveness of Statins is modified by the GNB3 C825T variant. The PHARMO-genetics study. Abstract from Unknown event, Asilomar, USA.

Martens, E. P., Pestman, W. R., de Boer, A., Belitser, S., & Klungel, O. H. (2007). The Use of the Overlapping Coefficient in Propensity Score Analysis. S1. Abstract from 23rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management.

2006

Wetenschappelijke publicaties

Gumbs, P. D., Verschuren, W. M. M., Mantel-Teeuwisse, A. K., de Wit, G. A., Hofman, A., Trienekens, P. H., Stricker, B. H. C., de Boer, A., & Klungel, O. H. (2006). Drug costs associated with non-adherence to cholesterol management guidelines for primary prevention of cardiovascular disease in an elderly population: The Rotterdam Study. Drugs and Aging, 23(9), 733-741. https://doi.org/10.2165/00002512-200623090-00003

Van Wijk, B. L. G., Klungel, O. H., Heerdink, E. R., & de Boer, A. (2006). Generic substitution of antihypertensive drugs: does it affect adherence? Annals of Pharmacotherapy, 40(1), 15-20. https://doi.org/10.1345/aph.1G163

Schalekamp, T., Boink, G. J. J., Visser, L. E., Stricker, B. H. C., de Boer, A., & Klungel, O. H. (2006). CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring? Clinical Pharmacology and Therapeutics, 79(6), 511-520. https://doi.org/10.1016/j.clpt.2006.03.008

Van Wijk, B. L. G., Klungel, O. H., Heerdink, E. R., & de Boer, A. (2006). A comparison of two multiple-characteristic decision-making models for the comparison of antihypertensive drug classes: Simple Additive Weighting (SAW) and Technique for Order Preference by Similarity to an Ideal Solution (TOPSIS). American journal of cardiovascular drugs : drugs, devices, and other interventions, 6(4), 251-258.

Schelleman, H., Klungel, O. H., Witteman, J. C. M., Breteler, M. M. B., Hofman, A., van Duijn, C. M., de Boer, A., & Stricker, B. H. C. (2006). Diuretic-gene interaction and the risk of myocardial infarction and stroke. The Pharmacogenomics Journal, 1-7.
https://dspace.library.uu.nl/bitstream/handle/1874/27460/schelleman_06_diureti-geneinteractionandtherisk.pdf?sequence=2

Martens, E. P., Pestman, W. R., de Boer, A., Belitser, S., & Klungel, O. H. (2006). Instrumental Variables. Application and limitations. Epidemiology, 17(3), 260-267. https://doi.org/10.1097/01.ede.0000215160.88317.cb

Storimans, M. J., Klungel, O. H., Talsma, H., & de Blaey, C. J. (2006). Regional influences on the dispensing of glucose test strips in Dutch community pharmacies. Pharmacy World & Science, 28, 26-32.
https://dspace.library.uu.nl/bitstream/handle/1874/27446/storimans_06_regionalinfluences.pdf?sequence=2

Schelleman, H., Klungel, O. H., van Duijn, C. M., Witteman, J. C. M., Hofman, A., de Boer, A., & Stricker, B. H. C. (2006). Drug-gene interaction between the insertion/deletion polymorphism of the angiotensin-converting enzyme gene and antihypertensive therapy. Annals of Pharmacotherapy, 40(2), 212-218. https://doi.org/10.1345/aph.1G316

Mantel-Teeuwisse, A. K., Klungel, O. H., Hofman, A., Verschuren, W. M. M., Trienekens, P. H., Porsius, A. J., Stricker, B. H. C., & de Boer, A. (2006). Prescribing behaviour according to Dutch and European guidelines on the management of hypercholesterolaemia (1992-1999). British Journal of Clinical Pharmacology, 61(5), 592-600. https://doi.org/10.1111/j.1365-2125.2006.02634.x

Van Wijk, B. L. G., Klungel, O. H., Heerdink, E. R., & de Boer, A. (2006). Initial non-compliance with antihypertensive monotherapy is followed by complete discontinuation of antihypertensive therapy. Pharmacoepidemiology and Drug Safety, 15(8), 587-93. https://doi.org/10.1002/pds.1239

Van Wijk, B. L. G., Klungel, O. H., Heerdink, E. R., & de Boer, A. (2006). Refill persistence with chronic medication assessed from a pharmacy database was influenced by method of calculation. Journal of Clinical Epidemiology, 59(1), 11-17. https://doi.org/10.1016/j.jclinepi.2005.05.005

Schelleman, H., Klungel, O. H., Witteman, J. C. M., Hofman, A., van Duijn, C. M., de Boer, A., & Stricker, B. H. C. (2006). The influence of the alpha-adducin G460W polymorphism and angiotensinogen M235T polymorphism on antihypertensive medication and blood pressure. European Journal of Human Genetics, 14, 860-866.
https://dspace.library.uu.nl/bitstream/handle/1874/27452/schelleman_06_theinfluenceofthealphaadducing460wpolymorphism.pdf?sequence=2

Vakpublicaties

Mantel-Teeuwisse, A. K., & Klungel, O. H. (2006). Zijn cholesterolverlagende margarines werkzaam en is er een interactie met statines? Internisten Vademecum, 11(10).
https://dspace.library.uu.nl/bitstream/handle/1874/27422/mantel_06_zijncholesterolverlagendemargarineswerkzaam.pdf?sequence=2

Overige resultaten

Bozkurt, O., Verschuren, M. W. M., de Boer, A., Grobbee, D. E., Geerlings, M. I., Heerdink, E. R., Stricker, B. H. C., & Klungel, O. H. (2006). Interaction between Genetic Polymorphisms in the Renin-Angiotensin-System and the Risk of Diabetes Associated with the Use of ACE Inhibitors. S135. Abstract from Unknown event, Asilomar, USA.

Knol, M. J., Heerdink, E. R., Egberts, A. C. G., Gorter, K. J., Numans, M. E., Grobbee, D. E., Klungel, O. H., & Burger, H. (2006). Depression in type 2 diabetes consequence rather than cause. European Journal of Epidemiology, 21(suppl.), 85.

Maitland-van der Zee, A. H., Boerwinkle, E., Arnett, D. K., Davis, B. R., Leiendecker-Foster, C., Miller, M. B., Klungel, O. H., Ford, C. E., & Eckfeldt, J. E. (2006). Absence of an Interaction between the Angiotensin Converting Enzyme (ACE) Insertion-Deletion Polymorphism and Pravastatin on Cardiovascular Disease in High-Risk Hypertensives: The GenHAT Study. S19. Abstract from Unknown event, Asilomar, USA.

Penning-van Beest, F. J. A., Goettsch, W. G., Klungel, O. H., Kastelein, J. J. P., & Herings, R. M. C. (2006). Adherence to Evidence-Based Statin Guidlines Reduces Risk for Acute Myocardial Infarction by 40%. S293. Abstract from Unknown event, Asilomar, USA.

van Wijk, B. L. G., Klungel, O. H., Heerdink, E. R., & de Boer, A. (2006). A Comparison of Two Multiple Characteristics Decision Making Techniques for the Comparison of Antihypertensive Drugs: Simple additive Weighting and Technique for Order Preference by Similarity to an Ideal Solution. S224. Abstract from Unknown event, Asilomar, USA.

Mantel-Teeuwisse, A. K., van der Elst, M. E., Klungel, O. H., Bouvy, M. L., de Blaey, C. J., & de Boer, A. (2006). Acute Effects of Discontinuation of Statin Treatment on the Occurrence of a First Myocardial Infarction. S247. Abstract from Unknown event, Asilomar, USA.

Schelleman, H., Klungel, O. H., Witteman, J. C. M., Breteler, M. M. B., Danser, J. H. J., Hofman, A., van Duijn, C. M., de Boer, A., & Stricker, B. H. C. (2006). Angiotensinogen M235T Polymorphism and the Risk of Myocardial Infarction and Stroke among Hypertensive Patients on ACE-Inhibitors or beta-Blockers. S144. Abstract from Unknown event, Asilomar, USA.

Bozkurt, O., Verschuren, W. M. M., de Boer, A., Grobbee, D. E., Geerlings, M. I., Heerdink, E. R., Stricker, B. H. C., & Klungel, O. H. (2006). Genetic polymorphisms in the ras and risk of diabetes associated with the use of ACE inhibitors: the Doetinchem study. 119. Abstract from Unknown event, Asilomar, USA.

Derijks, H. J., de Koning, G. H. P., Heerdink, E. R., Janknegt, R., Klungel, O. H., & Egberts, A. C. G. (2006). The Association between Antidepressant Use and Hypoglycemia in Diabetic Patients: A Nested Case-Control Study. S42. Abstract from Unknown event, Asilomar, USA.

Martens, E. P., Pestman, W. R., de Boer, A., Belitser, S., Smets, Y. F. C., Westendorp, R. G. J., & Klungel, O. H. (2006). Instrumental Variables and Survival Outcomes: The Effect of Pancreas-Kidney versus Kidney Transplantation on Mortality. S93. Abstract from Unknown event, Asilomar, USA.

Schelleman, H., Klungel, O. H., Witteman, J. C. M., van Duijn, C. M., Hofman, A., Breteler, M. M. B., de Boer, A., & Stricker, B. H. C. (2006). Diuretic-Gene Interactions and the Risk of Myocardial Infarction and Stroke. S17. Abstract from Unknown event, Asilomar, USA.

2005

Wetenschappelijke publicaties

Erkens, J. A., Panneman, M. M. J., Klungel, O. H., van de Boom, G., Prescott, M. F., & Herings, R. M. C. (2005). Differences in antihypertensive drug persistence associated with drug class and gender: A PHARMO study. Pharmacoepidemiology and Drug Safety, 14(11), 795-803. https://doi.org/10.1002/pds.1156

Van Wijk, B. L. G., Klungel, O. H., Heerdink, E. R., & De Boer, A. (2005). Compliantie, adherentie en persistentie bij antihypertensiva: Apotheker zou therapietrouw moeten bevorderen. Pharmaceutisch Weekblad, 140(48), 1543-1545.

Gumbs, P. D., Verschuren, W. M. M., Mantel-Teeuwisse, A. K., De Boer, A., & Klungel, O. H. (2005). Medicamenteuze behandling van hypercholesterolemie kosteneffectief. Pharmaceutisch Weekblad, 140(32), 982-983.

Storimans, M. J., Klungel, O. H., Talsma, H., Bouvy, M. L., & De Blaey, C. J. (2005). Collaborative services among community pharmacies for patients with diabetes. Annals of Pharmacotherapy, 39(10), 1647-1653. https://doi.org/10.1345/aph.1G109

van Wijk, B. L. G., Klungel, O. H., Heerdink, E. R., & De Boer, A. (2005). Rate and determinants of 10-year persistence with antihypertensive drugs. Journal of Hypertension, 23(11), 2101-2107. https://doi.org/10.1097/01.hjh.0000187261.40190.2e

Maitland-Van Der Zee, A. H., Klungel, O. H., Stricker, B. H. C., & De Boer, A. (2005). Farmacogenetica van statines. Hart Bulletin, 36(6), 159-161.

Wu, H. L., Nijssen, L. E., Van Der Salm, A., Denee, T. R., De Boer, A., & Klungel, O. H. (2005). Statines bij het acuut coronair syndroom. Pharmaceutisch Weekblad, 140(32), 995-997.

Gumbs, P. D., Verschuren, W. M. M., Mantel-Teeuwisse, A. K., De Boer, A., & Klungel, O. H. (2005). Kosteneffectiviteit van statines. Pharmaceutisch Weekblad, 140(32), 982-983.

Van Wijk, B. L., Klungel, O. H., Heerdink, E. R., & de Boer, A. (2005). Effectiveness of interventions by community pharmacists to improve patient adherence to chronic medication: a systematic review. Annals of Pharmacotherapy, 39(2), 319-28. https://doi.org/10.1345/aph.1E027

Maitland-van der Zee, A. H., Turner, S. T., Schwartz, G. L., Chapman, A. B., Klungel, O. H., & Boerwinkle, E. (2005). Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects. American Journal of Hypertension, 18, 1077-1083.
https://dspace.library.uu.nl/bitstream/handle/1874/11669/maitland_05_demographic_environmental_andgeneticpredictors.pdf?sequence=2

Maitland-van der Zee, A. H., Turner, S. T., Schwartz, G. L., Chapman, A. B., Klungel, O. H., & Boerwinkle, E. (2005). Multilocus approach to the pharmacogenetics of thiazide diuretics. In Circulation (pp. III-428)

Maitland-van der Zee, A. H., Klungel, O. H., & de Boer, A. (2005). Genetic Polymorphisms and Response to HMG-CoA Reductase Inhibitors. In M. K. Raizada, J. F. R. Paton, S. Kasparov, & M. J. Katovich (Eds.), Contemporary Cardiology: Cardiovascular Genomics (pp. 95-114). Humana Press.
https://dspace.library.uu.nl/bitstream/handle/1874/11671/maitland_geneticpolymorphismsandresponsetohmg_coa.pdf?sequence=2

Schelleman, H., Stricker, B. H. C., Verschuren, W. M. M., de Boer, A., Kroon, A. A., de Leeuw, P. W., Kromhout, D., & Klungel, O. H. (2005). Interactions between five candidate genes and antihypertensive drug therapy on blood pressure. The Pharmacogenomics Journal, 6(1), 22-26. https://doi.org/10.1038/sj.tpj.6500339

Hommerson, P., Nedeljkovic, S. I., Klungel, O. H., de Boer, A., Ostojic, M. C., Grujic, M. Z., Vojvodic, N. M., Bloemberg, B. P. M., & Kromhout, D. (2005). Cardiovascular drug use and differences in the incidence of cardiovascular mortality in elderly Serbian men. Pharmacy World & Science, 27(2), 124-128. https://doi.org/s11096-004-1559-y

Erkens, J. A., Panneman, M. M., Klungel, O. H., van den Boom, G., Prescott, M. F., & Herings, R. M. C. (2005). Differences in antihypertensive drug persitence associated with drug class and gender: a PHARMO study. Pharmacoepidemiology and Drug Safety, 14(11), 795-803.
https://dspace.library.uu.nl/bitstream/handle/1874/11655/klungel_05_differences_in_antihypertensivedrugpersistence.pdf?sequence=2

Maitland-van der Zee, A. H., Turner, S. T., Schwartz, G. L., Chapman, A. B., Klungel, O. H., & Boerwinkle, E. (2005). A multilocus approach to the pharmacogenetics of thiazide diuretics. American Journal of PharmacoGenomics, 15(5), 287-293.
https://dspace.library.uu.nl/bitstream/handle/1874/11668/maitland_05_amultilocus_approachtothepharmacogenetics.pdf?sequence=2

Storimans, M. J., Klungel, O. H., Talsma, H., Bouvy, M. L., & de Blaey, C. J. (2005). Collaborative Services Among Community Phamacies for Patients with Diabetes. Annals of Pharmacotherapy, 39.
https://dspace.library.uu.nl/bitstream/handle/1874/11815/storimans_05_collaborativeservicesamongcommunity.pdf?sequence=2

Mantel-Teeuwisse, A. K., Klungel, O. H., Schalekamp, T., Verschuren, W. M. M., Porsius, A. J., & de Boer, A. (2005). Suboptimal choices and dosing of statins at start of therapy. British Journal of Clinical Pharmacology, 60(1), 83-89.
https://dspace.library.uu.nl/bitstream/handle/1874/11872/boer_05_MantelSuboptimalChoicesandDosing.pdf?sequence=2

Schelleman, H., Klungel, O. H., van Duijn, C. M., Witteman, J. C. M., Hofman, A., de Boer, A., & Stricker, B. H. C. (2005). Insertion/deletion polymorphism of the ACE gene and adherence to ACE inhibitors. British Journal of Clinical Pharmacology, 59(4), 483-485. https://doi.org/10.1111/j.1365-2125.2004.02332.x

Vakpublicaties

Van Wijk, B. L. G., Klungel, O. H., Heerdink, E. R., & De Boer, A. (2005). apothekers en therapietrouw. Pharmaceutisch Weekblad, 140(48), 1543-1545.

Klungel, O. H., Grobbee, D. E., & De Boer, A. (2005). Onderbouwd voorschrijven van antihypertensiva. Geneesmiddelenbulletin, 39(2), 13-24.

Wu, H. L., Nijssen, L. E., van der Salm, A., Denee, T. R., de Boer, A., & Klungel, O. H. (2005). Statines bij acuut coronair syndroom. Pharmaceutisch Weekblad, 32, 995-997.
https://dspace.library.uu.nl/bitstream/handle/1874/11870/Boer_05_Statinesbijacuutcoronairsyndroom.pdf?sequence=2

Mantel-Teeuwisse, A. K., & Klungel, O. H. (2005). Zijn Cholesterolverlagende margarines werkzaam en is er een interactie met statines? Apothekers vademecum, 1(6).

Mantel-Teeuwisse, A. K., & Klungel, O. H. (2005). Zijn cholesterolverlagende margarines werkzaam en is er een interactie met statines? Cardiologen Vademecum, 9(3).
https://dspace.library.uu.nl/bitstream/handle/1874/11673/mantel_05_zijncholesterolverlagendemargarineswerkzaam.pdf?sequence=2

Gumbs, P. D., Verschuren, W. M. M., Mantel-Teeuwisse, A. K., de Boer, A., & Klungel, O. H. (2005). Medicamenteuze behandeling van hypercholesterolemie kosteneffectief. Pharmaceutisch Weekblad, 32, 982-983.
https://dspace.library.uu.nl/bitstream/handle/1874/11875/boer_05_GumbsMedicamenteuzebehandelingvanhypercholesterolemie.pdf?sequence=2

Overige resultaten

Maitland-van der Zee, A. H., Turner, S. T., Schwartz, G. L., Chapman, A. B., Klungel, O. H., & Boerwinkle, E. (2005). Demographic, Environmental, and Genetic Predictors of Metabolic Side Effects of Hydrochlorothiazide Treatment in Hypertensive Subjects. S168. Abstract from Unknown event, Asilomar, USA.

Storimans, M. J., Klungel, O. H., Talsma, H., Bouvy, M. L., & de Blaey, C. J. (2005). Local Collaborations Independently Affect the Provision of Community Pharmacy Services to Patients Performing Self-Monitoring of Blood Glucose. S122. Abstract from Unknown event, Asilomar, USA.

Schelleman, H., Stricker, B. H. C., Verschuren, W. M. M., de Boer, A., Kroon, A. A., de Leeuw, P. W., Kromhout, D., & Klungel, O. H. (2005). Drug-Gene Interaction between Five Candidate Genes and the Response to Antihypertensive Drug Therapy on Blood Pressure. S124. Abstract from Unknown event, Asilomar, USA.

Schelleman, H., Klungel, O. H., Witteman, J. C. M., Hofman, A., van Duijn, C. M., de Boer, A., & Stricker, B. H. C. (2005). The Influence of the alpha-Adducin G460W Polymorphism, Angiotensinogen M235T Polymorphism, and Angiotensin Converting Enzyme I/D Polymorphism on Blood Pressure Response to Antihypertensive Medication. S51. Abstract from Unknown event, Asilomar, USA.

van Wijk, B. L. G., Klungel, O. H., Heerdink, E. R., & de Boer, A. (2005). 10 Year Persistence in Use of Antihypertensive Drugs. S197. Abstract from Unknown event, Asilomar, USA.

Martens, E. P., Pestman, W. R., de Boer, A., Belitser, S., & Klungel, O. H. (2005). Lower and Upper Bounds on the Correlation between Treatment and Instrumental Variable Limit the Applicability of the Method. S40. Abstract from Unknown event, Asilomar, USA.

van Wijk, B. L. G., Klungel, O. H., Heerdink, E. R., & de Boer, A. (2005). Non-compliance with antihypertensive drugs is associated with discontinuation of antihypertensive drugs.. 137. Abstract from Unknown event, Asilomar, USA.

2004

Wetenschappelijke publicaties

Storimans, M. J., Klungel, O. H., Talsma, H., & De Blaey, C. J. (2004). Geographic region influences pharmacy's dispensing of blood glucose test strips [3]. Annals of Pharmacotherapy, 38(10), 1751-1752. https://doi.org/10.1345/aph.1E135

Florentinus, S. R., Heerdink, E. R., Klungel, O. H., De Boer, A., Kastelein, J. J. P., Wolfe, S. M., Cohen, J. S., Olsson, G. O., & Fox, J. C. (2004). Should rosuvastatin be withdrawn from the market? [1] (multiple letters). Lancet, 364(9445), 1577-1580. https://doi.org/10.1016/S0140-6736(04)17301-7

Maitland-van der Zee, A. H., Klungel, O. H., Stricker, B. H. C., Veenstra, D. L., Kastelein, J. J. P., Hofman, A., Witteman, J. C. M., Leufkens, H. G. M., van Duijn, C. M., & de Boer, A. (2004). Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor therapy in men. Pharmacogenetics, 14(1), 53-60. https://doi.org/10.1097/00008571-200401000-00006

Florentinus, S. R., Heerdink, E. R., Klungel, O. H., & de Boer, A. (2004). Should rosuvastatin be withdrawn from the market? The Lancet, 364(9445), 1577; author reply 1578-9. https://doi.org/10.1016/S0140-6736(04)17301-7

Maitland-van, D. Z. A-H., Klungel, O. H., & de Boer, A. (2004). Pharmacogenetics in health-care practice. Pharmacy World & Science, 26(5), 253-5.

Maitland-van der Zee, A-H., Klungel, O. H., Leufkens, H. G. M., de Boer, A., Stricker, B. H. C., Hofman, A., Witteman, J. C. M., van Duijn, C. M., & Kastelein, J. J. P. (2004). Effectiveness of HMG-CoA reductase inhibitors is modified by the ACE insertion deletion polymorphism. Atherosclerosis, 175(2), 377-379. https://doi.org/10.1016/j.atherosclerosis.2004.04.009

Mantel-Teeuwisse, A. K., Verschuren, W. M. M., Klungel, O. H., de Boer, A., & Kromhout, D. (2004). Recent trends in (under)treatment of hypercholesterolaemia in the Netherlands. British Journal of Clinical Pharmacology, 58(3), 310-316. https://doi.org/10.1111/j.1365-2125.2004.02152.x

Maitland-van der Zee, A. H., Klungel, O. H., & de Boer, A. (2004). Pharmcogenetics in health-care practice. Pharmacy World & Science, 26, 253-255.
https://dspace.library.uu.nl/bitstream/handle/1874/11888/boer_04_MaitlandPharmcogeneticsinhealth_carepractice.pdf?sequence=2

Goettsch, W. G., Yin, D. D., Alemao, E., Klungel, O. H., Stalenhoef, A. F., & Herings, R. M. C. (2004). Statins are less effective in common daily practice among patients with hypercholesterolemia: the REALITY-PHARMO study. Current Medical Research and Opinion, 20(7), 1025-1033.
https://dspace.library.uu.nl/bitstream/handle/1874/11654/klungel_04_statins_are_less_effective_via_pharma_statins.pdf?sequence=2

Mantel-Teeuwisse, A. K., Klungel, O. H., Egberts, T. C. G., Verschuren, W. M. M., Porsius, A. J., & de Boer, A. (2004). Failure to continue lipid-lowering drug use following the withdrawal of cerivastatin. Drug Safety, 27(1), 63-70.
https://dspace.library.uu.nl/bitstream/handle/1874/396967/boer_04_MantelFailuretoContinueLipid_LoweringDrugUse.pdf?sequence=1

Schelleman, H., Klungel, O. H., Kromhout, D., de Boer, A., Stricker, B. H. C., & Verschuren, W. M. M. (2004). Prevalence and determinants of undertreatment of hypertension in the Netherlands. Journal of Human Hypertension, 18(5), 317-324. https://doi.org/10.1038/sj.jhh.1001672

Storimans, M. J., Talsma, H., Klungel, O. H., & de Blaey, C. J. (2004). Dispensing glucose test materials in Dutch community pharmacies. Pharmacy World & Science, 26, 52-55.
https://dspace.library.uu.nl/bitstream/handle/1874/11812/storimans_04_dispensingglucosetestmaterialsindutch.pdf?sequence=2

Klungel, O. H., Martens, E. P., Psaty, B. M., Grobbee, D. E., Sullivan, S. D., Stricker, B. H. C., Leufkens, H. G. M., & de Boer, A. (2004). Methods to assess intended effects of drug treatment in observational studies are reviewed. Journal of Clinical Epidemiology, 57(12), 1223-1231. https://doi.org/10.1016/j.jclinepi.2004.03.011

Spoelstra, J. A., Stolk, R. P., Cohen, D., Klungel, O. H., Erkens, J. A., Leufkens, H. G. M., & Grobbee, D. E. (2004). Antipsychotic Drugs May Worsen Metabolic Control in Type 2 Diabetes Mellitus. Journal of Clinical Psychiatry, 65(5), 674-678.

Maitland-van der Zee, A. H., Klungel, O. H., Stricker, B. H. C., Verschuren, W. M. M., Witteman, J. C. M., Stijnen, T., Hofman, A., Breteler, M. M. B., Leufkens, H. G. M., & de Boer, A. (2004). Comparison of two methodologies to analyze exposure to statins in an observational study on effectiveness. Journal of Clinical Epidemiology, 57(3), 237-242. https://doi.org/10.1016/j.jclinepi.2003.07.011

van Wijk, B. L. G., Klungel, O. H., Heerdink, E. R., & de Boer, A. (2004). The association between compliance with antihypertensive drugs and modification of antihypertensive drug regimen. Journal of Hypertension, 22, 1831-1837.
https://dspace.library.uu.nl/bitstream/handle/1874/11879/boer_04_WijkvanTheAssociationBetweenCompliance.pdf?sequence=2

Maitland-van der Zee, A. H., Klungel, O. H., Stricker, B. H. C., Veenstra, D. L., Kastelein, J. J. P., Hofman, A., Witteman, J. C. M., Leufkens, H. G. M., van Duijn, C. M., & de Boer, A. (2004). Pharmacoeconomic evaluation of testing for angiotensinconverting enzyme genotype before starting ß-hydrocy-ß-methylglutaryl coenzyme A reductase inhibitor therapy in men. Pharmacogenetics, 14, 53-60.
https://dspace.library.uu.nl/bitstream/handle/1874/11889/boer_04_MaitlandPharmacoeconomicEvaluation.pdf?sequence=2

Erkens, J. A., Klungel, O. H., Stolk, R. P., Spoelstra, J. A., Grobbee, D. E., & Leufkens, H. G. M. (2004). Antihypertensive drug therapy and the risk of lower extremity amputations in pharmacologically treated type 2 diabetes patients. Pharmacoepidemiology and Drug Safety, 13, 139-146.
https://dspace.library.uu.nl/bitstream/handle/1874/315386/erkens_04_antihypertensivedrugtherapyandtherisk.pdf?sequence=1

Mantel-Teeuwisse, A. K., Goettsch, W. G., Klungel, O. H., de Boer, A., & Herings, R. M. C. (2004). Long term persistence with statin treatment in daily medical practice. Heart, 90(9), 1065-1066. https://doi.org/10.1136/hrt.2003.026187

Florentinus, S. R., Heerdink, E. R., Klungel, O. H., & de Boer, A. (2004). Should rosuvastatin be withdrawn from the market? The Lancet, 364, 1577-1580.
https://dspace.library.uu.nl/bitstream/handle/1874/11893/boer_04_FlorentinusShouldRosuvastatinBeWithdrawn.pdf?sequence=2

Spoelstra, J. A., Stolk, R. P., Klungel, O. H., Erkens, J. A., Rutten, G. E. H. M., Leufkens, H. G. M., & Grobbee, D. E. (2004). Initiation of glucose-lowering therapy in Type 2 diabetes mellitus patients in general practice. Diabetic Medicine, 21, 896-900.
https://dspace.library.uu.nl/bitstream/handle/1874/10658/Rutten_04_Spoelstra_Diab%2520Med_2004_21_896-900.pdf?sequence=2

Schelleman, H., Stricker, B. H. C., De Boer, A., Kroon, A. A., Verschuren, M. W. M., Van Duijn, C. M., Psaty, B. M., & Klungel, O. H. (2004). Drug-Gene Interactions between Genetic Polymorphisms and Antihypertensive Therapy. Drugs, 64(16), 1801-1816.
https://dspace.library.uu.nl/bitstream/handle/1874/11882/boer_04_SchellemanDrug_GeneInteractions_between.pdf?sequence=2

Storimans, M. J., Klungel, O. H., Talsma, H., & de Blaey, C. J. (2004). Geographic region influences pharmacy's dispensing of blood glucose test strips. Annals of Pharmacotherapy, 38, 1751-1752.
https://dspace.library.uu.nl/bitstream/handle/1874/11814/storimans_04_geograficregioninfluences.pdf?sequence=2

Vakpublicaties

Mantel-Teeuwisse, A. K., & Klungel, O. H. (2004). Zijn cholesterol verlagende margarines werkzaam en is er een interactie met statines? Apothekers vademecum, 5(7).
https://dspace.library.uu.nl/bitstream/handle/1874/11672/mantel_04_zijncholesterolverlagendemargarines.pdf?sequence=2

Overige resultaten

Maitland-van der Zee, A. H., Klungel, O. H., Stricker, B. H. C., Veenstra, D. L., Kastelein, J. J. P., Hofman, A., Witteman, J. C. M., Leufkens, H. G. M., van Duijn, C. M., & de Boer, A. (2004). Pharmacoecomic evaluation of testing for angiotensin converting enzyme (ACE) genotype before starting HMG-COA reductase therapy in men. 115. Abstract from Unknown event, Asilomar, USA.

Storimans, M. J., Klungel, O. H., Talsma, H., Floor-Schreudering, A., & de Blaey, C. J. (2004). Patients' Opinions of Their Diabetes Control Is Associated with the Frequenty of Self-Monitoring of Blood Glucose. S208. Abstract from Unknown event, Asilomar, USA.

Martens, E. P., de Boer, A., Pestman, W. R., Belitser, S., & Klungel, O. H. (2004). Comparing Intended Treatment Effects after Adjustment with a Multivariable Cox Proportional Hazards Model and Propensity Score Methods in an Observational Study. S16. Abstract from Unknown event, Asilomar, USA.

Mantel-Teeuwisse, A. K., Klungel, O. H., Hofman, A., Verschuren, W. M. M., Trienekens, P. H., Porsius, A. J., Stricker, B. H. C., & de Boer, A. (2004). The Need To Change Prescibing Behaviour According to Dutch and European Guidelines on the Management of Hypercholesterolemia. S28. Abstract from Unknown event, Asilomar, USA.

van Wijk, B. L. G., Klungel, O. H., Heerdink, E. R., & de Boer, A. (2004). Comparison of Different Methods To Calculate Persistance of Drug Use by Using Pharmacy Records. S44. Abstract from Unknown event, Asilomar, USA.

Storimans, M. J., Klungel, O. H., Talsma, H., & de Blaey, C. J. (2004). Community pharmacy is an independent determinant of the dispensing of blood glucose teststrips to diabetic patients.. 112. Abstract from Unknown event, Asilomar, USA.

Schelleman, H., Klungel, O. H., van Duijn, C. M., Witteman, J. C. M., Hofman, A., de Boer, A., & Stricker, B. H. C. (2004). Insertion/Deletion Ploymorphism of the Ace Gene and Antihypertensive Response to Ace-Inhibitors. S108. Abstract from Unknown event, Asilomar, USA.

Maitland-van der Zee, A. H., Stricker, B. H. C., Klungel, O. H., Kastelein, J. J. P., Hofman, A., Witteman, J. C. M., Leufkens, H. G. M., van Duijn, C. M., & de Boer, A. (2004). The effectiveness of HMG-COA reductase inhibitors is affected by ACE insertion deletion polymorphism. 361. Abstract from Unknown event, Asilomar, USA.

Storimans, M. J., Klungel, O. H., Talsma, H., Floor-Schreudering, A., & de Blaey, C. J. (2004). Patients' opinions of their diabetes control is associated with the frequency of self-monitoring of blood glucose.. S208-S209. Abstract from Unknown event, Asilomar, USA.

Mantel-Teeuwisse, A. K., Goettsch, W. G., Klungel, O. H., de Boer, A., & Herings, R. M. C. (2004). Determinants of persistence with statin use in daily medical practice. 361. Abstract from Unknown event, Asilomar, USA.

Lievers, C. J. A., de Boer, A., Stricker, B. H. C., de Wijer, B. M. A., Kroon, A. A., de Leeuw, P. W., van Duijn, C. M., Verschuren, W. M. M., & Klungel, O. H. (2004). Interactions between Genetic Polymorphisms and Antiypertensive Drugs in the Treatment of Hypertension. S109. Abstract from Unknown event, Asilomar, USA.

van Wijk, B. L. G., Klungel, O. H., Heerdink, E. R., & de Boer, A. (2004). Non-Compliance with Antihypertensive Drugs Is Associated with Discontinuation of Antihypertensive Drugs. S47. Abstract from Unknown event, Asilomar, USA.

2003

Wetenschappelijke publicaties

De Jong, I. E. J., Kloeg, P. H. A. M., Steenhoek, A., Klungel, O. H., & Cornel, J. H. (2003). De invloed van behandelrichtlijnen op farmacotherapie, morbiditeit en mortaliteit bij patiënten met hartfalen: Uitkomstenonderzoek in de cardiologie. Pharmaceutisch Weekblad, 138(12), 424-429.

Klungel, O. H. (2003). Werkgroep farmacogenetica van start. Pharmaceutisch Weekblad, 138(5).

Maitland-van der Zee, A-H., Stricker, B. H. C., Klungel, O. H., Mantel-Teeuwisse, A. K., Kastelein, J. J. P., Hofman, A., Leufkens, H. G. M., van Duijn, C. M., & de Boer, A. (2003). Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes. Pharmacogenetics, 13(4), 219-223. https://doi.org/10.1097/00008571-200304000-00006

Maitland-van der Zee, A. H., Klungel, O. H., Stricker, B. H. C., van der Kuip, D. A. M., Witteman, J. C. M., Hofman, A., Leufkens, H. G. M., & de Boer, A. (2003). Repeated nitrate prescriptions as a potential marker for angina pectoris. A comparison with medical information from the Rotterdam Study. Pharmacy World & Science, 25(2), 70-72.

Mantel-Teeuwisse, A. K., Verschuren, W. M. M., Klungel, O. H., Kromhout, D., Lindemans, A. D., Avorn, J., Porsius, A. J., & de Boer, A. (2003). Undertreatment of hypercholesterolaemia: a population-based study. British Journal of Clinical Pharmacology, 55, 389-397.
https://dspace.library.uu.nl/bitstream/handle/1874/27515/mantel_03_undertreatmentofhypercholesterolemia.pdf?sequence=2

Spoelstra, J. A., Stolk, R. P., Heerdink, E. R., Klungel, O. H., Erkens, J. A., Leufkens, H. G. M., & Grobbee, D. E. (2003). Refill compliance in type 2 diabetes mellitus: a predictor of switching to insulin therapy. Pharmacoepidemiology and Drug Safety, 12, 121-127.
https://dspace.library.uu.nl/bitstream/handle/1874/27484/spoelstra_03_refillcomplianceintype2diabetesmellitus.pdf?sequence=2

Vakpublicaties

Klungel, O. H., Mantel-Teeuwisse, A. K., & De Boer, A. (2003). Geslachtsverschillen in de epidemiologie, risico en behandeling. Farmacotherapie van hypertensie en hypercholesterolemie. Pharmaceutisch Weekblad, 138(40), 1383-1389.

Klungel, O. H., Mantel-Teeuwisse, A. K., & de Boer, A. (2003). Medicamenteuze behandeling van hypertensie en hypercholesterolemie. Sekseverschillen in epidemiologie, risico en therapie. Pharmaceutisch Weekblad, 138(40), 1383-1389.
https://dspace.library.uu.nl/bitstream/handle/1874/27485/klungel_03_sekseverschilleninepidemiologie.pdf?sequence=1

Erkens, J. A., Klungel, O. H., Stolk, R. P., Grobbee, D. E., & Leufkens, H. G. M. (2003). Multifactoriële behandeling van diabetes mellitus type 2. Belaagd aan alle zijden. Pharmaceutisch Weekblad, 138(45), 1574-1578.
https://dspace.library.uu.nl/bitstream/handle/1874/27503/klungel_03_belaagdaanallezijden.pdf?sequence=1

Overige resultaten

Kastelein, J. J. P., Hofman, A., van Duijn, C. M., Witteman, J. C. M., de Boer, A., Klungel, O. H., Leufkens, H. G. M., Maitland-van der Zee, A. H., Veenstra, D. L., & Stricker, B. H. C. (2003). Economic evaluation of testing for angiotensin converting enzyme(ACE) genotype before starting HMG.CoA reductase therapy in men.. S67-S68. Abstract from Unknown event, Asilomar, USA.

Hofman, A., van Duijn, C. M., Witteman, J. C. M., de Boer, A., Klungel, O. H., Leufkens, H. G. M., Maitland-van der Zee, A. H., & Stricker, B. H. C. (2003). Pharmacoeconomic Evaluation of Testing for Angiotensin Converting Enzym (ACE) Genotype before Starting HMG-COA Reductase Therapy in Men. S67. Abstract from Unknown event, Asilomar, USA.

Schelleman, H., Klungel, O. H., Verschuren, W. M. M., de Boer, A., Stricker, B. H. C., & Kromhout, D. (2003). Prevelance and Determinants of Undertreatment of Hypertension in the Netherlands. Pharmacoepidemiology and Drug Safety, 12(1), S100.

Kastelein, J. J. P., Hofman, A., van Duijn, C. M., Witteman, J. C. M., Breteler, M. M. B., de Boer, A., Klungel, O. H., Maitland-van der Zee, A. H., & Stricker, B. H. C. (2003). The effectiveness of HMG-CoA Reductase Inhibitors is affected by ACE Insertion/Deletion polymorphism. Abstract from Unknown event, Asilomar, USA.

Kromhout, D., de Boer, A., Klungel, O. H., Verschuren, W. M. M., Schelleman, H., & Stricker, B. H. C. (2003). Prevalence and Determinants of Undertreatment of Hypertension in the Netherlands. S. Abstract from Unknown event, Asilomar, USA.

Klungel, O. H., Talsma, H., de Blaey, C. J., & Storimans, M. J. (2003). Community pharmacy is an independent determinant of the dispensing of blood glucose teststrips to diabetic patients. 32. Abstract from Unknown event, Asilomar, USA.

Gorecka, K., de Boer, A., Vleck, J., Stolk, R. P., Grobbee, D. E., & Klungel, O. H. (2003). Statins and the Risk of Diabetes Mellitus: Utrecht Diabetes Epidemiology Studies (UDES). S71. Abstract from Unknown event, Asilomar, USA.

Mantel-Teeuwisse, A. K., Goettsch, W. G., Klungel, O. H., de Boer, A., & Herings, R. M. C. (2003). Discontinuation of Statin Use in Daily Medical Practice. S76. Abstract from Unknown event, Asilomar, USA.

de Boer, A., Herings, R. M. C., Mantel-Teeuwisse, A. K., Goettsch, W. G., & Klungel, O. H. (2003). Discontinuation of Satin Use in Daily Medical Practice. S76. Abstract from Unknown event, Asilomar, USA.

2002

Wetenschappelijke publicaties

Bosman, A. A. P., Van der Zee, A. H. M., Klungel, O. H., Leufkens, H. G. M., & De Boer, A. (2002). Laveren tussen hoog en laag. Pharmaceutisch Weekblad, 137(9), 329-332.

Mantel-Teeuwisse, A. K., Klungel, O. H., Verschuren, W. M. M., Porsius, A. J., & De Boer, A. (2002). Time trends in lipid lowering drug use in the Netherlands. Has the backlog of candidates for treatment been eliminated? British Journal of Clinical Pharmacology, 53(4), 379-385. https://doi.org/10.1046/j.1365-2125.2002.01562.x

Maitland-van der Zee, A. H., Klungel, O. H., Stricker, B. H. C., Monique Verschuren, W. M., Kastelein, J. J. P., Leufkens, H. G. M., & de Boer, A. (2002). Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors. Atherosclerosis, 163(2), 213-22. https://doi.org/10.1016/S0021-9150(01)00725-0

Klungel, O. H. (2002). Quality of hypertension treatment and risk of stroke in the general population. Journal of Hypertension, 20, 1949-1950.
https://dspace.library.uu.nl/bitstream/handle/1874/29400/klungel_02_qualityofhypertensiontreatment.pdf?sequence=1

Erkens, J. A., Klungel, O. H., Herings, R. M. C., Stolk, R. P., Spoelstra, J. A., Grobbee, D. E., & Leufkens, H. G. M. (2002). Use of fluorquinolones is associated with a reduced risk of coronary heart disease in diabetes mellitus type 2 patients. European Heart Journal, 23, 1575-1579.
https://dspace.library.uu.nl/bitstream/handle/1874/29344/erkens_02_useoffluorquinolones.pdf?sequence=1

Maitland-van der Zee, A. H., Stricker, B. H. C., Klungel, O. H., Kastelein, J. J. P., Hofman, A., Witteman, J. C. M., Breteler, M. M. B., Leufkens, H. G. M., van Duijn, C. M., & de Boer, A. (2002). The effectiveness of hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) in the elderly is not influenced by apolipoprotein E genotype. Pharmacogenetics, 12(8), 647-653. https://doi.org/10.1097/00008571-200211000-00009
https://dspace.library.uu.nl/bitstream/handle/1874/29425/maitland_03_theeffectivenessofhydroxy-methylglutaryl.pdf?sequence=2

Maitland-van der Zee, A. H., Stricker, B. H. C., Klungel, O. H., Kastelein, J. J. P., Hofman, A., Witteman, J. C. M., Breteler, M. M. B., Leufkens, H. G. M., van Duijn, C. M., & de Boer, A. (2002). The effectiveness of Hydroxy-Methylglutaryl Coenzyme A reductase inhibitors in the elderly is not influenced by Apolipoprotein E-genotypes. Pharmacogenetics, 12(8), 647-653.
https://dspace.library.uu.nl/bitstream/handle/1874/29404/maitland_02_theeffectivenessofhydroxymethylglutaryl.pdf?sequence=2

Mantel-Teeuwisse, A. K., Klungel, O. H., Herings, R. M. C., van Puijenbroek, E. P., Porsius, A. J., & de Boer, A. (2002). Myopathy due to statin/fibrate use in the Netherlands. Annals of Pharmacotherapy, 36(12), 1957-1960.

Klungel, O. H., Heckbert, S. R., de Boer, A., Leufkens, H. G. M., Sullivan, S. D., Fishman, P. A., Veenstra, D. L., & Psaty, B. M. (2002). Lipid-lowering drug use and cardiovascular events after myocardial infarction. Annals of Pharmacotherapy, 36(5), 751-757. https://doi.org/10.1345/aph.1A308

Vakpublicaties

Bosman, A. A. P., Van der Zee, A. H. M., Klungel, O. H., Leufkens, B., & De Boer, A. (2002). Cholesterol als risicofactor van een hersenberoerte. Pharmaceutisch Weekblad, 137(9), 329-332.

Overige resultaten

Erkens, J. A., Klungel, O. H., Stolk, R. P., Spoelstra, J. A., Grobbee, D. E., & Leufkens, H. G. M. (2002). Type 2 diabetes mellitus and the choice of antihypertensive drugs. S5-S5. Abstract from Unknown event, Asilomar, USA.

Mantel-Teeuwisse, A. K., Klungel, O. H., Egberts, A. C. G., Verschuren, W. M. M., Porsius, A. J., & de Boer, A. (2002). Patterns of lipid lowering drug use after the withdrawal of cerivastatin. 234 P011-235. Abstract from Unknown event, Asilomar, USA.

Maitland-van der Zee, A. H., Stricker, B. H. C., Klungel, O. H., Kastelein, J. J. P., Hofman, A., Witteman, J. C. M., Breteler, M. M. B., van Duijn, C. M., & de Boer, A. (2002). The effectiveness of HMG-CoA Refuctase Inhibitors is affected by ACE Insertion/Deletion polymorphism. s10-s11. Abstract from Unknown event, Asilomar, USA.

Erkens, J. A., Klungel, O. H., Stolk, R. P., Spoelstra, J. A., Grobbee, D. E., & Leufkens, H. G. M. (2002). Antihypertensive drug therapy and the risk of lower extremity amputations in type 2 diabetes mellitus patients. S4-S4. Abstract from Unknown event, Asilomar, USA.

Hommerson, P., Nedeljkovic, S., Klungel, O. H., de Boer, A., Ostojic, M., Grujic, M. Z., & Kromhout, D. (2002). Cardiovascular drug use and differences in the incidence of cardiovascular mortality in elderly men. The serbian cohort of the seven countries study. S106-S106. Abstract from Unknown event, Asilomar, USA.

Maitland-van der Zee, A. H., Stricker, B. H. C., Klungel, O. H., Mantel-Teeuwisse, A. K., Kastelein, J. J. P., Hofman, A., Leufkens, H. G. M., van Duijn, C. M., & de Boer, A. (2002). Adherence to and dosing of HMG-CoA reductase inhibitors differs according to apolipoprotein E-genotypes. s15. Abstract from Unknown event, Asilomar, USA.

Maitland-van der Zee, A. H., Stricker, B. H. C., Klungel, O. H., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., van Duijn, C. M., & de Boer, A. (2002). The use of statins in the general population differ according to APOE-genotypes. 559. Abstract from Unknown event, Asilomar, USA.

Maitland-van der Zee, A. H., Stricker, B. H. C., Klungel, O. H., Kastelein, J. J. P., Hofman, A., Leufkens, H. G. M., van Duijn, C. M., van Broekhoven, C., & de Boer, A. (2002). The effectiveness of HMG-CoA reductase inhibitors in an elderly population is independent of Apolipoprotein E-genotypes. 548P. Abstract from Unknown event, Asilomar, USA.

Spoelstra, J. A., Stolk, R. P., Heerdink, E. R., Klungel, O. H., Erkens, J. A., Leufkens, H. G. M., & Grobbee, D. E. (2002). Refill compliance in type 2 diabetes mellitus: A predictor of switching to insuline therapy?. S16-S16. Abstract from Unknown event, Asilomar, USA.

Mantel-Teeuwisse, A. K., Egberts, A. C. G., Klungel, O. H., Verschuren, W. M. M., Porsius, A. J., & de Boer, A. (2002). Patterns of lipid lowering drug use after the withdrawal of cerivastatin.. 559P. Abstract from Unknown event, Asilomar, USA.

Erkens, J. A., Klungel, O. H., Herings, R. M. C., Stolk, R. P., Spoelstra, J. A., Grobbee, D. E., & Leufkens, H. G. M. (2002). Use of fluorquinolones is associated with a reduced risk of coronary heart disease in diabetes mellitus type 2 patients. S5-S5. Abstract from Unknown event, Asilomar, USA.

Mantel-Teeuwisse, A. K., Verschuren, W. M. M., Klungel, O. H., Porsius, A. J., & de Boer, A. (2002). Determinants of undertreatment of hypercholesterolemia in a population-based study in the Netherlands. 557P. Abstract from Unknown event, Asilomar, USA.

Mantel-Teeuwisse, A. K., Klungel, O. H., Verschuren, W. M. M., Porsius, A. J., & de Boer, A. (2002). Patterns of lipid lowering drug use after withdrawal of cerivastatin. S68-S68. Abstract from Unknown event, Asilomar, USA.

Maitland-van der Zee, A. H., Stricker, B. H. C., Klungel, O. H., Kastelein, J. J. P., Hofman, A., Witteman, J. C. M., Breteler, M. M. B., van Duijn, C. M., & de Boer, A. (2002). The effectiveness of HMG-CoA reduction inhibitors is affected by ACE insertion/delection polymorphism. S10-S10. Abstract from Unknown event, Asilomar, USA.

2001

Wetenschappelijke publicaties

Erkens, J. A., Klungel, O. H., Stolk, R. P., Spoelstra, J. A., Grobbee, D. E., & Leufkens, H. G. M. (2001). Cardiovascular drug use and hospitalizations attributable to type 2 diabetes. Diabetes Care, 24(8), 1428-1432. https://doi.org/10.2337/diacare.24.8.1428

Klungel, O. H. (2001). Thiazides and stroke prevention. Hospital Practice, 36(3), 23-24.

Herings, R. M. C., & Klungel, O. H. (2001). Gastro-intestinale bijwerkingen door NSAID-gebruik - De kosten epidemiologisch benaderd. Pharmaceutisch Weekblad, 136(47), 1771-1772.

Fournier, A., Oprisiu, R., Michel Achard, J., Klungel, O. H., Leufkens, H. G. M., De Boer, A., Longstreth Jr., W. T., Kaplan, R. C., Smith, N. L., & Psaty, B. M. (2001). Differences between primary vs secondary prevention trials regarding the stroke protective effect of antihypertensive drugs [3] (multiple letters). Archives of Internal Medicine, 161(17), 2152-2153. https://doi.org/10.1001/archinte.161.17.2152

Klungel, O. H., Stricker, B. H., Breteler, M. M., Seidell, J. C., Psaty, B. M., & de Boer, A. (2001). Is drug treatment of hypertension in clinical practice as effective as in randomized controlled trials with regard to the reduction of the incidence of stroke? Epidemiology, 12(3), 339-344.

Mantel-Teeuwisse, A. K., Kloosterman, J. M., Maitland-van der Zee, A. H., Klungel, O. H., Porsius, A. J., & de Boer, A. (2001). Drug-Induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels. Drug Safety, 24(6), 443-56.

Mantel-Teeuwisse, A. K., Klungel, O. H., & de Boer, A. (2001). Lipid abnormalities induced by novel antipsychotic drugs. Drug Safety, 24(13), 1017-1018.
https://dspace.library.uu.nl/bitstream/handle/1874/29287/mantel_01_lipidabnormalities.pdf?sequence=2

Klungel, O. H., Heckbert, S. R., Longstreth, W. T., Furberg, C. D., Kaplan, R. C., Smith, N. L., Lemaitre, R. N., Leufkens, H. G., de Boer, A., & Psaty, B. M. (2001). Antihypertensive Drug Therapies and the Risk of Ischemic Stroke. Archives of Internal Medicine, 161(1), 37-43.
https://dspace.library.uu.nl/bitstream/handle/1874/388234/klungel_01_antihypertensivedrugtherapies.pdf?sequence=1

Mantel-Teeuwisse, A. K., Klungel, O. H., Verschuren, W. M., Porsius, A., & de Boer, A. (2001). Comparison of different methods to estimate prevalence of drug use by using pharmacy records. Journal of Clinical Epidemiology, 54(11), 1181-1186.

Klungel, O. H., Leufkens, H. G. M., de Boer, A., Longstreth, W. T., Kaplan, R. C., Smith, N. L., & Psaty, B. M. (2001). Differences Between Primary vs Secondary Prevention Trials Regarding the STroke Protective Effect of Antihypertensive Drugs. Archives of Internal Medicine, 161.
https://dspace.library.uu.nl/bitstream/handle/1874/27950/klungel_01_differencesbetweenprimaryvssecondary.pdf?sequence=1

Erkens, J. A., Klungel, O. H., Stolk, R. P., Herings, R. M. C., Spoelstra, J. A., Grobbee, D. E., & Leufkens, H. G. M. (2001). Cardiovascular drug use and complications attributable to diabetes mellitus type 2. Diabetes Care, 24, 1428-1432.
https://dspace.library.uu.nl/bitstream/handle/1874/27864/erkens_01_cardovasculardruguse.pdf?sequence=1

Herings, R. M. C., & Klungel, O. H. (2001). An epidemiological approach to assess the economic burden of NSAID-induced gastrointestinal events in the Netherlands. PharmacoEconomics, 19(6), 655-665.

Zwart - van Rijkom, J. E. F., Klungel, O. H., Leufkens, H. G. M., Broekmans, A. W., Schrijver-van Velthoven, S., & Umans, V. A. (2001). Costs and effects of combining stenting and abciximab (ReoPro ®) in daily practice. International Journal of Cardiology, 77, 299-303.
https://dspace.library.uu.nl/bitstream/handle/1874/27896/zwart_01_costsandeffectsofcomniningstenting.pdf?sequence=2

Mantel-Teeuwisse, A. K., Kloosterman, J. M. E., Maitland-van der Zee, A. H., Klungel, O. H., Porsius, A. J., & de Boer, A. (2001). Drug-Induces Lipid Changes. Drug Safety, 24(6), 443-456.

Maitland-van der Zee, A. H., Klungel, O. H., Kloosterman, J. M. E., Seidell, J. C., Leufkens, H. G. M., & de Boer, A. (2001). The association between antihypertensive drug therapies and plasma lipid levels in the general population. Journal of Human Hypertension, 15, 701-705.
https://dspace.library.uu.nl/bitstream/handle/1874/27955/maitland_01_theassociationbetweenantihypertensivedrug.pdf?sequence=2

Overige resultaten

Spoelstra, J. A., Stolk, R. P., Klungel, O. H., Erkens, J. A., Leufkens, H. G. M., & Grobbee, D. E. (2001). Antipsychotics May Worsen Metabolic Control in Type 2 Diabetes Mellitus. S46. Abstract from Unknown event, Asilomar, USA.

Erkens, J. A., Klungel, O. H., Stolk, R. P., Belitser, S., Spoelstra, J. A., Grobbee, D. E., & Leufkens, H. G. M. (2001). Diabetes mellitus type 2 drives prescription of antibiotic drugs. S29-S29. Abstract from Unknown event, Asilomar, USA.

Erkens, J. A., Klungel, O. H., Stolk, R. P., Spoelstra, J. A., Grobbee, D. E., & Leufkens, H. G. M. (2001). Cardiovascular drug use and hospitalizations atrributable to diabetes mellitus type 2. S28-S29. Abstract from Unknown event, Asilomar, USA.

Mantel-Teeuwisse, A. K., Klungel, O. H., Verschuren, W. M. M., Porsius, A. J., & de Boer, A. (2001). Time trends in lipid lowering drug use in The Netherlands. Has the backlog of candidates for treatment been eliminatied. S72-S72. Abstract from Unknown event, Asilomar, USA.

Klungel, O. H., Heerdink, E. R., Jones, J. K., Urquhart, J., & Leufkens, H. G. M. (2001). Assessing discontinuation of antihypertensive drug therapies its causes and potential solutions. S74-S74. Abstract from Unknown event, Asilomar, USA.

Sarac, M., Klungel, O. H., Herings, R. M. C., & Leufkens, H. G. M. (2001). Discontination of antihypertensive drug therapy in the Netherlands. S73-S73. Abstract from Unknown event, Asilomar, USA.

Mantel-Teeuwisse, A. K., Lindemans, A. D., Verschuren, W. M. M., Klungel, O. H., Porsius, A. J., & de Boer, A. (2001). Undertreatment of hypercholesterolemia in a population-based study in The Netherlands. S73-S73. Abstract from Unknown event, Asilomar, USA.

Herings, R. M. C., & Klungel, O. H. (2001). An epidemiological approach to assess the economic burden of NSAID-induced gastrointestinal event in the Netherlands. S117-S118. Abstract from Unknown event, Asilomar, USA.

2000

Wetenschappelijke publicaties

Klungel, O. H., Paes, A. H. P., Seidell, J. C., Kuijvenhoven, M. M., & De Boer, A. (2000). Sekseverschillen bij de medicamenteuze behandeling van hypertensie door de huisarts. Huisarts en Wetenschap, 43(7), 303-305.

Klungel, O. H., De Boer, A., Seidell, J. C., Lloyd-Jones, D. M., & Levy, D. (2000). Overestimation of the number of individuals with hypertension who are eligible for treatment according to the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [4] (multiple letters). Archives of Internal Medicine, 160(10), 1540.

Klungel, O. H., Paes, A. H. P., Seidell, J. C., Kuijvenhoven, M. M., & De Boer, A. (2000). Geslachtsverschillen behandeling hypertensie. Huisarts en Wetenschap, 43(7), 303-305.

Maitland-van der Zee, A. H., Klungel, O. H., Leufkens, H. G. M., & De Boer, A. (2000). Farmacotherapie en genotype. Pharmaceutisch Weekblad, 135(11), 378-379.

Teeuwisse, A., Klungel, O., Porsius, A., & De Boer, A. (2000). Doelmatigheid van cholesterolverlagende geneesmiddelen. Pharmaceutisch Weekblad, 135(4), 106.

Klungel, O. H., Paes, A. H. P., De Boer, A., Kuyvenhoven, M. M., Seidell, J. C., & Bakker, A. (2000). Sex differences in the medication choice for hypertension in general practice: A study with written case simulations. Pharmacy World and Science, 22(4), 140-146. https://doi.org/10.1023/A:1008713714549

Klungel, O. H., de Boer, A., Paes, A. H., Nagelkerke, N. J., Seidell, J. C., & Bakker, A. (2000). Influence of correction for within-person variability in blood pressure on the prevalence, awareness, treatment, and control of hypertension. American Journal of Hypertension, 13(1 ), 88-91. https://doi.org/10.1016/S0895-7061(99)00101-6

Klungel, O. H., de Boer, A., & Seidell, J. C. (2000). Overestimation of the number of individuals with hypertension who are eligible for treatment according to the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Archives of Internal Medicine, 160(10), 1540.

Klungel, O. H., de Boer, A., Paes, A. H., Herings, R. M., Seidell, J. C., & Bakker, A. (2000). Influence of question structure on the recall of self-reported drug use. Journal of Clinical Epidemiology, 53(3), 273-277. https://doi.org/10.1016/S0895-4356(99)00167-5

Klungel, O. H., Stricker, B. H., Breteler, M. M., Seidell, J. C., & de Boer, A. (2000). Onderbehandeling van hypertensie en het risico op beroerte bij de oudste ouderen. Tijdschrift voor Gerontologie en Geriatrie, 31(3), 119-122.

Klungel, O. H., Leufkens, H. G. M., & de Boer, A. (2000). Prediction or assessment of the number of averted events by treatment of hypertension. BMJ - Clinical research. http://www.bmj.com/cgi/eletters/320/7236/680#7077

Klungel, O. H., Leufkens, H. G. M., & de Boer, A. (2000). Estimation of the absolute benefit of drug treatment of hypertension in the general population. Hypertension. http://hyper.ahajournals.org/cgi/eletters/35/2/539

Klungel, O. H., Kaplan, R. C., Heckbert, S. R., Smith, N. L., Lemaitre, R. N., Longstreth, W. T., Leufkens, H. G., de Boer, A., & Psaty, B. M. (2000). Control of blood pressure and risk of stroke among pharmacologically treated hypertensive patients. Stroke, 31(2), 420-424.
https://dspace.library.uu.nl/bitstream/handle/1874/407045/klungel_00_controlofbloodpressureandriskofstroke.pdf?sequence=1

Klungel, O. H., de Boer, A., Paes, A. H., Nagelkerke, N. J., Seidell, J. C., & Bakker, A. (2000). Estimating the prevalence of hypertension corrected for the effect of within-person variability in blood pressure. Journal of Clinical Epidemiology, 53(11), 1158-1163.

Vakpublicaties

Klungel, O. H., Stricker, B. H. C., Breteler, M. M. B., Seidell, J. C., & De Boer, A. (2000). Ondrrbehandeling van hypertensie en het risico op hersenberoerte bij ouderen. Tijdschrift voor Gerontologie en Geriatrie, 31(3), 119-122.

Klungel, O. H., Paes, A. H. P., Seidell, J. C., Kuijvenhoven, M. M., & de Boer, A. (2000). Sekseverschillen bij de medicamentueze behandeling van hypertensie door de huisarts. Huisarts en Wetenschap, 43(7), 303-305.

Mantel-Teeuwisse, A. K., Klungel, O. H., Porsius, A. J., & de Boer, A. (2000). Cholesterolverlagers en doelmatigheid. Pharmaceutisch Weekblad, 135(4), 108.

Klungel, O. H., de Boer, A., & Leufkens, H. G. M. (2000). Effectiviteit van geneesmiddelen in de dagelijkse praktijk. Conceptuur, 22, 10-11.

Maitland-van der Zee, A. H., Klungel, O. H., Leufkens, H. G. M., & de Boer, A. (2000). Geneesmiddeltherapie en het genotype van de patiënt. Pharmaceutisch Weekblad, 135, 378-379.

Overige resultaten

Maitland-van der Zee, A. H., Klungel, O. H., Seidell, J. C., & Leufkens, H. G. M. (2000). The association between antihypertensive drug therapies and plasma lipid levels in the general population. 492-492. Abstract from Unknown event, Asilomar, USA.

Mantel-Teeuwisse, A. K., Klungel, O. H., Verschuren, W. M. M., Porsius, A. J., & de Boer, A. (2000). Comparison of different methods to estimate prevalence of drug use by using pharmacy records. S1-S1. Abstract from Unknown event, Asilomar, USA.

Klungel, O. H., Stricker, B. H. C., Seidell, J. C., Breteler, M. M. B., Psaty, B. M., & de Boer, A. (2000). Effectiviteit van medicamenteuze behandeling van hypertensie in de reductie van de incidentie van hersenberoerte in de algemene bevolking. 29-29. Abstract from Unknown event, Asilomar, USA.

Klungel, O. H., Stricker, B. H. C., Seidell, J. C., Breteler, M. M. B., Psaty, B. M., & de Boer, A. (2000). Effectiviness of the pharmacological treatment of hypertension in the reduction of the incidence of stroke in the general population. 394P-395P. Abstract from Unknown event, Asilomar, USA.

Klungel, O. H., Heckbert, S. R., Longstreth, W. T., Furberg, C. D., Smith, N. L., Kaplan, R. C., Lemaitre, R. N., Leufkens, H. G. M., de Boer, A., & Psaty, B. M. (2000). Antihypertensive drug therapies and the risk of ischemic stroke. 720-720. Abstract from Unknown event, Asilomar, USA.

1999

Wetenschappelijke publicaties

Bouvy, M. L., Heerdink, E. R., Klungel, O. H., De Boer, A., Stuurman-Bieze, A. G. G., & Leufkens, H. G. (1999). Women with angina pectoris receive less antiplatelet treatment than men. British Journal of General Practice, 49(441), 299-300.

Klungel, O. H., De Boer, A., Paes, A. H. P., Herings, R. M. C., Seidell, J. C., & Bakker, A. (1999). Agreement between self-reported antihypertensive drug use and pharmacy records in a population-based study in The Netherlands. Pharmacy World and Science, 21(5), 217-220. https://doi.org/10.1023/A:1008741321384

Klungel, O. H., De Boer, A., Paes, A. H. P., Seidell, J. C., & Bakker, A. (1999). Cardiovascular diseases and risk factors in a population-based study in The Netherlands: Agreement between questionnaire information and medical records. Netherlands Journal of Medicine, 55(4), 177-183. https://doi.org/10.1016/S0300-2977(99)00045-5

Klungel, O. H., Paes, A. H. P., de Boer, A., Kuyvenhoven, M. M., Seidell, J. C., & Bakker, A. (1999). Sex differences in the medication choice for hypertension in general practice. A study written case simulations. In Studies on the quality of the pharmacological treatment of hypertension in the general population.

Bouvy, M. L., Heerdink, E. R., Klungel, O. H., de Boer, A., Stuurman-Bieze, A. G. G., & Leufkens, H. G. M. (1999). Women with angina pectoris receive less antiplatelet treatment then men. British Journal of General Practice, 49, 299-300.

Klungel, O. H., Stricker, B. H. C., Paes, A. H. P., Seidell, J. C., Bakker, A., Voko, Z., Breteler, M. M. B., & de Boer, A. (1999). Excess Stroke Among Hypertensive Men and Women Attributable to Undertreatment of Hypertension. Stroke, 30, 1312-1318.

Vakpublicaties

Klungel, O. H., Seidell, J. C., Paes, A. H. P., & de Boer, A. (1999). Onderbehandeling van hypertensie: voorkomen, gevolgen en determinanten. Cardiologie, 6, 556-560.

Overige resultaten

Klungel, O. H., Kaplan, R. C., Heckbert, S. R., Smith, N. L., Lemaitre, R. N., Longstreth, W. T., Leufkens, H. G. M., de Boer, A., & Psaty, B. M. (1999). Control of blood pressure and risk of stroke among pharmacologically treated hypertensive patients. 1-807-1-808. Abstract from Unknown event, Asilomar, USA.

Klungel, O. H., Stricker, B. H. C., Seidell, J. C., Breteler, M. M. B., Psaty, B. M., & de Boer, A. (1999). Effectiveness of the pharmacological treatment of hypertension under everyday circumstances with regard to the reduction of the incidence of stroke. 355-356. Abstract from Unknown event, Asilomar, USA.

Klungel, O. H., Stricker, B. H. C., Seidell, J. C., Breteler, M. M. B., Psaty, B. M., & de Boer, A. (1999). Effectiveness of the pharmacological treatment of hypertension in the reduction of the incidence of stroke in the general population. 394P-395P. Abstract from Unknown event, Asilomar, USA.

Klungel, O. H., Stricker, B. H. C., Paes, A. H. P., Seidell, J. C., Bakker, A., Voko, Z., Breteler, M. M. B., & de Boer, A. (1999). Excess stroke among hypertensive men and women attributable to undertreatment of hypertension. 129-130. Abstract from Unknown event, Asilomar, USA.

1998

Wetenschappelijke publicaties

Klungel, O. H., & De Boer, A. (1998). SEKSEVERSCHILLEN IN DE FARMACOLOGISCHE BEHANDELING VAN HYPERTENSIE: AANZIENLIJKE ONDERBEHANDEKING BIJ MANNEN EN VROUWEN AANGETOOND. Pharmaceutisch Weekblad, 133(23), 872-876.

Klungel, O. H., Seidell, J. C., De Boer, A., & Marques-Vidal, P. (1998). Assessment of control of hypertension in the population (multiple letters) [1]. Journal of Hypertension, 16(3), 395-396.

Klungel, O. H., Seidell, J. C., De Boer, A., Colhoun, H., Dong, W., & Poulter, N. (1998). Overestimation of the prevalence of hypertension in the population (multiple letters) [2]. Journal of Hypertension, 16(11), 1702-1703.

Klungel, O. H., & De Boer, A. (1998). Geslachtsverschillen bij de behandeling van hypertensie. Pharmaceutisch Weekblad, 133(23), 872-876.

Klungel, O. H., Seidell, J. C., & de Boer, A. (1998). Assessment of control of hypertension in the population. Journal of Hypertension, 16(3), 395-6.

Klungel, O. H., de Boer, A., Paes, A. H., Seidell, J. C., & Bakker, A. (1998). Sex differences in antihypertensive drug use: determinants of the choice of medication for hypertension. Journal of Hypertension, 16(10), 1545-1553. https://doi.org/10.1097/00004872-199816100-00021

Klungel, O. H., Seidell, J. C., & de Boer, A. (1998). Overestimation of the prevalence of hypertension in the population. Journal of Hypertension, 16(11), 1702-3.

Klungel, O. H., de Boer, A., Paes, A. H. P., Seidell, J. C., Nagelkerke, N. J. D., & Bakker, A. (1998). Undertreatment of hypertension in a population-based study in The Netherlands. Journal of Hypertension, 16, 1371-1378.

Vakpublicaties

Klungel, O. H., de Boer, A., Paes, A. H. P., Seidell, J. C., & Bakker, A. (1998). Aanzienlijke onderbehandeling vrouwen aangetoond. Pharmaceutisch Weekblad, 133, 872-876.

Overige resultaten

Klungel, O. H., de Boer, A., Paes, A. H. P., Seidell, J. C., Nagelkerke, N. J. D., & Bakker, A. (1998). Estimating the prevalence of hypertension corrected for the effect of within-Person-variability. S172-S172. Abstract from Unknown event, Asilomar, USA.

Bouvy, M. L., Heerdink, E. R., Klungel, O. H., de Boer, A., & Leufkens, H. G. M. (1998). Women with angina pectoris receive less anti-platelet treatment than men. S176-S176. Abstract from Unknown event, Asilomar, USA.

1997

Wetenschappelijke publicaties

Klungel, O. H., de Boer, A., Paes, A. H. P., Seidell, J. C., & Bakker, A. (1997). Sex‐based differences in the pharmacological treatment of hypertension: Insights from health services research. Journal of Hypertension, 15(12). https://doi.org/10.1097/00004872-199715120-00023

McAlister, F. A., Klungel, O. H., De Boer, A., Paes, A. H. P., Seidell, J. C., & Bakker, A. (1997). Sex-based differences in the pharmacological treatment of hypertension: Insights from health services research (multiple letters) [1]. Journal of Hypertension, 15(12 I), 1527-1528. https://doi.org/10.1097/00004872-199715120-00022

Klungel, O. H., de Boer, A., Paes, A. H., Seidell, J. C., & Bakker, A. (1997). Sex differences in the pharmacological treatment of hypertension: a review of population-based studies. Journal of Hypertension, 15(6), 591-600. https://doi.org/10.1097/00004872-199715060-00004

Overige resultaten

Klungel, O. H., de Boer, A., Paes, A. H. P., Seidell, J. C., & Bakker, A. (1997). Undertreatment of hypertension in The Netherlands 1987 - 1995. S25-S25. Abstract from Unknown event, Asilomar, USA.

Klungel, O. H., de Boer, A., Paes, A. H. P., Seidell, J. C., & Bakker, A. (1997). Influence of correction for within-person variability on the prevelance estimation of hypertension treatment and undertreatment of hypertension. S25-S25. Abstract from Unknown event, Asilomar, USA.

1996

Vakpublicaties

Klungel, O. H., de Boer, A., Paes, A. H. P., Seidell, J. C., & Bakker, A. (1996). Man/vrouw verschillen in de behandeling van hypertensie: internationale trends. Tijdschrift voor Sociale Gezondheidszorg, 4, 51-51.

Klungel, O. H., de Boer, A., Paes, A. H. P., Seidell, J. C., & Bakker, A. (1996). Onderbehandeling van hypertensie bij mannen en vrouwen: een dwarsdoorsnede populatie-onderzoek in Nederland. Tijdschrift voor Sociale Gezondheidszorg, 4, 26-26.

Overige resultaten

Klungel, O. H., Paes, A. H. P., de Boer, A., Seidell, J. C., & Bakker, A. (1996). Sex differences in the treatment of hypertension; international trends. S57-S57. Abstract from Unknown event, Asilomar, USA.

Klungel, O. H., Paes, A. H. P., de Boer, A., Seidell, J. C., & Bakker, A. (1996). Undertreatment of hypertension in men and women: a population based survey in the Netherlands. S57-S57. Abstract from Unknown event, Asilomar, USA.

Klungel, O. H., Paes, A. H. P., de Boer, A., Schut-Meijwes, F. B., Seidell, J. C., & Bakker, A. (1996). Gender differences in self-reported antihypertensive drug use in the Netherlands. 165-167. Abstract from Unknown event, Asilomar, USA.